Understanding the role of the tumour microenvironment in chemoresistance and tumour progression by Ireland, LV
  
 
 
 
Understanding the role of the tumour 
microenvironment in chemoresistance 
and tumour progression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis submitted in accordance with the requirements of the University of 
Liverpool for the degree of Doctor in Philosophy 
 
 
 
By 
 
Lucy Victoria Ireland  
 
September 2018
 DECLARATION  
 
 
 
This thesis is the result of my own work. The material contained within this thesis has 
not been presented, nor is currently being presented, either wholly or in part for any 
other degree or qualification.  
 
 
 
 
 
 
 
 
 
Lucy Victoria Ireland  
 
 
 
 
 
 
This research was carried out in the Department of Molecular and Clinical Cancer 
Medicine, Institute of Translational Medicine, University of Liverpool, UK. 
 
 
 
 
 
 
 
 
 
 
 
 
 140 
 
 
CONTENTS 
ACKNOWLEDGEMENTS         i 
PUBLICATIONS          ii 
ABSTRACT           iii 
ABBREVIATIONS          v 
LIST OF FIGURES         ix 
 
CHAPTER ONE:                     1 
General Introduction   
         
CHAPTER TWO:                         47 
Materials and Methods         
 
CHAPTER THREE                                                                                    66 
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like 
Growth Factors 
            
CHAPTER FOUR:                   111 
Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic 
breast cancer          
 
CHAPTER FIVE:                   145 
PDAC tumours with varying metastatic potential express differing secretome profiles 
 
CHAPTER SIX:                   178 
Concluding Discussion 
  
SUPPLEMENTARY DATA                 188 
APPENDIX                    207 
BIBLIOGRAPHY                   211
              
 i 
 
ACKNOWLEDGEMENTS 
 
An enormous and unbridled thank you is deserved by my supervisor Dr Ainhoa Mielgo 
for all support, time and encouragement which has been put into my PhD and my 
scientific career. A massive thanks is also deserved by Dr Michael Schmid, who also 
provided support and scientific insight. I must also thank North West Cancer Research 
for funding my PhD and the Wellcome trust who also provided funding. Another 
acknowledgement must be made of all the facilities used at the University of Liverpool, 
the Centre for Proteome Research, Biomedical services unit and MARIAC FACS 
facility and to all the colleagues who provided support in these facilities.  
 
All my colleagues in the Mielgo and Schmid labs (past and present) have provided 
daily comradery, academic support and who would all make time to assist with 
experimental design or hands on work during large in vivo studies. So thank you to 
Andrea, Peppy, Seb, Valeria, Carolyn, Almudena, Carlos, Shamsher and Meirion.  
 
A huge appreciation for all my fellow PhD candidate peers who have made the long 
hours and experimental woes appear normal; Sammie Jones, Amy Ball, James 
Waddington, Joel Watkinson, Georgia Greaves, Nirajh Shah and Lucia Livoti. You 
guys have been there through the ups and downs which we have all shared at some 
point throughout our 3 years. You guys rock! 
 
A big and humble thank you is required for Lawrence Howell. Not only a PhD peer but 
a supportive boyfriend who has had to deal with both scientific and personal crises 
and elations. Thank you for your daily encouragement and pep talks when things got 
hectic. 
 
Heartfelt appreciation must also go out to my whole family who have supported my 
studies and proudly printed my papers despite not understanding a word. A special 
mention must go out to my Nanny Dorothy who succumbed to pancreatic cancer 
triggering my passion for cancer research. 
 
 
 
 
 ii 
 
PUBLICATIONS 
(* joint publications) 
 
 Ireland L and Mielgo A ‘Macrophages and fibroblasts, key players in cancer 
chemoresistance’ Frontiers in Cell and Developmental Biology. 2018 October;   
doi: 10.3389/fcell.2018.00131 
 
 Figueiredo CR, Azevedo RA, Mousdell S, Resende-Lara PT, Ireland L, 
Santos A, Girola N, Cunha RL, Schmid MC, Polonelli L, Travassos LR, Mielgo 
A ‘Interfering with MIF-CD74 signalling on macrophages and dendritic cells 
with a peptide-based approach restores the immune response against 
metastatic melanoma’ Frontiers in Immunology. 2018 May; doi: 
10.3389/fimmu.2018.01132 
 
 Ireland L, Santos A, Campbell F, Figueiredo C, Hammond D, Ellies LG, 
Weyer-Czernilofsky U, Bogenrieder T, Schmid M, Mielgo A ‘Blockade of 
insulin-like growth factors increases efficacy of paclitaxel in metastatic breast 
cancer’ Oncogene. 2017 Nov; doi: 10.1038/s41388-017-0115-x 
 
 Howell LS, Ireland L, Park BK, Goldring GE ‘MiR-122 and other microRNAs 
as potential circulating biomarkers of drug-induced liver injury’ Expert Review 
of Molecular Diagnostics. 2017 Dec 18:1, 47-54, DOI: 
10.1080/14737159.2018.1415145 
 
 Ireland L*, Santos A*, Ahmed MS, Rainer C, Nielsen SR, Quaranta V, Weyer-
Czernilofsky U, Engle DD, Perez-Mancera PA, Coupland SE, Taktak A, 
Bogenrieder T, Tuveson DA, Campbell F, Schmid MC, Mielgo A 
‘Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-
Like Growth Factors’ Cancer Research. 2016 Dec 1;76(23):6851-6863. doi: 
10.1158/0008-5472.CAN-16-1201. 
 
 Nielsen SR, Quaranta V, Linford A, Emeagi P, Rainer C, Santos A, Ireland L, 
Sakai T, Sakai K, Kim YS, Engle D, Campbell F, Palmer P, Ko JH, Tuveson 
DA, Hirsch E, Mielgo A, Schmid MC ‘Macrophage-secreted granulin supports 
pancreatic cancer metastasis by inducing liver fibrosis’ Nature Cell Biology. 
2016 May; 18(5):549-60. doi: 10.1038/ncb3340.  
 iii 
 
ABSTRACT 
Cancer resistance to therapies and metastasis remain two of the biggest challenges 
in the cancer field. Solid tumours are characteristically surrounded by a stroma. The 
tumour stroma is composed of non-malignant stromal cells and extracellular matrix 
proteins. Tumour-associated macrophages (TAMs) and cancer-associated fibroblasts 
(CAFs) are the most abundant cell types in the tumour stroma and can affect cancer 
resistance to therapies and metastasis. However, how exactly TAMs and CAFs confer 
chemoresistance towards tumour cells and support metastasis is only partly 
elucidated.  
 
Two solid tumours which acquire resistance to their standard therapies and exhibit 
high rates of metastasis are pancreatic ductal adenocarcinoma (PDAC) and invasive 
breast cancer. Both tumour types possess a rich tumour microenvironment (TME) 
which partakes in bi-directional signalling with tumour cells to confer survival as well 
as promote metastasis and growth. However, the exact mechanisms by which TAMs 
and CAFs promote resistance to therapies and metastasis in these cancers are not 
fully understood. 
 
The aims of this thesis were 1) to elucidate how TAMs and CAFs in the TME of PDAC 
and invasive breast cancer promote tumour cell survival and resistance to 
chemotherapy. 2) To investigate the effect of blocking the mechanisms of therapy 
resistance identified, in combination with standard chemotherapy, in preclinical PDAC 
and breast cancer mouse models recapitulative of the human disease. 3) To identify 
factors supporting PDAC metastasis identification of factors mediating tumour 
progression.   
 
Using primary isolated macrophages and pancreatic stellate cells (PaSCs) in vitro 
identified insulin-like growth factor 1 and 2 (IGF-1/2) as secreted factors which 
activate insulin and IGF-1 receptors on tumour cells on both PDAC and breast cancer 
cells. Isolation of tumour cells, non-immune stromal cells and macrophages from 
orthotopic PDAC and TNBC-like invasive breast cancer models revealed non-immune 
stromal cells and macrophages as the main sources of IGF-1 and IGF-2 activating 
insulin/IGF-1R on tumour cells in vivo. Blockade of IGF signalling using an IGF-
blocking antibody in combination with standard chemotherapy resulted in a decrease 
in tumour cell proliferation in PDAC and a decrease in primary breast tumour size and 
reduction in total metastatic burden in an invasive breast cancer model. These studies 
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provide the rationale to trial IGF-blocking antibodies in combination with 
chemotherapy in PDAC and breast cancer patients.  
 
Investigation into the metastatic potential of three PDAC cell lines, FC1199, FC1242 
and FC1245, derived from the genetically engineered KPC (Kras LSL.G12D/+; 
p53R172H/+; PdxCretg/+) mouse model showed that these cells possessed varied 
aggressiveness and metastatic propensity. Implantation of FC1245 cells resulted in 
mice having a severely reduced quality of life and reduced life expectancy to around 
20 days after implantation. FC1245-tumour bearing mice exhibited both spontaneous 
liver and lung metastasis at higher levels compared to the other implanted mice.  
Stable isotope labelling with amino acids in cell culture (SILAC) proteomic analysis of 
the three cell lines revealed nineteen consistently upregulated proteins from FC1245 
cells, of which mesothelin was identified as one of the top candidates upregulated in 
the highly metastatic FC1245 cells. Immunohistochemical analysis of PDAC tissues 
revealed that mesothelin expression was limited to the tumour tissue. Mesothelin 
expression by FC1245 cells was also confirmed by immunoblotting analysis. 
 
Overall, this work has identified new therapeutic targets IGF-1 and IGF-2 to combat 
chemoresistance in both PDAC and breast cancer which trialled in preclinical models, 
in combination with chemotherapy, has shown a more favourable outcome compared 
to standard chemotherapy alone. This work has also identified mesothelin as a 
potential protein of interest in metastatic PDAC. 
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1.1 Hallmarks of cancer  
Cancer is a group of diseases categorised by abnormal cell growth and spread 
throughout the body. Cells become neoplastic through a stepwise accumulation of 
genetic aberrations which ultimately disrupt regulated cell growth. The genetic 
alterations accumulated may include deletions, amplifications, point mutations, 
translocations and epigenetic modifications which ultimately alter the function or 
expression of afflicted genes (Iengar, 2012). However, when these alterations occur 
in proto-oncogenes or tumour suppressor genes, cancer is more likely to develop. 
Proto-oncogenes are present in normal parenchymal cells and upon mutation become 
oncogenes, resulting in either hyperactivity of the encoded protein, increased levels 
of transcription/translation or expression by inappropriate cell types (Lee and Muller, 
2010). Tumour suppressor genes act to prevent tumourigenesis through the control 
of proliferation and survival. In cancer, tumour suppressor genes become inactivated 
through mutation resulting in the uncontrolled proliferation of neoplastic cells (Lee and 
Muller, 2010).  
 
Heterogeneity of tumour cells was acknowledged as early as 1958 (Huxley, 1958). 
Advancements in technology has now led us to understand that tumours function as 
complex tissues comprising of cells with varying genetic aberrations, performing 
diverse functions and displaying phenotypes which are described as hallmarks of 
cancer (summarised in Fig 1.1). The first hallmark of cancer is the ability to sustain 
proliferative signalling. Cancer cells can evade the usually tight mitogenic controls 
that act during homeostasis to limit unchecked proliferation resulting in an escape 
from regulation of cell numbers. This phenomenon can be mediated by 
hypersensitivity to available growth factors through upregulated expression of 
receptors, self-production of growth factors promoting autocrine activation, stimulation 
of cells in the surrounding tumour microenvironment (TME) to produce growth factors 
Chapter One 
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or constitutive activation of downstream signalling components (Fedi et al., 1997, 
Hanahan and Weinberg, 2000).  
 
Another underlying hallmark of cancer is the evasion of growth suppressor signals. 
Tumour suppressor genes or contact inhibition produce signals which force cells to 
enter a quiescent or post-mitotic state however, these are both overcome by 
neoplastic cells (Weinberg, 1995, Hanahan and Weinberg, 2011). Normal 
parenchymal cells are capable of proliferating for a restricted number of times, known 
as their Hayflick limit (Hayflick, 1965). This limit is determined by telomere length and 
the eventual uncapping of chromosomes which triggers cellular senescence. Cancer 
cells bypass this barrier through the reactivation of telomerase meaning telomeres 
can be regenerated escaping crisis and senescence resulting in reproductive 
immortality (Hayflick, 1997).   
 
Another key attribute acquired by cancer cells is the resistance of cell death. Tumour 
cells actively resist apoptosis through various mechanisms. The most common 
mechanism is the loss or inactivation of tumour protein 53 (P53) tumour suppressor 
gene preventing the detection of DNA damage and the subsequent onset of apoptosis 
(Rivlin et al., 2011). Alternatively, increased expression of survival factors and anti-
apoptotic regulators can also circumvent established means of prompting cell death 
(Hanahan and Weinberg, 2000).   
 
As tumour cells increase in number, the size of the tumour mass becomes limited due 
to an inadequate supply of nutrients and inefficient removal of waste products. To 
bypass this problem, tumour cells acquire the ability to induce angiogenesis. Tumour-
mediated angiogenesis creates blood vessels with enlarged diameters, leaky 
branches and a more tortuous structure (Bergers and Benjamin, 2003).  
Chapter One 
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An important hallmark in invasive cancers is the ability to effectively metastasise to 
distant organs. Cancer cells gain the ability to invade their basement membrane 
through downregulation of cytostatic-associated adhesion molecules and 
upregulation of adhesion molecules promoting cell movement such as those 
associated with embryogenesis and inflammation (Christofori and Semb, 1999, 
Hanahan and Weinberg, 2000).  
 
More recently, enabling characteristics have been described which serve to facilitate 
neoplastic transition. Genomic instability and increased frequency  of mutations are 
characteristics which govern the acquisition of several other hallmarks and therefore 
can confer a selective advantage to cells during multistep tumour progression 
(Hanahan and Weinberg, 2011). Tumour-promoting inflammation was identified as an 
enabling characteristic. Tumours are infiltrated by immune cells due to innate and 
adaptive immune responses which contribute to tumour-associated inflammation 
(Hanahan and Weinberg, 2011). This inflammation can serve to promote tumour 
progression through the supply of growth, survival and proangiogenic factors along 
with extracellular matrix modifying enzymes (DeNardo et al., 2010, Qian and Pollard, 
2010, Grivennikov et al., 2010).  
 
Advancements in cancer research have recognised two emerging hallmarks 
(Hanahan and Weinberg, 2011). Tumour cells have been shown to both deregulate 
their cellular energetics and to actively avoid immune destruction. Tumour cells must 
adapt their metabolism to support elevated levels of proliferation and cell growth. This 
metabolic alteration is called the Warburg effect, where cancer cells shift their 
metabolism towards aerobic glycolysis even in the presence of oxygen (House et al., 
1956, Warburg and Dickens, 1930). Tumours have also developed methods to avoid 
immune destruction through bi-directional signalling with immune components as well 
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as upregulation of immune checkpoint markers which result in the exhaustion of CD8 
cytotoxic T lymphocytes (Juneja et al., 2017).  
 
 
 
1.2 Chemotherapy  
The treatment of cancer with chemical substances, known as chemotherapy, is 
routinely used for cancer treatment. A benefit of chemotherapy is as it circulates 
throughout the body it targets not only the primary tumour site but disseminated 
 
Figure 1.1 The hallmarks of cancer  
Cancer cells have been shown to develop a number of hallmark characteristics 
which promote neoplasia. These include evasion of growth suppressors, enabling 
replicative immortality, activation of invasion and metastasis, induction of 
angiogenesis, resistance of cell death and proliferative signalling. Emerging 
hallmarks include deregulation of cellular energetics and avoidance of immune 
destruction. Enabling characteristics have been identified as genome instability and 
mutation and tumour-promoting inflammation. (Adapted from Hanahan and 
Weinberg, 2011) 
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tumour cells present in distant organs which are often missed with surgical 
intervention or radiotherapy treatment (Eguchi et al., 2008).  
 
The birth of chemotherapy came after the first world war, using nitrogen mustard as 
an anti-cancer agent in non-Hodgkin’s lymphoma (Gilman, 1963). This agent was 
non-specific and showed limited effectiveness as patients experienced relapse after 
a few weeks of treatment. However, this discovery prompted investigation into the  
mechanism of action leading to the development of other alkylating agents (Haddow 
et al., 1948). Targeted chemotherapy was developed in the late 1980’s after the 
elucidation of a few signalling pathways aberrantly regulated in tumours. Targeted 
chemotherapy included pharmacological targeting of cell cycle regulating proteins, 
growth factors and angiogenesis mediators (Hanahan and Weinberg, 2000, Chabner 
and Roberts, 2005). 
 
Since its beginning, chemotherapy has provided a plethora of benefits for many 
cancer patients (Gebski et al., 2007, Klastersky and Paesmans, 2001, Benedetti-
Panici et al., 2003). Chemotherapeutic agents given before surgery as ‘neoadjuvant’ 
therapy are used to reduce the tumour mass before surgical resection. This has many 
benefits as a reduction in  tumour size may decrease the level of invasiveness 
required for resection and often improves the distinction between healthy and 
neoplastic tissue (Hayes and Schott, 2015). Adjuvant administration of chemotherapy 
occurs post-surgery with the purpose of minimising the chance of recurrence. 
Adjuvant therapy is effective in two ways: firstly, against micro or macro-metastasis 
which are already seeded but were not detectable at the time of surgery, and 
secondly, against micro-metastasis created as a by-product of resection due to tissue 
regeneration-promoting cytokine storms released after invasive surgery (Hayes and 
Schott, 2015).   
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Despite the development of targeted agents with improved toxicity profiles, 
unfortunately in some cancers chemotherapeutic agents only provide a minimal 
improvement in overall survival (Burris et al., 1997, Marquette and Nabell, 2012). Drug 
resistance has become one of the largest hurdles in effective cancer treatment 
causing the relapse of the majority of cancer patients (Holohan et al., 2013, McMillin 
et al., 2013). Tumour resistance mechanisms in patients, can be either tumour cell 
autonomous and/or mediated by the tumour surrounding non-malignant cells present 
in the TME (Joyce and Pollard, 2009, Mielgo and Schmid, 2013, De Palma and Lewis, 
2013, Zheng, 2017).  
 
1.3 Tumour microenvironment (TME) 
The TME describes the complete tumour milieu including the malignant tumour cells 
and the surrounding stroma. The tumour stroma is comprised of non-malignant cells 
including immune cells (macrophages, neutrophils, T cells), fibroblasts, cells from the 
vasculature (pericytes and endothelial cells) and extracellular matrix proteins 
(Hanahan and Weinberg, 2011). Accumulating evidence shows that the stroma 
develops with the tumour and interacts with the neoplastic cells, participating in bi-
directional tumour-stroma signalling which supports tumour progression, metastasis 
and resistance to therapy (Hanahan and Coussens, 2012, Quail and Joyce, 2013). 
The most abundant non-cancerous cell types present in the tumour stroma are tumour 
associated macrophages (TAMs) and cancer associated fibroblasts (CAFs).  
 
1.4 Origin of macrophages and fibroblasts 
1.4.1 Macrophages 
Tissue resident macrophages are a diverse population of cells which perform tissue-
specific functions in tissue homeostasis, repair, immunity and angiogenesis (Davies 
et al., 2013b). Macrophages can originate from three independent sources. 
Embryonic macrophage populations have been mapped back to two sources: foetal 
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liver-derived monocytes or precursor cells found in the yolk sac (Yona et al., 2013, 
Mass et al., 2016). In adult tissue, macrophage populations differentiate from 
hematopoietic stem cells in the bone marrow (Orkin and Zon, 2008). 
Once established in adult tissue, macrophages maintain their population via self-
renewal in the steady state but increase their rate of proliferation in response to stimuli 
such as interleukin 4 (IL-4) and colony stimulating factor 1 (CSF-1) (Davies et al., 
2013b, Jenkins et al., 2011, Jenkins et al., 2013).  During inflammation, bone marrow-
derived monocytes are recruited into the tissue and mature into macrophage 
populations which act alongside tissue resident macrophages (Shi and Pamer, 2011). 
These converted monocytes display cell surface markers associated with resident 
macrophages increasing their responsiveness to IL-4 and IL-3 (Dal-Secco et al., 
2015, Yona et al., 2013). 
 
Bone marrow derived macrophages (BM-DMs) and tissue resident macrophages 
appear to intermingle and work together to resolve inflammation and promote tissue 
repair. However, it is currently undetermined if BM-DMs play the exact same role as 
tissue resident macrophages (Davies et al., 2013a). Bone marrow transplant studies 
have shown that BM-DMs and tissue resident macrophages share similar 
characteristics (van de Laar et al., 2016). Nevertheless, transcriptome analysis of lung 
alveolar resident macrophages has revealed different genes expressed in BM-DMs 
compared to tissue resident macrophages (Gibbings et al., 2015). 
 
1.4.2 Fibroblasts  
Fibroblasts are predicted to be of mesenchymal origin and possess a distinct 
transcriptional profile dependent on their tissue of origin (Chang et al., 2002). 
Fibroblasts have never been identified in embryonic tissue but are hypothesised to 
arise during the epithelial-to-mesenchymal transition (EMT) of the epiblast during 
gastrulation, along with the generation of mesoderm tissue (Kalluri, 2016). Virchow 
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identified cells in adult tissue that produced collagen, were resistant to apoptosis, and 
reverted to quiescence upon the completion of tissue development. These cells were 
later called fibroblasts (Virchow, 1858). Due to the inability to identify fibroblasts in 
embryonic tissue it remains unknown whether the majority of activated fibroblasts 
originate from fibrocytes or mesenchymal stem cells (MSCs) in adult tissue (Kalluri, 
2016). 
 
Stellate cells are found in the pancreas, liver, lung and kidney. Although stellate cells 
are similar to fibroblasts, they display some distinctly different functions such as 
vitamin A storage as retinol droplets in their cytoplasm that is required for cellular 
homeostasis (Erkan et al., 2010, Liu, 2006, Keane et al., 2005). Quiescent stellate 
cells usually constitute <10 % of the organ where they reside and are found in peri-
vascular and peri-parenchymal regions (Apte et al., 1998, Bachem et al., 1998, Wake 
and Sato, 1993). Like fibroblasts, the origin of stellate cells is still debated. 
Neuroectoderm is suggested as a potential origin of pancreatic stellate cells (PaSCs) 
and hepatic stellate cells (hStCs) (Friedman, 2000).  Lineage tracing studies have 
shown that hStCs can originate from mesoderm in mice, however lineage-tracing 
studies are currently lacking for PaSCs (Asahina et al., 2009, Asahina et al., 2011). 
Activated fibroblasts (also known as myofibroblasts) can originate from several 
different cell types that include quiescent fibroblasts from normal parenchyma, 
endothelial cells, MSCs, and stellate cells (Kalluri, 2016, LeBleu et al., 2013). 
Assorted origins may play a role in generating myofibroblast populations with diverse 
phenotypes and functions. Recent studies have described heterogeneous 
populations of myofibroblasts present in both pancreatic and breast tumours (Ohlund 
et al., 2017, Costa et al., 2018) and understanding the functions of these different 
myofibroblast populations in cancer is currently an intensive field of research.  
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1.5 Physiological functions of macrophages and fibroblasts  
Macrophages represent a heterogeneous population of cells that are highly plastic 
and which adapt to their surroundings to perform a variety of functions in tissue 
homeostasis, repair and immunity (Wynn et al., 2013). Macrophages are responsive 
to tissue-derived or external stimuli adapting their phenotype and function accordingly 
(Biswas and Mantovani, 2010). A spectrum of macrophage subsets with diverse 
phenotypes and functions co-exist in tissues and the subsets at the extremes of this 
spectrum are known as M1 (or classically-activated) and M2 (or alternatively-
activated) macrophages (Mills, 2012, Murray and Wynn, 2011). Macrophage 
polarisation into M1-like or M2-like depends on the stimulating cytokine and the length 
of their exposure (Gordon and Martinez, 2010). However, the nomenclature and 
understanding of macrophage subtypes and functions is still evolving. 
 
M1-like macrophages are generated in response to interferon gamma (IFNƴ) and 
lipopolysaccharide (LPS) stimulation, factors produced by infiltrating bacteria and 
pathogens. M1-like macrophages are pro-inflammatory and secrete factors to 
promote inflammation, microbicidal activity and immunostimulation, such as cytokines 
IL-12, IL-6, IL-1ß, tumour-necrosis factor alpha (TNFα) as well as reactive oxygen 
species (ROS) and nitric oxide (NO) (Gordon and Martinez, 2010, Biswas et al., 2013) 
(Fig 1.2).  
 
In contrast, M2-like macrophages are polarised by IL-4 and IL-13 produced by 
invading parasites and in response release anti-inflammatory cytokines IL-10, 
arginase I and transforming growth factor beta (TGF-β), as well as vascular 
endothelial growth factor (VEGF), promoting the remodelling of their surrounding 
tissue. Concurrently, macrophages upregulate expression of scavenging receptors 
while downregulating receptors and markers associated with antigen presentation 
(Biswas and Mantovani, 2010, Mantovani and Sica, 2010) (Fig 1.2).  
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Tissue resident macrophages play a variety of roles in a tissue context-dependent 
manner. Largely, they perform functions usually associated with an M2 phenotype 
including mediating resolution of inflammation, maintaining tissue homeostasis via the 
removal of debris, supporting angiogenesis and partaking in immune surveillance 
(Davies et al., 2013b).  
 
Angiogenesis occurs as part of homeostasis and is tightly regulated by macrophages 
(Fantin et al., 2010, Outtz et al., 2011).  In mouse embryos, microglia (central-nervous 
system specific macrophages) migrate to the brain and assist in developmental 
angiogenesis (Arnold and Betsholtz, 2013). In the central nervous system, 
 
Figure 1.2 Macrophage polarisation 
Bone marrow derived monocytes or tissue derived macrophages can be polarised 
towards either an M1 or M2 phenotype. Classical activation towards M1 polarisation 
occurs in response to interferon gamma (IFNƴ) and lipopolysaccharide (LPS) 
leading to a Th1 response associated with bacteria and viruses as well as 
possessing anti-tumourigenic properties. Alternative activation towards an M2 
phenotype is triggered in response to toll-like receptors (TLRs), immune 
complexes, IL-4, IL-13, IL-10 and glucocorticoids. M2 macrophages lead to a Th2 
response and exhibit anti-parasitic behaviour. In cancer, M2-like macrophages 
promote tumour progression. 
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macrophages promote endothelial tip cell fusion by acting as a chaperone for 
endothelial cells in vascular development (Fantin et al., 2010). However, it appears 
that the actions undertaken by macrophages are tissue-dependent as, conversely, 
macrophages mediate the regression of blood vessels in the developing retina (Lobov 
et al., 2005, Fantin et al., 2010). 
 
Another homeostatic function of macrophages is the removal of apoptotic and excess 
cell debris. This function is extremely important in the regulation of haematopoiesis in 
which macrophages phagocytose excess erythrocytes and neutrophils (Klei et al., 
2017, Gordy et al., 2011). When this process was interrupted in mice they suffered 
severe neutrophilia, splenomegaly, extramedullary haematopoiesis and decreased 
body weight (Gordy et al., 2011). Macrophages also regulate immune responses 
through the ingestion of apoptotic cells preventing leakage of cell-death related 
factors which could promote inflammation (Savill et al., 2002).  
 
In the event of injury or infection, pro-inflammatory M1-like macrophages are recruited 
to the afflicted area and secrete factors including IL-1ß, NO and TNFα as a defence 
mechanism to kill invading pathogens (Murray and Wynn, 2011). The release of these 
factors can also result in secondary damage to host tissue. To limit the impact of this 
damage, macrophages either undergo apoptosis or reprogram towards an anti-
inflammatory M2-like phenotype (Murray and Wynn, 2011). However, when this 
process goes awry, and macrophages maintain their pro-inflammatory functions, 
chronic inflammation occurs and becomes the basis of some auto-immune diseases 
such as crohn’s disease, rheumatoid arthritis and autoimmune hepatitis (Sindrilaru et 
al., 2011, Navegantes et al., 2017). Along with mediating the immunity side of wound 
healing, macrophages alter their secretory phenotype after inflammation subsides to 
promote tissue regeneration. To promote the closure of the wound, macrophages 
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attract and activate fibroblasts through the secretion of TGF-ß (Murray and Wynn, 
2011, Khalil et al., 1989). 
In healthy tissue, fibroblasts and stellate cells exist in a quiescent state within the 
extracellular matrix (ECM) making few cell-cell or cell-basement membrane 
connections.  They are usually found as single cells, elongated and spindle-like in 
morphology situated in the interstitial space between the functional tissues of adult 
organs (Tarin and Croft, 1969). Quiescent fibroblasts and stellate cells produce very 
little ECM components such as collagen 1 and fibronectin and secrete a few factors 
including pigment epithelium-derived factor (PEDF) and thrombospondin-2, although 
their actual role whilst quiescent is yet to be fully elucidated (Tarin and Croft, 1969, 
Pollina et al., 2008). Specific markers for fully quiescent fibroblasts are not yet known, 
however, fibroblasts specific protein-1 positive (FSP1+) cells are often considered as 
quiescent (Strutz et al., 1995) (Fig 1.3).  
 
The activation of fibroblasts and stellate cells is triggered in response to stress factors 
produced during tissue stress and damage, including TGF-β and reactive oxygen 
species (ROS) (Kalluri and Zeisberg, 2006). Activated fibroblasts acquire smooth 
muscle-like properties with increased contractility, motility, proliferation and a stellate 
morphology, and are known as myofibroblasts (Ronnovjessen and Petersen, 1993, 
Sappino et al., 1988). Upon activation, stellate cells also acquire a myoblastic 
phenotype but lose their cytoplasmic retinol lipid droplets (Blaner et al., 2009). 
Common markers of myofibroblasts include alpha-smooth muscle actin (αSMA), 
platelet derived growth factor receptor beta (PDGFRβ), PDGFRα, fibroblast activated 
protein (FAP), vimentin, desmin and discoidin domain-containing receptor 2 (DDR2) 
(Ronnovjessen and Petersen, 1993, Quail and Joyce, 2013, Kalluri, 2016, Sugimoto 
et al., 2006, Jiang et al., 2017) (Fig 1.3).  
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Myofibroblasts classically function in acute wound healing, becoming ‘reversibly’ 
activated and deposit ECM proteins, collagens and fibronectin to close the wound 
(Darby and Hewitson, 2007, Dvorak et al., 1986). Myofibroblasts also modulate ECM 
consistency by secreting matrix metalloproteases (MMPs) and tissue inhibitor of 
metalloproteinase (TIMPs)  (Tampe and Zeisberg, 2014). Activated myofibroblasts 
also possess an altered secretory phenotype producing factors such as TGFβ, VEGF, 
C-X-C motif chemokine ligand 10 (CXCL10), CXCL12, IL- 6 and epidermal growth 
factor (EGF) to promote proliferation and mediate recruitment of other cell types to 
the damaged tissue (Dvorak et al., 1986) (Fig 1.3). 
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Chronic activation of fibroblasts and stellate cells occurs in response to prolonged 
stimulation including toxins or autoimmune disorders. This results in chronic tissue 
fibrosis with myofibroblasts continuing to aberrantly perform their wound healing 
functions without resolution. These myofibroblasts become fibrosis-associated 
fibroblasts (FAFs), are irreversibly activated and exhibit enhanced proliferation and 
survival (Zeisberg and Zeisberg, 2013, Rock et al., 2011, Kalluri, 2016). 
 
Figure 1.3 Fibroblast activation   
Quiescent fibroblasts produce fibronectin and collagen type 1 (Col1a1) 
extracellular matrix (ECM) components, express fibroblasts specific protein-1 
(FSP-1), actin and vimentin and secrete pigment epithelium-derived factor (PEDF) 
and thrombospondin-2 (THBS2). Stimulation by transforming growth factor beta 
(TGFß), reactive oxygen species (ROS) or hypoxia, quiescent cells become 
activated increasing their contractility, proliferation and secretion. Activated 
myofibroblasts produce larger volumes of fibronectin and collagen along with 
tenascin-c and secreted protein acidic and rich in cysteine (SPARC). Increased 
secretion includes IL-6, tissue inhibitor of metalloproteinase (TIMPs), TGFß, 
vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and C-
X-C motif chemokine ligand 10 (CXCL10). Upregulated receptors/markers include 
alpha smooth muscle actin (αSMA), platelet derived growth factor receptor 
alpha/beta (PDGFRα/ß), fibroblast activation protein (FAP), Discoidin domain-
containing receptor 2 (DDR2), desmin and vimentin. 
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1.6 Tumour-associated macrophages (TAMs) and cancer-associated 
fibroblasts (CAFs)  
Macrophages and fibroblasts are the two most abundant non-cancerous cells in 
tumours. Tumours become infiltrated with BM-DMs that are attracted to the tumour 
via the secretion of damage associated molecular patterns (DAMPs) and specific 
macrophage chemoattractants CSF-1 and chemokine (C-C motif) ligand 2 (CCL2). 
M1-like macrophages derived from the bone marrow and tissue resident 
macrophages are recruited to and activated in the tumour site in response to antigen 
presentation and inflammatory responses (Zhu et al., 2017). Once the tumour is 
established, tumour cells secrete cytokines IL-4, IL-10, IL-13 and lactic acid, and 
along with the presence of CD4+ Th2 cells, cause the polarisation of TAMs towards 
an M2-like phenotype. The M2 TAMs no longer serve to destroy the tumour but rather 
support cancer growth, metastasis and resistance to therapies (Ruffell et al., 2012, 
Colegio et al., 2014, Qian and Pollard, 2010, Gocheva et al., 2010).  M2 TAMs support 
tumour progression by directly stimulating the growth of cancer cells through the 
production of growth factors, including EGF, TNFα, IL-6 (Grivennikov et al., 2010).   
 
Solid tumours can undergo periods of hypoxia as its growing size limits the disposal 
of waste products and nutrient delivery becomes limited as simple diffusion can longer 
provide sufficient levels, triggering the angiogenic switch (Hanahan and Weinberg, 
2011, Bergers and Benjamin, 2003). The activation of the angiogenic switch in 
tumours triggers dysregulated angiogenesis resulting in leaky vasculature with 
abnormal branching and enlarged diameter (Bergers and Benjamin, 2003). 
Macrophages are a source of VEGF and are known to support angiogenesis under 
normal physiological conditions (Fantin et al., 2010, Outtz et al., 2011). However, 
tumours depleted of myeloid-derived VEGF have a normalised vasculature with 
increased pericyte coverage and reduced vessel length and this accelerates tumour 
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progression (Stockmann et al., 2008). Conversely, another study showed that 
hypoxia-related TAMs possess reduced mTOR activation, and that stimulation of 
mTOR activity in TAMs resulted in normalised vasculature with decreased vessel 
leakiness, hypoxia and metastasis (Wenes et al., 2016). TAMs are attracted to areas 
of tumour hypoxia through the release of Semaphorin 3A by cancer cells and TAMs 
promote angiogenesis via the phosphorylation of VEGF-receptor on endothelial cells 
(Casazza et al., 2013). CSF-1 stimulation has been shown to upregulate Tie2 
expression on macrophages (Forget et al., 2014). Once inside the tumour, Tie2+ 
macrophages bind to angiopoietin-2 (Ang-2) expressed by endothelial cells and 
stimulate the growth of blood vessels promoting tumour growth and metastasis 
(Mazzieri et al., 2011, De Palma et al., 2005).  
 
Metastatic spread of tumour cells to distant organs involves a multi-step process that 
requires local tissue invasion, intravasation, circulation through the blood stream, 
extravasation and successful colonisation of the distant organ by the cancer cells 
(Hanahan and Coussens, 2012, Massague and Obenauf, 2016). Macrophages play 
a role in each of these stages of the metastatic cascade. Macrophages help tumour 
cell invasion into the basement membrane (Wyckoff et al., 2007, Condeelis and 
Pollard, 2006).  In the PyMT breast cancer mouse model, CSF-1 produced by tumour 
cells and EGF secreted by TAMs results in the migration of both macrophages and 
cancer cells along collagen fibres and intravasation into the blood vessels (Wyckoff 
et al., 2007, Goswami et al., 2005). This phenomenon was also seen in glioblastoma, 
resulting in enhanced cancer cell invasion (Coniglio et al., 2012). TAMs can also 
promote tumour cell migration and invasion through the secretion of MMPs, secreted 
protein acidic and rich in cysteine (SPARC) and cathepsins which degrade and 
remodel the ECM (Bergers et al., 2000, Gocheva et al., 2006) as well as through the 
secretion of TGF-ß which promotes EMT of tumour cells and increased tumour cell 
migration (Bonde et al., 2012).  
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As outlined earlier, fibroblasts are activated in response to tissue damage. After 
resolution of the insult, fibroblasts will reprogram back to quiescence or undergo 
apoptosis (Tomasek et al., 2002). However, tumours are referred to as “wounds that 
do not heal” (Dvorak et al., 1986). Persistent activation signals, in the context of 
cancer, maintain fibroblasts in a chronically activated state triggering a desmoplastic 
reaction and generating a dense fibrotic stroma which envelopes the tumour mass. 
Fibroblast activation signals are tumour-specific and determine the phenotype and 
function of the resulting myofibroblast. In the TME, a myofibroblast will exert a pro- or 
anti-tumourigenic response depending upon which chemokines/cytokines it 
encounters (Tampe and Zeisberg, 2014). TGF-ß is a common activating factor 
released by tumours which increases the expression of PDGF receptors on activated 
PaSCs (Apte et al., 1999). Sonic hedgehog (Shh) signalling in pancreatic ductal 
adenocarcinomas (PDAC) tumours has been reported to promote fibroblast activation 
and fibrosis in the pancreas (Bailey et al., 2008, Yauch et al., 2008). Other common 
factors involved in CAF activation include fibroblast growth factor (FGF), platelet 
derived growth factor (PDGF) and monocyte chemotactic protein (MCP1) (Kalluri and 
Zeisberg, 2006, Marsh et al., 2013).  
 
Concurrent with their activated state, CAFs express an altered secretory phenotype, 
compared to quiescent fibroblasts, including ECM proteins and ECM modulating 
factors such as tenascin C, periostin,  SPARC and extradomain A-fibronectin (EDA-
FN); and tumour promoting factors such as nuclear factor-kB (NF-kB), IL-8, 
Prostaglandin E2 (PGE2), connective tissue growth factor (CTGF) and CXCL7 
(Kalluri, 2003, Hanahan and Coussens, 2012). 
 
Recent advances in the field of CAF research has shown that different subsets of CAF 
populations with different functions co-exist within tumours (Costa et al., 2018, Ohlund 
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et al., 2017, Costea et al., 2013, Brechbuhl et al., 2017). For example, in PDAC a 
specific subset of CAFs expressing high levels of αSMA but low levels of IL-6 was 
found in the fibrotic area juxtaposed to cancer cells and was called the myofibroblast 
CAF subset (myCAFs) (Ohlund et al., 2017). A different subset of CAFs, expressing 
low levels of αSMA but high levels of IL-6 was found at the periphery of the tumour 
and was termed the inflammatory CAF subset (iCAFs) (Ohlund et al., 2017).  Öhlund 
et al., showed that the proximity of the myofibroblasts to the PDAC tumour cells, and 
the concentration of tumour-secreted factors alters the phenotype of the CAFs and 
the proteins they secrete (Ohlund et al., 2017). Another recent study performed with 
luminal A, human epidermal growth factor receptor 2 + (HER2+) and triple negative 
breast cancer (TNBC) patient samples revealed the co-existence of four different CAF 
subsets in breast tumours (Costa et al., 2018). TNBC samples predominantly had two 
types of myofibroblast-like CAFs; CAF-S1 and CAF-S4 identified by their high 
expression of αSMA.  However, only CAF-S1 defined as CD29Med, FAPHi, FSP1Low-Hi, 
aSMAHi, PDGFRbMed-Hi and CAV1Low; showed an immunosuppressive role by 
attracting T lymphocytes and promoting their survival and differentiation into 
immunosuppressive T regulatory cells (Costa et al., 2018).  Thus, CAFs, like TAMs, 
are a heterogeneous population of cells and uncovering the different CAF populations 
and their functions in cancer is currently an important area of research.  
 
TAMs and CAFs take part in a complex interplay and can regulate each other’s 
functions. For example, cancer cells and myofibroblasts are known sources of VEGF 
which promotes the accumulation of immune cells including macrophages at the site 
of fibrosis (Fukumura et al., 1998). VEGF-dependent recruitment and activation of 
macrophages promotes tumourigenesis, angiogenesis and invasion in skin cancer 
(Linde et al., 2012). Reciprocally, in liver metastasis of pancreatic cancer, 
macrophages recruited to the metastatic liver secrete granulin and activate resident 
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quiescent hStCs which subsequently produce periostin supporting the growth of 
metastatic cancer cells in the liver (Nielsen et al., 2016).  
 
1.7 Mechanisms of chemotherapy resistance driven by TAMs and CAFs 
Chemotherapy is used as a treatment for many different cancer types and is used 
either alone or in combination with surgical resection or radiation. Chemotherapy 
targets tumour cells at both the primary tumour site and the metastatic site. However, 
a common problem encountered with the treatment of many tumours is an acquired 
resistance to chemotherapeutic agents. Chemoresistance can be mediated by tumour 
cell-autonomous mechanisms, including changes in tumour cell epigenetics, drug 
inactivation, EMT, activation of alternative survival and proliferative pathways, and/or 
selection of drug-resistant cancer cell clones (Housman et al., 2014). However, many 
solid tumours such as breast cancer and PDAC have a rich stroma which contains, 
as described before, a plethora of non-malignant cell types that influence cancer 
progression and response to therapy in various ways.  In fact, these non-malignant 
stromal cells are not simple bystanders but engage in bi-directional tumour- stroma 
signalling which can result in impaired therapeutic efficacy. For instance, the attraction 
of TAMs in a MCF-7 breast cancer xenograft model, via CSF-1 signalling, reduces 
the efficacy of a combination treatment with cyclophosphamide, methotrexate and 5-
fluorouracil (CMF) (Paulus et al., 2006) (Fig 1.4 A). The presence of TAMs in the 
genetic MMTV-PyMT mouse model of breast cancer makes tumours more resistant 
to paclitaxel therapy (DeNardo et al., 2011). Another study revealed TAM-derived 
cathepsins B and S as responsible for mediating chemoresistance to taxol in the 
MMTV-PyMT mouse model (Shree et al., 2011) (Fig 1.4 B). In a subcutaneous mouse 
model of colorectal cancer, IL-6 released by TAMs mediates chemoresistance to 5-
FU via activation of the IL-6R/STAT3 signalling axis (Yin et al., 2017). IGF-1 was also 
shown to be secreted by TAMs in glioblastoma multiforme and to mediate resistance 
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to a CSF-1R small molecule inhibitor through activation of phosphoinositide 3- kinase 
(PI3K) signalling (Quail et al., 2016). 
 
TAMs can also regulate the delivery of chemotherapy to tumour cells. In the MMTV-
PyMT transgenic breast cancer mouse model, doxorubicin administration causes 
necrosis of cancer cells with the release of CCL2, a chemokine that attracts 
monocytes/macrophages. MMP-9 secretion by the recruited myeloid cells was shown 
to decrease vasculature leakiness and to impair doxorubicin delivery into the tumours 
(Nakasone et al., 2012). In fact, MMP-9 null mice showed an improved response to 
doxorubicin that correlated with increased vascular leakage (Nakasone et al., 2012) 
(Fig 1.4 C). Conversely, in a Lewis lung carcinoma subcutaneous isograft model, 
myeloid derived VEGF promotes resistance to cyclophosphamide treatment by 
promoting the formation of abnormal vessels with reduced pericyte coverage, 
tortuosity and vessel density (Stockmann et al., 2008). 
 
CAFs also play a role in tumour chemoresistance. In fact, a dense fibrotic stroma 
correlates with a poor response to neoadjuvant treatment with 5-fluorouracil, 
epirubicin and cyclophosphamide (FEC) in breast cancer and with gemcitabine in 
PDAC (Farmer et al., 2009, Pandol et al., 2009, Olive et al., 2009). One way fibrosis 
promotes chemoresistance in PDAC is through CAF secretion of hyaluronan, 
generating high interstitial pressure within the tumour, causing the collapse of blood 
vessels supplying the tumour mass and impairing drug delivery (DuFort et al., 2016) 
(Fig 1.4 D).     
                                                    
In oesophageal squamous cell carcinoma, CXCR7 expression is upregulated in 
tumour cells through STAT3/NF-kB signalling stimulated by CAF-derived IL-6, 
ultimately promoting resistance against cisplatin and 5-fluorouracil (Qiao et al., 2018) 
(Fig 1.4 E). IL-6 has pleiotropic effects in the tumour microenvironment and also 
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mediates chemoresistance by promoting EMT of cancer cells (Shintani et al., 2016). 
TGFß secretion by CAFs was shown to confer resistance of oesophageal squamous 
cell carcinoma against cisplatin, taxol, irinotecan (CPT-11), 5-fluorouracil (5-FU), 
carboplatin, docetaxel, pharmorubicin, and vincristine (Zhang et al., 2017) (Fig 1.4 F).   
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Figure 1.4 Mechanisms of chemoresistance mediated by TAMs and CAFs 
A) Cancer cells attract TAMs via CSF-1. TAMs confer resistance of MCF-7 breast 
cancer cells towards cyclophosphamide, methotrexate and 5-fluorouracil (Paulus 
et al., 2006). B) Cathepsins B and S secreted by TAMS mediate resistance of 
breast cancer cells to taxol in MMTV-PyMT mouse model (Shree et al., 2011). C) 
In the MMTV-PyMT transgenic mouse model, cancer cell necrosis caused by 
doxorubicin treatment stimulates cancer cells to release the monocyte 
chemoattractant CCL2. Recruited TAMs produce MMP-9 which promotes 
leakiness of blood vessels and reduction in doxorubicin delivery (Nakasone et al., 
2012). D) In PDAC, CAFs increase deposition of hyaluronan (HA) creating an 
increase in fluid retention and subsequently interstitial pressure in the tumour rises 
causing the collapse of blood vessels and limiting the delivery of chemotherapeutic 
agents (DuFort et al., 2016). E) CAF secreted IL-6 stimulates the upregulation of 
CXCR7 through STAT3/NF-kB signalling promoting resistance of oesophageal 
squamous cell carcinoma cells against cisplatin and 5-fluorouracil (Qiao et al., 
2018). F) CAF-derived TGFß upregulates FOXO1 expression in oesophageal 
squamous cell carcinoma cells triggering reciprocal TGFß secretion which in turn 
increases the levels of αSMA expression in CAFs and resistance to cisplatin, taxol, 
irinotecan (CPT-11), 5-fluorouracil (5-FU), carboplatin, docetaxel, pharmorubicin, 
and vincristine (Zhang et al., 2017).  
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1.8 Targeting TAMs and CAFs in cancer. 
Currently, approaches are being undertaken to block macrophage recruitment to the 
tumour site, to repolarize TAMs back into an M1-like anti-tumourigenic phenotype, 
and to target specific tumourigenic functions of TAMs. Preventing recruitment of 
macrophages to the tumour site has been achieved through targeting macrophage 
chemoattractants such as CSF-1 and CCL2 or their corresponding receptors: CSF-1 
receptor (CSF-1R) and C-C chemokine receptor type 2 (CCR2).  Anti-CSF-1R agents 
have been shown to be effective against recruitment of M2-like macrophages in breast 
cancer models, and anti-CSF1R inhibitors used in combination with paclitaxel 
decreased tumour growth and pulmonary metastasis (DeNardo et al., 2011). CSF-1R 
and CCR2 antagonists have been reported to prevent infiltration of TAMs into the 
tumour mass increasing response to gemcitabine treatment in mouse models of 
PDAC (Mitchem et al., 2013). CCL2 inhibition in combination with docetaxel has 
shown increased efficacy, compared to docetaxel treatment alone, resulting in 
decreased tumour growth and metastatic spread in prostate cancer (Loberg et al., 
2007). This combination has also shown promise in lung cancer, breast cancer 
metastasis and PDAC (Lu and Kang, 2009, Kalbasi et al., 2017, Fridlender et al., 
2011). Due to these successes CSF-1, CCL2 and CSF-1R targeting agents are being 
investigated in clinical trials in combination with chemotherapy in a range of solid 
tumours (ClinicalTrial.gov identifiers: NCT01596751, NCT01525602, NCT02435680, 
and NCT01204996). However, the targeting of chemokines and cytokines has 
limitations due to their redundant and promiscuous nature. In fact, chemokines and 
cytokines can often bind to more than one receptor, and at the same time different 
cytokines/chemokines can bind to the same receptor and activate the same signalling 
pathway (O'Shea and Murray, 2008, Turner et al., 2014). In addition, to add more 
complexity, certain cytokine receptors are expressed by several cell types and as a 
result, inhibiting the cytokine/receptor affects all cell populations expressing the 
receptor. This is the case with CSF-1R which is not exclusively expressed by M2-like 
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macrophages but is also expressed by M1-like macrophages, neutrophils, myeloid-
derived suppressor cells (MDSCs) and dendritic cells (Cannarile et al., 2017).  
 
Repolarizing macrophages back into an M1-like tumoricidal phenotype appears an 
attractive approach as the M2 TAMs are already present in the tumour and 
repolarization could therefore provide an effective strategy to restore the tumoricidal 
function of macrophages and prevent cancer progression. This has been investigated 
using an anti-CD40 antibody in combination with gemcitabine in a PDAC genetically 
engineered mouse model (GEMM) KPC (Kras LSL.G12D/+; p53R172H/+; 
PdxCretg/+) and in PDAC patients (Beatty et al., 2011). The administration of an 
agonist CD40 antibody repolarised TAMs back into an M1-like phenotype leading to 
an increased response to gemcitabine and reduced tumour burden (Beatty et al., 
2011). A phase 1 clinical trial has recently been completed for the use of dacetuzumab 
(human anti-CD40 mAb) with bortezomib chemotherapy in patients with relapsed or 
refractory multiple myeloma, however results have yet to be published 
(ClinicalTrial.gov identifier: NCT00664898). 
 
Since TAMs can act as a double edge sword in cancer, with M1-like TAMs exerting 
anti-tumourigenic functions and M2-like TAMs exerting pro-tumourigenic functions, 
targeting TAMs pro-tumourigenic functions seems a more promising approach 
compared to ablation therapies targeting all TAMs. As previously mentioned, TAMs 
are known to facilitate the intravasation of tumour cells and promote angiogenesis 
(Wyckoff et al., 2007). Therefore, targeting TAMs role in pathological angiogenesis is 
an attractive therapeutic opportunity. In MMTV-PyMT mammary carcinomas and 
RIP1-Tag2 pancreatic insulinomas, an Ang-2 neutralising antibody administration did 
not reduce the recruitment of Tie-2+ TAMs but instead, prevented their binding to 
Ang-2 on activated endothelial cells subsequently decreasing angiogenesis and 
tumour progression (Mazzieri et al., 2011). CSF-1R inhibition increased the efficacy 
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of anti-VEGFR-2 anti-angiogenic therapy in a mouse model of Lewis lung carcinoma 
(Priceman et al., 2010). M2 TAMs produce IL-10 at the tumour site leading to 
resistance of breast cancer to paclitaxel treatment and this resistance can be 
abrogated with the administration of an IL-10 neutralising antibody (Yang et al., 2015) 
(Fig 1.5). TAMs in glioblastoma have been shown to regulate resistance to CSF-1R 
inhibition through the production of IGF upregulating PI3K signalling in tumour cells, 
however this effect was abrogated through the blockade of IGF-1 receptor signalling 
with IGF-1R inhibitors (Quail et al., 2016) (Fig 1.5).  
 
It is currently unclear whether CAFs play a supportive or restrictive role in tumour 
progression. Based on the correlation between a large desmoplastic reaction and 
poor patient outcome it was hypothesised that ablation of the myofibroblasts would 
improve therapy response and decrease tumour growth. Shh is overexpressed by 
neoplastic PDAC cells (Thayer et al., 2003), stimulating Gli activity in surrounding 
fibroblasts and triggering their activation (Tian et al., 2009). Therefore, Shh became 
a target to inhibit fibroblast activation and Shh inhibition initially showed promising 
results in a preclinical PDAC mouse models. Shh inhibition reduced fibrosis and 
increased tumour vascularization, improving the delivery of gemcitabine to PDAC 
tumours (Olive et al., 2009). However, a clinical trial of Saridegib, a Shh inhibitor, with 
gemcitabine, in metastatic PDAC patients, failed at phase II as patients had reduced 
survival (Madden, 2012). Further investigation into fibroblast function in PDAC in 
longer-term experiments with mouse PDAC models showed that fibroblast ablation 
using smoothened inhibitor or genetic depletion of Shh or αSMA+ myofibroblasts, in 
fact showed that the stroma restrained tumour growth and metastasis (Rhim et al., 
2014, Oezdemir et al., 2014).  These conflicting results, combined with the emerging 
evidence that different CAF populations co-exist in tumours, suggest that different 
CAF populations may have different and possibly opposing effects in cancer 
progression (Ohlund et al., 2017, Costa et al., 2018). Despite these results, a phase 
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3 trial in medulloblastoma, using an oral sonidegib (smoothened inhibitor) in 
combination with temozolomide showed promising results with an objective response 
rate of 18.8 % (ClinicalTrial.gov identifier: NCT01708174).   
 
One approach which warrants further investigation is the reprogramming of the 
activated CAFs back into their quiescent state. This approach has seen some success 
in PDAC mouse models using calcipotriol (vitamin D analogue) which reverts 
myofibroblasts to quiescence, reducing the desmoplastic reaction which in turn 
improves gemcitabine delivery (Sherman et al., 2014).  In 3D models and genetic 
mouse models of PDAC the use of all-trans retinoic acid to restore the quiescence of 
stellate cells increased vascularity, resulting in increased response to gemcitabine 
and reduced tumour growth (Carapuca et al., 2016). In estrogen receptor positive 
breast cancer, CAF-derived FGF-2 promotes resistance to anti-estrogens which is 
abrogated with administration of an FGF-2 neutralising antibody (Shee et al., 2018) 
(Fig 1.5). 
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1.9 Pancreatic cancer 
1.9.1 Pancreas anatomy and physiology  
The pancreas is situated within the abdominal cavity and is located behind the 
stomach. It is a glandular organ functioning as part of the digestive system, regulating 
and aiding the digestion of proteins and carbohydrates, as well as mediating glucose 
homeostasis (Standring et al., 2005).  
 
Figure 1.5 Therapeutic strategies to overcome chemoresistance mediated 
by TAMs and CAFs 
CAFs: Reprogramming activated CAFs back towards a quiescent phenotype by 
anti-smoothened (Smo), anti-sonic hedgehog (Shh), all-trans retinoic acid and 
calcipotriol (vitamin D analogue) while fibroblast growth factor 2 (FGF2) targeting 
agents prevents resistance of tumour cells to anti-estrogens in breast cancer. 
TAMs: Repolarizing M2 macrophages back to an M1-like phenotype can be 
mediated by a CD40 agonist. Prevention of macrophage recruitment to tumour 
sites is currently being achieved by targeting the colony-stimulating factor 1 (CSF-
1) and C-C motif chemokine 2 (CCL2) signalling axis. Anti-angiopoietin-2 (Ang-2) 
antibodies prevent TAM interaction with blood vessels. IL-10 produced by TAMs 
promotes chemoresistance which can be abrogated by treatment with anti-IL-10 
antibodies. TAMs secrete insulin-like growth factor 1 (IGF-1) promoted survival in 
glioblastoma, blockade with IGF-1R inhibitor decreased tumour growth. 
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Anatomically the pancreas is separated into three sections: head, body and tail. The 
head of the pancreas is situated adjacent to the duodenum and the body, which is the 
largest part of the pancreas, is situated beneath the stomach (Fig 1.6). Finally, the tail 
of the pancreas extends to the left, neighbouring the hilum of the spleen (Fig 1.6). The 
head of the pancreas receives its blood supply through both the superior mesenteric 
and coeliac arteries. The splenic artery runs along the top of the pancreas and 
supplies the whole organ through its branching network. Due to its size, the different 
pancreas sections drain into specific veins; the body and neck sections drain into the 
splenic vein, and the pancreas head drains into the superior mesenteric and portal 
veins (Standring et al., 2005). 
 
The pancreas performs both endocrine and exocrine functions. Endocrine units called 
the Islets of Langerhans produce of insulin and glucagon hormones which regulate 
blood sugar levels (Hezel et al., 2006). The other 80 % of the pancreas performs the 
 
Figure 1.6 Anatomy of pancreas within the abdomen 
The pancreas is located below the liver and the stomach in the abdomen. The 
head of the pancreas is abutted in the duodenum and the tail extends out towards 
the spleen. The bile duct from the liver and the pancreatic duct converge at the 
duodenum creating the ampulla of Vater to deliver digestive enzymes.  
Gall 
bladder 
Liver
SpleenPancreas
Stomach
Pancreatic
duct
Duodenum
Ampulla of 
vater
Bile duct
Chapter One 
32 
 
exocrine function, producing and delivering zymogen digestive enzymes to the 
duodenum and intestinal tract (Hezel et al., 2006). A branching network of acinar and 
ductal cells is present throughout the pancreas which culminate at the pancreatic duct. 
Zymogens released by acinar cells are channelled into the duodenum, along with bile, 
through the ampulla of Vater to aid digestion (Standring et al., 2005) (Fig 1.6).  
 
1.9.2 Non-invasive precursor lesions 
Malignancy in the pancreas begins as a non-invasive precursor lesions, most 
commonly pancreatic intraepithelial neoplasia (PanIN) and less commonly intraductal 
papillary mucinous neoplasm (IPMN) or mucinous cystic neoplasm (MCN) (Cooper et 
al., 2013). As genomic instability increases, and further oncogenic mutations are 
acquired, these precursor lesions progress into pancreatic ductal adenocarcinoma 
(PDAC) (Hezel et al., 2006, Hruban et al., 2007).  
 
PanINs have three defined histological stages which mark the development of 
malignancy and the accumulation of genetic alterations. PanIN development begins 
with the reprogramming of acini and ductal cells causing them to lose their cellular 
identity (Fig 1.7) (Morris et al., 2010). At PanIN stage 1, it is estimated that 15-40 % 
of lesions acquire oncogenic Kirsten rat sarcoma viral oncogene homologG12D 
(KrasG12D) mutation, triggering its constitutive activation resulting in enhanced cell 
proliferation (Aguirre et al., 2003) (Fig 1.7). Another common mutation seen at PanIN 
stage 1 is the inactivation of INK4a tumour suppressor gene which usually functions 
as a cyclin-dependent kinase inhibitor, therefore, at this stage control of the cell cycle 
is lost (Morris et al., 2010, Aguirre et al., 2003) (Fig 1.7). PanIN stage 3 is most likely 
to possess inactivating P53 mutations promoting evasion of apoptosis and preventing 
growth arrest in PanIN cells (Bailey et al., 2016, Morton et al., 2010). Around 53 % of 
PanINs possess Mothers against decapentaplegic homolog 4 (SMAD4) aberrations 
by stage 3 (Hansel et al., 2003, Maitra et al., 2003) (Fig 1.7). The loss of SMAD4 
Chapter One 
33 
 
results in aberrant TGFß signalling leading to increased growth stimulation and 
reduced apoptosis cues (Furukawa et al., 2006, Duda et al., 2003) 
 
 
1.9.3 Pancreatic ductal adenocarcinoma (PDAC) 
PDAC is the 11th most prevalent form of cancer in the UK, with a 5 year survival rate 
of <7 % (Siegel et al., 2017). Establishment of PDAC in the pancreas can take up to 
ten years from non-invasive precursor lesions to a fully developed malignancy with 
established metastatic outgrowth (Yachida et al., 2010).  Despite this long latency 
period, PDAC accounts for >85 % of pancreatic cancers detected (Li et al., 2004). Its 
nomenclature is based on histology studies which revealed PDAC grows with a ductal 
 
Figure 1.7 PDAC initiation and progression 
The onset of PanIN development begins with reprogramming of acini and ductal 
cells through ductal reprogramming. PanIN stage 1 starts to form as the cells 
acquire KRas and INK4a mutations and cell morphology begins to alter. PanIN 
stage 2 shows cells with a loss of polarity and enlarged nuclei. PanIN stage 3 
acquires P53 and SMAD4 mutations with the cell clustered to form lumens. Stage 
3 leads to the development of pancreatic ductal adenocarcinoma (PDAC) with 
atypical neoplastic cells creating a lumen. Adapted from Morris et al., 2010. 
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morphology despite arising in acini or ductal cells (Humphris et al., 2014). PDAC 
occurs in the head of the pancreas in around 60-70 % of patients, a 20 % incidence 
in the pancreas body and 10-20 % of cases are spread diffusely throughout the 
pancreas (Humphris et al., 2014). The PDAC TME consists of a rich desmoplastic 
reaction comprised of myofibroblasts which can account for up to 80 % of the tumour 
mass along with infiltrating immune cells especially macrophages (Gunderson et al., 
2016). 
 
PDAC is often described as asymptomatic for the majority of the disease, however, 
this view is now changing with the discovery of type 3c diabetes mellitus caused by 
chronic pancreatitis and pancreatic cancer (Hart et al., 2016). Tumour growth often 
results in the obstruction of the common bile duct and pancreatic duct leading to 
jaundice and steatorrhoea respectively, usually resulting in tumour detection (Porta et 
al., 2005). A tumour mass arising in the head of the pancreas will require less time to 
create an obstruction than those lesions developed in the body and tail. This implies 
tumours in the body and tail of the pancreas may be more advanced when detected 
(Porta et al., 2005).   
 
1.9.4 Risk factors  
PDAC is known to carry a familial risk. It has been reported that PDAC sufferers in 
families with ≥ 2 affected first degree relatives represent 10% of all PDAC cases (Shi 
et al., 2009). Other risk factors for the development of PDAC include smoking, high 
alcohol usage, obesity with a BMI >35, chronic pancreatitis, diabetes mellitus and 
being of the male gender (Vincent et al., 2011, Kleeff et al., 2016).  
 
1.9.5 PDAC metastasis  
Due to the late detection of PDAC, it is characterised by a high rate of metastasis. 
Disseminated tumour cells from the primary mass travel through the lymphatic and 
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vascular systems to the liver and lungs. As the primary tumour grows, it penetrates 
the peritoneal cavity and spreads into the spleen (Humphris et al., 2014, Pandol et 
al., 2009). Detection and diagnosis are typically a consequence of symptoms of 
metastasis. Once the tumour has metastasised to the lungs patients will often 
experience breathing difficulties and metastatic outgrowth in the liver can lead to 
jaundice which usually results more invasive investigation and often will lead to a 
PDAC diagnosis (Claire et al., 2016).   
 
Molecular aberrations acquired during PanIN progression and PDAC development 
have been shown to play key functions in metastasis. Mutated KRasG12D promotes 
migration of tumour cells whilst permitting survival in low-nutrient conditions which are 
often encountered during initial movement and seeding of metastatic cells (Qiu et al., 
2011). Cells possessing Kras and INK4a mutations can promote NF-ҡB signalling  
promoting metastasis to liver and lungs in genetic PDAC mouse models (Aguirre et 
al., 2003). SMAD4 mutations specifically correlate with a higher metastatic burden 
(Iacobuzio-Donahue et al., 2009). 
 
1.9.6 PDAC treatment  
Treatment options for PDAC sufferers are limited due to the advanced nature of the 
disease at the time of diagnosis and the lack of effective chemotherapeutic agents. 
Approximately 20 % of patients are deemed viable for tumour resection, which along 
with adjuvant chemotherapy is the only potentially curative treatment available at this 
time. Despite this, it has been reported that many patients experience recurrence of 
the disease within a year of surgery, largely due to undetected micro-metastasis 
present in the body and/or the development of drug resistance during treatment 
(Labori et al., 2016). Resectable patients undergo a procedure to remove the primary 
lesion and a portion of the surrounding tissue.  Borderline resectable patients are 
treated with neoadjuvant chemotherapy to shrink the tumour and are restaged before 
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proceeding. The majority of PDAC patients possess unresectable disease and are 
offered chemotherapy treatment which has shown low rates of prolonged survival 
(Spanheimer et al., 2014). 
 
Gemcitabine chemotherapy administration is utilised for metastatic and locally 
advanced PDAC patients. Despite being the standard agent of care, gemcitabine has 
only a very modest effect, increasing survival of patients to 5.65 months compared to 
4.41 months of untreated patients (Burris et al., 1997). Limited improvement is seen 
as initially gemcitabine-susceptible tumours become resistant within mere weeks of 
treatment (Kim and Gallick, 2008).  Exactly how this occurs, and the role of the TME 
in chemoresistance is still under investigation.   
 
 A new regimen combining leucovorin, fluorouracil, irinotecan and oxaliplatin anti-
neoplastic agents (FOLFIRINOX) has been studied in phase III trials in comparison 
to single agent gemcitabine. Median overall survival of FOLFIRINOX treated patients 
was increased to 11.1 months compared to 6.8 months of the gemcitabine group (p < 
0.001). Despite this, median progression free survival with FOLFIRINOX was only 3.1 
months longer than gemcitabine (Conroy et al., 2011). Although FOLFIRINOX 
provided a slightly increased survival time, its administration resulted in a significant 
number of frequent substantial toxicities compared to gemcitabine, thus limiting its 
administration (Conroy et al., 2011). 
 
Albumin-bound paclitaxel (nab-paclitaxel) has shown promise as part of a multi-drug 
regimen in combination with FOLFIRINOX , shown in one study  to convert > 20 % of 
locally advanced PDAC patients to resectable status (Faris et al., 2013). Nab-
paclitaxel has also been trialled in combination with gemcitabine versus gemcitabine 
single agent. Nab-paclitaxel treatment increased median overall survival by 1.8 
months (Von Hoff et al., 2011). Adverse events such as myelosuppression and 
Chapter One 
37 
 
peripheral neuropathy were increased with nab-paclitaxel administration, restricting 
its use in the clinic (Von Hoff et al., 2011). 
 
1.9.7 PDAC mouse models  
The first model to faithfully reproduce human PDAC disease progression was the KC 
model, using a knock-in KRasG12D mutated oncogene in pancreatic lineages during 
embryonic development. KC mice were created by conditional KRasG12D mutation 
flanked by floxed STOP transcriptional cassette (LSL-KRasG12D) crossed with mice 
expressing Cre recombinase under control of Pdx1 promoter creating Pdx1-Cre;LSL-
KRasG12D (Hingorani et al., 2003).  These KC mice have been extensively 
characterised and exhibit the full extent of PDAC development including the complete 
spectrum of PanIN lesions which occur in human patients (Hingorani et al., 2003).  
Further development of this model to fully recapitulate the invasive and metastatic 
nature of PDAC was achieved in the KPC mouse model (LSL-KrasG12D/+; LSL-
Trp53R172H/+; Pdx-1-Cre) (Hingorani et al., 2005). The KPC mouse model 
incorporated the conditionally expressed point mutation in P53R175H a mutant allele of 
the Li-Fraumeni human ortholog and routinely show full penetrance of PDAC 
metastasis (Olive et al., 2004).    
 
1.10 Breast cancer 
1.10.1 Breast anatomy and physiology 
The breast is located above the ribcage and is situated on top of the pectoralis major 
muscle (Fig 1.8). The female breast is largely comprised of adipose and fibrous tissue 
which is penetrated by epithelial lobules. These lobules create to ductal networks 
leading to the nipple (Fig 1.8). This ductal structure is determined by the breasts 
function in milk production during lactation. When stimulated, epithelial cells secrete 
milk which travels through the network to the nipple. It is in these lobules and terminal 
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ducts in which cancer commonly arises (Fig 1.8). The male breast is also comprised 
of adipose and fibrous tissue but lacks lobules due to a lack of physiological need 
(Pandya and Moore, 2011).  The internal mammary artery runs underneath the breast 
and serves as the blood supply for the breast tissue. Lymphatic vessels drain the 
tissue and flow either to internal mammary lymph nodes or towards the axillary lymph 
nodes (Pandya and Moore, 2011). 
  
 
1.10.2 Breast cancer subtypes 
Breast cancer is the leading cause of cancer death in females worldwide, predicted 
to create 268,670 new cases and cause 41,400 deaths in the United States in 2018 
(Siegel et al., 2017).  Subtype nomenclature relays to the invasive nature of the breast 
 
 
Figure 1.8 Breast anatomy  
The breast is located on top of the rib cage and pectoralis major muscle. The 
majority of the breast tissue is comprised of adipose and fibrous tissue. Lobules 
running throughout the breast are comprised of milk-producing alveoli connected 
to extralobular ducts which ultimately culminate at the nipple delivery milk secretion.  
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cancer and presence of receptors on the tumour cells. Non-invasive breast cancer is 
usually located within the ducts of the breast and lacks the ability to spread further. 
Invasive breast cancer is the most common type of breast cancer identified and has 
the potential to disseminate out from the breast tissue (Dai et al., 2015).  A further 
three subtypes are defined based on molecular markers present on the tumour cells; 
hormone receptor positive (HR+) tumours which express estrogen (ER) and 
progesterone receptors (PR), HER2+ tumours (also HR-) and TNBC which is ER-, 
PR- and HER2- (Dai et al., 2015).   
 
TNBC is a highly metastatic subtype that accounts for approximately 20 % of all breast 
cancer cases (Wahba and El-Hadaad, 2015). Overall TNBC has the poorest 
prognosis compared to other subtypes with a shorter progression free survival, higher 
risk of relapse and a lack of specific targeted treatment options (Chacon and 
Costanzo, 2010). TNBC is associated with younger women and a higher grade of 
tumour however this does not seem to impact the rate of women which elect to have 
their tumours surgically removed (Freedman et al., 2009). 
 
Breast cancer begins with the development of atypical breast hyperplasia as a 
collection of abnormal yet benign cells, usually in a terminal duct. Accumulation of 
genetic aberrations in genes such as BRCA1 and BRCA2 tumour suppressor genes 
prompts the development of ductal carcinoma in situ (DCIS) contained within the 
ducts in 60-80 % of women. DCIS is described as a non-obligate precursor to invasive 
cancer, which occurs in 40% of patients (Sanders et al., 2005). The symptoms of 
breast cancer can vary and are not specific to subtype (Rivenbark et al., 2013). They 
generally include an area of thickened tissue in the breast, pain in armpit or breast, 
pitting or redness of the skin and a change in size or shape of the breast (McPherson 
et al., 2000).  
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1.10.3 Risk factors  
Risk factors for developing breast cancer including aging, with most patients 
diagnosed over 50 years of age. A family history of breast cancer is associated with 
an increased risk, especially when linked to genes such as BRCA1 and BRCA2. ER+ 
breast cancer is promoted by estrogen therefore an early age of menstruation, 
pregnancy late in life or no pregnancy at all or starting menopause after the age of 55 
can all influence tumour development. In the same vein, use of oral contraceptives or 
the use of combination hormone treatment for menopause has also been linked to an 
increased risk of breast cancer.  Other risk factors are common to most types of 
cancer and include excessive alcohol consumption, obesity and lack of physical 
activity (McPherson et al., 2000, Garcia-Closas et al., 2006, Howell et al., 2014). 
 
1.10.4 Breast cancer metastasis 
Breast cancer has a propensity to give rise to metastasis in lungs, bones and brain, 
which can present up to ten years after treatment (Weigelt et al., 2005). However, 10-
15 % of breast cancer patients develop metastasis within 3 years of primary tumour 
detection (Weigelt et al., 2005). Migrating tumour cells are often detected in axillary 
lymph nodes due to lymphatic drainage (Blackburn et al., 2017).  
 
1.10.5 Breast cancer treatment  
Breast cancer screenings are now performed for women aged 50-70 years. 
Mammograms image the breast tissue to identify cancerous lesions even before 
symptoms appear visible. If a mass is detected, patients receive adjuvant 
chemotherapy, however this treatment only produces a 3 % increase of 15-year 
survival rate in women aged >50 years (Abe et al., 2005). 
 
For HR+ breast cancers (ER+ and PR+), hormone therapy is used to prevent the 
stimulation of estrogen signalling on cancer cells. Tamoxifen administration blocks 
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estrogen receptor binding and is used for the first line treatment of HR+ tumours. 
However, when patients become resistant to tamoxifen administration and a second 
treatment option of Fulvestrant is used to block the estrogen receptor. Administration 
studies of tamoxifen responders have shown receiving tamoxifen for 10 years post-
initial treatment, reduced both breast cancer recurrence and mortality (Davies et al., 
2013a).  
 
HER2+ breast cancers are usually treated with trastuzumab, a monoclonal antibody 
specific to the HER2 receptor, to block downstream signalling. Trastuzumab also 
binds and flags the tumour cell for destruction by the immune system. Studies of 
trastuzumab administration have shown improved survival for HER2+ metastatic 
patients when treated with trastuzumab in combination with chemotherapy, such as 
docetaxel (Inoue et al., 2011). 
 
Treatment of TNBC is problematic as it completely lacks the receptors for which many 
drugs have been developed such as trastuzumab or hormonal-based therapies 
(Bauer et al., 2007). Therefore, the treatment of metastatic TNBC includes 
radiotherapy and chemotherapy such as paclitaxel, as the standard of care, or 
docetaxel (Rakha et al., 2007, Schneider et al., 2008). Metastatic TNBC patients often 
become resistant to current chemotherapy treatments and as a result account for >90 
% of breast cancer deaths (Marquette and Nabell, 2012). This highlights the need for 
new therapeutic targets to treat metastatic burden more effectively, especially that of 
TNBC. 
 
1.10.6 Mouse models of TNBC 
Invasive TNBC mouse models have been developed to recapitulate the human 
disease for use in scientific research. One such model uses mouse mammary tumour 
virus (MMTV) long terminal repeat (LTR) to drive the expression of mammary gland 
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specific polyomavirus middle T-antigen (PyMT). Expression of the middle T antigen 
results in the appearance of multifocal tumours in the mammary gland epithelium. 
Along with primary site tumours, the MMTV-PyMT mice also exhibit pulmonary 
metastasis. Py230 tumour cells isolated from this model have been identified as HR 
negative and HER2 low expression (Guy et al., 1992, Davie et al., 2007).  
 
Orthotopic implantation of mammary cancer cells into syngeneic mice has also been 
shown to recapitulate the human disease. 4T1 mammary tumour cells were originally 
isolated from subpopulation 410.4 derived from a spontaneously arising mammary 
tumour in BALB/cfC3H mice (Dexter et al., 1978). Implantation of 4T1 cells into the 
mammary fatpad of BALB/c mice has been shown to create a primary tumour similar 
to the human disease along with metastasis the lung (Pulaski and Ostrand-
Rosenberg, 1998).  
 
1.11 Insulin and Insulin-like Growth Factor (IGF) signalling  
The IGF and insulin signalling axis is comprised of three ligands: insulin, IGF-1 and 
IGF-2. These ligands bind to members of the receptor tyrosine kinase (RTK) family: 
IGF-1 receptor (IGF-1R), IGF-2 receptor (IGF-2R) and the insulin receptor (InsR) with 
varying degrees of affinity (Fig 1.9).  IGF-1 and IGF-2 ligands bind primarily to IGF-
1R which is expressed in almost every tissue (Bailyes et al., 1997, Federici et al., 
1997). IGF-2R is generally regarded as a decoy receptor with no downstream 
signalling which binds and sequesters IGF-2 (Pollak, 2008). The InsR exists in two 
forms: InsR-A and InsR-B. InsR-B splice variant includes exon 11 and mediates 
glucose metabolism through the exclusive binding of insulin. InsR-A lacks exon 11 
and can bind to all three ligands (Haeusler et al., 2018). To add further complexity, 
40-90 % of IGF-1R exist as a hemi-receptor combined with either InsR-A or InsR-B. 
These hemi-receptors are bound by IGF-1 and IGF-2 with higher affinity than InsR-A 
(Fig 1.9) (Bailyes et al., 1997, Federici et al., 1997).  
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1.11.1 Downstream signalling  
InsR-A, IGF-1R and IGF:InsR hemi-receptors mediate a variety of downstream 
signalling pathways. Upon ligand binding, IGF-1R and InsR undergo 
autophosphorylation and subsequently phosphorylate and activate downstream 
insulin receptor substrate 1 or insulin receptor substrate 2 (IRS1, IRS2). IRS1 and 
IRS2 function to increase and activate downstream PI3K and protein kinase B (AKT) 
(Zha and Lackner, 2010).  Through AKT activation IGF signalling mediates a variety 
of pathways to prevent cell death, including resisting apoptosis via the release of B-
cell lymphoma 2 (Bcl-2), promotion of glucose metabolism through the inhibition of 
Glycogen synthase kinase-3 (GSK-3) and the activation of protein synthesis by 
mechanistic target of rapamycin (mTOR) activation (Baserga, 1999).  
Another activated pathway signals through SHC-transforming protein (Shc) and 
growth factor receptor associated protein 2 (Grb2) which in turn activate the 
Ras/Raf/MAPK signalling axis  stimulating cellular proliferation (Pollak, 2008, Greer 
and Brunet, 2005).  Downstream signalling specific to the insulin receptor mediates 
 
Figure 1.9 IGF and insulin ligands and receptors  
IGF-1 and IGF-2 can bind to IGF-1R, InsR-A, IGF-1R: InsR-A hemi-receptor and IGF-
1R: Ins-B hemi-receptor with varying affinity. Insulin ligand can bind InsR-A, InsR-B 
and IGF-1R: InsR-A hemi-receptor. IGF-2R can only bind IGF-2.  
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glucose metabolism through PI3K associated mechanisms and the upregulation of 
glucose transporter Glut4 (Chang et al., 2004).  
 
1.11.2 IGF/insulin function in normal tissues  
As previously outlined, IGF signalling can regulate cell survival and has been shown 
to play a critical role in embryogenesis and tissue changes during puberty 
(Agrogiannis et al., 2014). IGF mediated promotion of cell survival can also interrupt 
programmed cell death mechanisms (Vincent and Feldman, 2002). Expression levels 
of IGF-1R correlate with induction of apoptosis; lower expression is detected in cells 
more susceptible to programmed cell death (Resnicoff et al., 1995). In normal tissues, 
InsR signalling functions to regulate glucose homeostasis by reducing the release and 
production of glucose therefore regulating blood glucose levels as well as mediating 
cell growth and differentiation (Chang et al., 2004).  
 
1.11.3 IGF in PDAC  
IGF signalling has been implicated in the progression of many cancers but also in 
mediating chemoresistance (Denduluri et al., 2015). The pancreas has a sufficient 
supply of ligands due to  insulin  production by ß cells in the islets of Langerhans in 
the pancreas and the production of IGF-1 and IGF-2 in the liver in response to growth 
hormone stimulation (Pollak, 2012).  Based on this knowledge, it is unsurprising that 
IGF-1R has been reported as highly expressed in PDAC and IGF signalling could 
affect the basal growth of tumour cells (Bergmann et al., 1995, Ohmura et al., 1990). 
In fact, IGF-1R co-expression with epidermal growth factor receptor (EGFR) 
significantly correlates with poorer survival in PDAC patients (Valsecchi et al., 2012).  
Research into the role of IGF in the TME is now beginning to emerge, recently it was 
discovered fibroblasts exposed to pancreatic cancer cells secrete IGF, leading to 
pancreatic cancer cell survival and proliferation in vitro (Tape et al., 2016).  However, 
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research into the effect of stromal IGF signalling and chemoresistance has been 
lacking in PDAC and requires further elucidation. 
 
1.11.4 IGF in breast cancer  
The IGF signalling axis has also been implicated in the promotion of breast cancer 
(Zhang et al., 2011, Denduluri et al., 2015, Pollak, 2012). Interestingly, IGF signalling 
has also been implicated in acquisition of resistance to ER and HER2 inhibition (Lu et 
al., 2001, Massarweh et al., 2008, Farabaugh et al., 2015). Of particular interest, it 
has been shown that tamoxifen ER+ cells possess a reduced number of IGF-1R, 
despite this InsR and AKT activation is unaltered with insulin and IGF-2 stimulation 
(Fagan et al., 2012). This report indicates both IGF-1 and IGF-2 signalling may 
support resistance of breast cancer cells to therapies (Fagan et al., 2012). Despite 
these insights, the role of IGF signalling in tumour progression and resistance to 
chemotherapy in breast cancer is not yet completely understood. IGF signalling has 
been shown to play a role in TNBC cancer. A panel of TNBC cell lines were shown to 
express IGF receptors and that stimulation with IGF-1 increases proliferation and 
promotes cell survival (Davison et al., 2011). However, the role of IGF signalling in 
chemoresistance seen in TNBC has yet to be investigated.  
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1.12 Aims of thesis 
The aims of this thesis are:  
1) to investigate the mechanisms of chemoresistance in PDAC and breast cancer 
mediated by the TME;  
2) to identify specific molecules for targeting in preclinical models for use in 
combination with standard chemotherapeutic agents;  
3) to identify factors that promote pancreatic cancer metastasis in preclinical models. 
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2.1 Primary cells  
2.1.1 Generation of primary KPC-derived pancreatic cancer cells 
The murine pancreatic cancer cells KPC 3.5, FC1199, FC1242 and FC1245 were 
generated in the Tuveson lab (Cold Spring Harbor Laboratory, New York, USA). The 
cells were isolated from PDAC tumour tissues from LSL-KRasG12D; LSL-Trp53R172H; 
Pdx1-Cre (KPC) mice of a pure C57BL/6J background. Pancreatic tumours were 
harvested from KPC mice; a 3 mm3  fragment of PDAC was excised, washed in 10 mL 
phosphate buffered saline (PBS), and finely diced with sterile razors. Tissues were 
incubated in 10 mL collagenase type V solution (2 mg/mL in Dulbecco’s modified 
eagle medium (DMEM, Sigma Aldrich)) at 37 °C for 45 min with mixing to digest. Cells 
were centrifuged (300 x g) and resuspended in DMEM supplemented with 10 % foetal 
bovine serum (FBS, Sigma Aldrich) and 1 % penicillin/streptomycin (Sigma Aldrich) 
and plated in tissue culture treated plates. Cells were initially split at high dilutions 
(1:20 to 1:100) to dilute out contaminating stromal cells which do not tolerate 
aggressive splitting, whilst the cancer cells formed ductal-like colonies (Olive et al., 
2009). 
 
2.1.2 Generation of primary PyMT-derived breast cancer cells 
Py230 cells (HR- and HER2 low) were generated in the Ellies lab (University of 
California San Diego, USA) and obtained from spontaneously arising tumours in 
MMTV-PyMT C57BL/6J female mice by serial trypsinization and limiting dilution 
(Gibby et al., 2012).  
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2.2 Cell lines 
All cells were authenticated, and periodically tested for mycoplasma contamination. 
2.2.1 Pancreatic ductal adenocarcinoma (PDAC) 
SUIT-2 and MIA-PaCa-2 human pancreatic cancer cell lines (both ATCC) were 
cultured in DMEM supplemented with 10 % FBS, 1 % penicillin/streptomycin, at 37 
oC, 5 % CO2 incubator.  
 
Murine KPC 3.5, FC1199, FC1242 and FC1245 cells were cultured in DMEM 
supplemented with 10 % FBS, 1 % penicillin/streptomycin, at 37 oC, 5 % CO2 
incubator. 
 
2.2.2 Breast cancer 
Murine 4T1 cells (ATCC) were cultured in Roswell Park Memorial Institute (RPMI-
1640) culture media (Life Technologies) supplemented with 10 % FBS, 1 % 
penicillin/streptomycin at 37 °C, in a 5 % CO2 incubator. 4T1 cells are characterised 
as ER−, PR−, HER2− (Kau et al., 2012). 
 
Murine Py230 cells were cultured in DMEM/F-12 culture media (Life Technologies) 
supplemented with 10 % FBS and 500 µL MITO serum extender (Corning), 1 % 
penicillin/ streptomycin at 37 °C, in a 5 % CO2 incubator.  
 
2.3 Generation of primary macrophages and primary pancreatic stellate cells 
2.3.1 Primary human macrophages 
Blood samples were taken from healthy human volunteers by a licensed phlebotomist. 
The blood was diluted 1:1 with MAC buffer (PBS (Ca2+, Mg2+ free, Life Technologies) 
+ 2 mM ethylenediaminetetraacetic acid (EDTA, Sigma Aldrich) + 0.5 % bovine serum 
albumin (BSA, Sigma Aldrich)). The blood/MAC buffer mix was layered on top of 12.5 
mL histopaque-1077 (Sigma Aldrich) in a 50 mL falcon tube and subjected to density 
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gradient centrifugation 270 x g for 25 min, 1 acceleration and 0 brake at room 
temperature (RT). The middle serum layer was removed to facilitate the harvesting of 
the buffy coat layer. The collected monolayer was subsequently washed with MAC 
buffer and centrifuged at 270 x g for 10 min at 4 oC. CD14b+ monocytes were purified 
from the samples using magnetic bead affinity chromatography according to 
manufacturer's directions (Miltenyi Biotec). The monocytes were incubated with 
RPMI-1640 containing 10 % FBS and 50 ng/mL recombinant human macrophage 
colony stimulating factor (mCSF) (PeproTech) for 5 days to mature the monocytes 
into macrophages.  
 
2.3.2 Primary murine macrophages 
Murine macrophages were generated by flushing bone marrow from the femur and 
tibia of C57BL/6J or mixed 129/SvJae/C57BL/6 (PC) mice and flow through collected 
into MAC buffer. The bone marrow isolated cells were pelleted by centrifugation at 
368 x g for 10 min at RT and the supernatant discarded. Red blood cells (RBC) were 
removed by a 5 min incubation with 5 mL RBC lysis buffer (Biolegend) and the 
reaction stopped with the addition of 10 mL of PBS. Leukocytes were pelleted by 
centrifugation at 368 x g for 10 min and the supernatant discarded. Monocytes were 
isolated through density gradient centrifugation by layering 5 mL leukocyte 
suspension on top of 4.5 mL histopaque-1083 (Sigma Aldrich) and centrifuged at 368 
x g for 25 min, 1 acceleration and 0 brake at RT. The monocytes were harvested from 
the buffy coat layer and subsequently washed in MAC buffer, counted and plated for 
5 days in DMEM containing 10 % FBS and 10 ng/mL murine mCSF (PeproTech) to 
promote macrophage differentiation.  
 
2.3.3 Primary pancreatic stellate cells (PaSCs) 
C57BL/6J mice were sacrificed via a schedule one method and pancreas extracted 
and placed in 0.9 % NaCl (Fisher Scientific) solution. Pancreas tissue was injected 
Chapter Two 
53 
 
with 1 mL enzyme mix (1.3 mg/mL collagenase D (Sigma Aldrich), 1 mg/mL protease 
from Streptomyces griseus (Sigma Aldrich) and 0.01 mg/mL DNase (Roche 
diagnostics)). The pancreas was then incubated in 10 mL enzyme mix in a 50 mL 
falcon tube at 37 oC and agitated at 240 rpm for 10 min and reduced to 120 rpm for 4 
min using in a shaking incubator (Incu-shaker mini, Benchmark). The tissue was finely 
minced using scalpels until it resembled a fine paste and then further incubated at 37 
oC for 7 min at 120 rpm agitation. The cells were pelleted at 500 x g for 10 min and 
subsequently washed in Gey’s balanced salt solution (GBSS, recipe in table 3.1). The 
cell solution was passed through a 500 µm mesh (Spectrum Labs) and washed again 
with 20 mL GBSS. The PaSCs were isolated from the cell mixture using density 
gradient centrifugation. The cells were resuspended in a mixture of 9.5 mL of GBSS 
and 8 mL 28.7 % nycodenz (Progen) and split evenly into two 15 mL falcon tubes and 
3 mL GBSS layered on top. Tubes were centrifuged at 1400 x g for 2 min at 4 oC with 
1 acceleration and 0 brake and PaSCs were harvested from the fuzzy layer. PaSCs 
were activated by culturing on uncoated plastic dishes with in Iscove's Modified 
Dulbecco's Medium (IMDM) (Sigma Aldrich) supplemented with 10 % FBS. 
Table 3.1 Gey’s Balanced Salt Solution (GBSS) recipe  
 
Reagent Weight(g/L) 
NaCl 7 
KCl 0.37 
MgCl2 ∙ 6H2O 0.210 
MgSO4 (anhydrous) 0.0342 
Na2HPO4 (anhydrous) 0.1196 
KH2PO4 (anhydrous) 0.030 
Glucose 1 
NaHCO3 2.27 
CaCl2 ∙ 2H2O 0.2252 
 
2.4 Generation of conditioned media (CM) 
2.4.1 Macrophage (MCM) and myofibroblast (MyoCM) conditioned media 
To generate macrophage (MCM) and myofibroblasts conditioned media (MyoCM), 
murine macrophages or activated PaSCs were plated to 70 % confluency in 10 cm 
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dishes, were washed twice with PBS and cultured in serum-free DMEM for 24 to 36 
hr. Supernatant was harvested and filtered to remove debris and dead cells using a 
0.22 µm syringe filter (Fisher Scientific) and stored at 4 oC until use.  
 
2.4.2 Tumour conditioned media (TCM) 
To generate KPC 3.5, FC1199, FC1242 and FC1245 conditioned media, 500,000 
cells were plated into 10 cm dishes and were cultured in serum-free DMEM for 24 to 
36 hr. Conditioned media was then processed as described in section 2.4.1.  
 
2.5 Treatment with chemotherapy, MCM, blocking antibodies, and recombinant 
IGF 
SUIT-2, MIA-PaCa-2, and KPC-derived cells were cultured in DMEM with 2 % FBS 
for 24 hr, pre-treated for 3 hr with MCM, or MyoCM, recombinant IGF (PeproTech 
100-11) at 100 ng/mL, or IGF-blocking antibody (Abcam 9572) at 10 mg/mL followed 
by gemcitabine (Sigma Aldrich G2463) at 200 nmol/L, nab-paclitaxel 10, 100, or 1,000 
nmol/L, paclitaxel (Sigma Aldrich T7402) at 200 nmol/L or 5-FU (Sigma Aldrich F6627) 
at 100 mmol/L. Cells were harvested after 24 to 36 hr and analyzed for cell death by 
annexin-V / propidium iodide staining kit (Affymetrix) and flow cytometry analysis. 
 
2.6 Cell cycle analysis  
KPC-derived pancreatic cancer cells were treated with isogenic mouse MCM, IGF 
blocking antibody (Abcam 9572) at 10 µg/mL or recombinant IGF (PeproTech 100-
11) at 100 ng/mL. Cells were harvested via trypsinisation and subsequently fixed with 
100 % ice-cold methanol (Sigma Aldrich) for 10-15 min. The cells were centrifuged at 
956 x g for 5 min. To remove RNA contamination, cells were treated with 10 μg/mL of 
RNase A (Sigma Aldrich) for 45 min at RT whilst being passed through an insulin 
syringe to ensure a single cell suspension.  Cells were mixed with PBS containing 10 
μg/mL of propidium iodide (Invitrogen) and subjected to flow cytometry analysis. 
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2.7 RTK array 
Performed by Dr. Ainhoa Mielgo 
Cells were either serum starved for 24 hr and treated with MCM for 2 hr, harvested, 
and lysed in radioimmunoprecipitation assay buffer (RIPA) (150 mmol/L NaCl, 10 
mmol/L Tris-HCl pH 7.2 (Sigma Aldrich), 0.1 % SDS (Fisher Scientific), 1 % Triton X-
100 (Sigma Aldrich), 5 mmol/L EDTA) supplemented with complete protease inhibitor 
mixture (Sigma Aldrich), Halt phosphatase inhibitor cocktail (Invitrogen), 1 mmol/L 
phenylmethylsufonylfluoride (Sigma Aldrich) and 0.2 mmol/L sodium orthovanadate 
(Sigma Aldrich).  Cell lysates were analyzed with the Phospho-RTK Array Kit (R&D 
Systems) according to manufacturer’s instructions.  
 
2.8 Syngeneic mouse models 
2.8.1 PDAC preclinical mouse models  
2.8.1.1 Pancreatic cancer orthotopic model 1 
1 x 106 primary FC1242 KPC-derived luciferase/zsGreen cells (luc/zsGreen) isolated 
from a pure C57BL/6J background, as previously described in section 2.1.1, were 
resuspended in 30 µL Corning growth factor reduced Matrigel Basement Membrane 
Matrix (VWR). The cells were injected into the tail of the pancreas of 
immunocompetent syngeneic C57BL/6J 6-8 week-old female mice. Tumours were 
established for one week before beginning treatment. Mice were dosed by 
intraperitoneal injection (i.p.) with gemcitabine (100 mg/kg) (Selleckchem), IGF-1/2 
blocking antibody xentuzumab (100 mg/kg) kindly provided by Boehringer Ingelheim, 
or IgG1 isotype control antibody (Abcam), every 2–3 days for 10–15 days before 
harvest.  
 
2.8.1.2 Pancreatic cancer orthotopic model 2 
Orthotopic pancreatic tumours were initiated by implanting 1 x 106 primary KPC-
derived cells in 30 µL Corning growth factor reduced Matrigel Basement Membrane 
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Matrix into the pancreas of immunocompetent syngeneic female 6-8 week-old mice 
on a mixed background 129/SvJae/C57BL/6J. As tumours in this model grow slower, 
tumours were established for three weeks before beginning treatment. 
 
2.8.1.3 Pancreatic cancer orthotopic model 3 
1 x 106 FC1199 luc/zsGreen, FC1242 luc/zsGreen or FC1245 luc/zsGreen cells from 
a pure C57BL/6J background, were injected in 30 µL Corning growth factor reduced 
Matrigel Basement Membrane Matrix into the tail of the pancreas in 
immunocompetent syngeneic C57BL/6J 6-8 week-old female mice. Tumours were left 
to grow until meeting humane endpoint point as dictated by project license restrictions, 
requiring culling by a schedule one method. Humane endpoint for the moderate study 
plan dictated as: 20 % weight loss, restrictions in movement, loss of appetite and 
dehydration. 
 
2.8.2 Invasive breast cancer preclinical model 
2.8.2.1 Syngeneic orthotopic breast cancer model 1 
2 x 106 Py230 luc/zsGreen labelled cells in 60 µL Corning growth factor reduced 
Matrigel Basement Membrane Matrix were injected into the fatpad of the third 
mammary gland of immunocompetent syngeneic C57BL/6J 6–8 week-old female 
mice.  
2.8.2.2 Syngeneic orthotopic breast cancer model 2  
5 x 105 4T1 luc/zsGreen labelled cells in 60 µL of Corning growth factor reduced 
Matrigel Basement Membrane Matrix were injected into the fatpad of the third 
mammary gland of syngeneic BALB/c 6–8 week-old female mice.  
 
Breast tumours were measured with calipers twice a week and treatment started when 
tumours measured between 5-8 mm2 mean diameter. Mice were administered i.p. 
with IgG isotype control antibody (Abcam), paclitaxel (100 mg/kg) (Sigma Aldrich), 
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IGF-1/2 blocking antibody xentuzumab (100 mg/kg) or paclitaxel with xentuzumab, 
twice a week for 15 days. At humane endpoint, primary tumours and lungs were 
harvested, imaged using IVIS spectrum technology (Perkin Elmer) and tissues were 
digested for FACS sorting and analysis or formalin-fixed and paraffin-embedded by 
Liverpool Tissue Bank. Humane endpoint for the moderate study plan dictated as 
tumour maximum of mean diameter of 1.5 cm for therapeutic studies (according to 
Workman et al., 2010), 20% emaciation, limited movement and ulceration.  
 
2.9 IVIS spectral imaging  
IVIS spectral imaging of bioluminescence was used for orthotopically implanted 
tumour cells expressing firefly luciferase using IVIS spectrum system (Caliper Life 
Sciences). In vivo imaging of tumours required i.p. injection of 200 µL D-luciferin 
dissolved in PBS (150 mg/kg, PerkinElmer) with an incubation time of 10 min. Animals 
were anaesthetised and imaged using automated optimal exposure for 1 min. Organs 
were resected for ex vivo imaging coated in 100 µL D-luciferin for 1 min and imaged 
for 1 min at automated optimal exposure.  
 
The luciferase-generated light emitted from organs was measured by Living Image 
software (PerkinElmer). A region of interest (ROI) was drawn around the entire organ 
to calculate photons and area size. Normalisation of photon values was performed to 
abrogate differences in fields of view and times of acquisition. Relative 
bioluminescence signal was calculated using photon per second mode in the living 
image software normalising to imaging area (total flux) as recommended by the 
manufacturer.   
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2.10 Hematoxylin and Eosin (H&E) staining 
Formalin fixed and paraffin embedded (FFPE) tissues generated by Liverpool Tissue 
Bank were sectioned at 4 µm thickness and processed through hydration, H&E 
staining and dehydration steps (Table 3.2). 
Table 3.2 H&E staining steps and incubation times 
Hydration 
Step Solution Time 
1 Xylene  5 mins  
2 100% ethanol x 3 20 secs 
3 95% ethanol 20 secs 
4 80% ethanol 20 secs 
5 70% ethanol 20 secs 
6 Tap water 2 mins 
H&E 
1 Haematoxylin  10 mins 
2 Tap water 20 secs 
3 1% Acid alcohol 5 secs 
4 Scott’s Tap Water 2 mins 
5 Eosin 2 mins pancreas 
3 min liver/lung 
6 Tap water Till water runs clear 
Dehydration  
1 70% ethanol 1min 
2 80% ethanol 1min 
3 95% ethanol 1min 
4 Absolute ethanol 1min X 3 
5 Xylene 3 mins X 2 
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All reagents listed above from Sigma Aldrich 
Acid alcohol: 1 mL Hydrochloric acid (Thermo Fisher), 50 mL 70 % Ethanol  
Eosin: 1 g Eosin Y (Sigma Aldrich), 20 mL distilled water (dH2O), 80 mL 100% Ethanol 
 
2.11 Identification and quantification metastatic burden  
FFPE lungs were serially sectioned through the entire lung using microtome at 4-5 
µm thickness. Sections were stained with H&E and images were taken using a Zeiss 
Observer Z1 Microscope (Zeiss) to identify foci. The number of foci were counted, 
and total area of metastatic foci were measured using Zen imaging software. 
Metastatic burden was calculated by the following equations: 
No. of foci per 100 mm2: (Average no. foci per section/ average tissue area per 
section (mm2)) *100 
Average metastatic lesion size (mm2): Average total area of metastasis (mm2)/ 
average number of foci per section 
Total metastatic burden: Sum of area of each foci of each section 
 
2.12 Immunoblotting of protein lysates 
Cells were harvested and lysed in RIPA buffer supplemented with a complete 
protease inhibitor mixture, a phosphatase inhibitor cocktail, 1 mmol/L 
phenylmethylsufonylfluoride and 0.2 mmol/L sodium orthovanadate. Protein lysate 
concentrations were quantified using a bicinchoninic acid (BCA) assay (Pierce). 
Samples were made to 1 µg/µL with 3x loading buffer (187.5 mM Tris base, 9 % SDS, 
30 % glycerol, 0.05 % bromophenol blue and 10 % β-mercaptoethanol (all Sigma 
Aldrich)), heated to 95 oC for 10 min and run on SDS-PAGE gels. Proteins were 
transferred onto polyvinylidene fluoride (PVDF) membranes (Bio-Rad) using a 
transblot turbo (Bio-Rad) and blocked 1 hr with either 5 % non-fat dry milk (NFDM) or 
BSA depending on antibody requirements. Membranes were incubated with primary 
antibodies overnight rocking at 4 oC. Membranes were washed three times for 10 min 
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in tris-buffered saline with Tween 20 (TBS-T) and incubated with their corresponding 
secondary antibodies for 1 hr rocking at RT. Membranes were imaged in a dark room 
using X-ray film or using ChemiDoc imaging system (Bio-Rad). Antibodies used in 
these experiments are listed in appendix (i). 
 
2.12.1 Immunoblotting of secreted proteins  
Proteins from CM were concentrated using StrataClean Resin (Agilent Technologies). 
10 µL of strataclean resin was used per sample and 1 mL of CM incubated at a time 
and vortexed for 1 min to allow protein binding. Samples were centrifuged for 2 min 
at 2000 x g and steps repeated for total 5 mL CM binding. Strataclean resin was mixed 
with 2x loading buffer and heated to 95 oC for 10 min. Samples were run and 
membranes treated as described in section 2.12. 
 
2.13 Gene expression by quantitative PCR (qPCR) 
Total RNA was isolated from purified cells using Qiagen RNeasy kit (Qiagen) following 
manufacturer’s instructions. cDNA was prepared from 1 µg RNA per sample using 
QuantiTect reverse transcription kit (Qiagen) according to manufacturer’s instructions, 
and qPCR was performed using gene-specific QuantiTect Primer Assay primers 
(Qiagen) using 5x HOT FIREPol® EvaGreen® qPCR Mix Plus (Solis Biodyne). The 
qPCR reaction was run on Stratagene Mx3005P (Thermo Fisher) under the following 
cycling conditions: 1 cycle: 95 oC for 15 min. 45 cycles: 95 oC for 15 sec, 60 oC for 20 
sec, 72 oC for 30 sec, 78 oC for 11 sec. 1 cycle: 95 oC for 1 min, 55 oC for 30 sec and 
97 oC continuously. Relative expression levels were normalized to gapdh expression 
according to the formula: 2 –(ΔCTgene of interest ΔCtgapdh) (Schmittgen and Livak, 2008). 
Primers used in these experiments are listed in appendix (iv). 
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2.14 Immunohistochemistry  
FFPE tissues were sectioned at 4-5 µm width using a microtome and mounted onto 
glass slides (VWR). The mounted sections were deparaffinised and primed by antigen 
retrieval using an automated DAKO PT-link system (Agilent), using either high pH (9 
pH) or low pH (6 pH) retrieval buffers (DAKO) depending on antibody specifications. 
Tissues were blocked for 20 min with peroxidase (DAKO) to prevent non-specific 
staining and washed three times for 10 min in TBS-T. Tissues were immunostained 
using the DAKO envision+ system-HRP (DAKO). Tissues were incubated with 
primary antibodies for 2 hr at RT and were subsequently washed three times with 
TBS-T for 10 min. Subsequently, samples were incubated with secondary HRP-
conjugated antibody (from DAKO envision kit) for 1 hr at RT. Tissue staining was 
developed using diamino-benzidine (DAB) (DAKO) and counterstained with 
haematoxylin and fixed in xylene. Coverslips were mounted using DPX mountant 
(Sigma Aldrich).  All antibodies were prepared in antibody diluent from DAKO envision 
kit and are listed in appendix (ii). 
 
2.15 Immunofluorescence  
PDAC tissue was frozen in Tissue-tek Optimal cutting temperature compound (OCT) 
(Sakura Finetek UK Ltd) and stored at -80 oC. Tissue sections were cut at 4-5 µm 
thickness using a Cryostat (Leica) and mounted on a glass slide. The sections were 
fixed for 2 min in ice-cold acetone (Sigma Aldrich) and washed three times for 5 min 
in PBS. Tissues were subsequently permeabilized using 0.1 % Triton X-100 in PBS 
for 2 min and again washed three times for 5 min in PBS. Non-specific binding was 
reduced by blocking with 8 % goat serum (Abcam) in PBS for 1 hr at RT in a humid 
chamber. Tissues were incubated with primary antibodies overnight at RT in a humid 
chamber. The slides were washed three times in PBS for 5 min and incubated with 
their corresponding secondary antibody (1:500 dilution) and DAPI nuclear stain 
(1:600) for 2 hr at room temperature. The slides were washed three times for 5 min 
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with a final wash in dH20 and mounted with fluorescent mounting media (DAKO). 
Antibodies used in these experiments are listed in appendix (iii). 
 
2.16 FACS sorting of cell populations from murine tumours 
Single cell suspensions from murine pancreatic and breast tumours were prepared 
by mechanical and enzymatic disruption in Hanks Balanced Salt Solution (HBSS) 
(Sigma Aldrich) with 1 mg/mL Collagenase P (Roche). Cell suspensions were 
centrifuged for 5 min at 423 x g, resuspended in HBSS and filtered through a 500 µm 
polypropylene mesh (Spectrum Laboratories). Cells were resuspended in 1 mL 0.05 
% Trypsin (Life Technologies) and incubated at 37 oC for 5 min. Cells were filtered 
through a 70 µm cell strainer (VWR) and resuspended in PBS + 1 % BSA. Cells were 
blocked for 10 min on ice with Fc Block (BD Pharmingen, Clone 2.4G2) and then 
stained with FACS antibodies listed in appendix (iv). Samples were sorted on the 
FACS ARIA (BD Biosciences) for tumour cells (Sytox-/ CD45-/ zsGreen+), non-
immune stromal cells (Sytox-/CD45-/zsGreen-), macrophages (Sytox-/CD45+/F4/80+) 
/M1-like TAMs (Sytox-/CD45+/F4/80+/CD206-) /M2-like TAMs (Sytox-
/CD45+/F4/80+/CD206+).  
 
2.17 SILAC mass spectrometry secretome sample preparation  
FC1199, FC1242 and FC1245 cells were incubated with non-phenol red serum-free 
R6K6, R10K8 and R0K0 SILAC media respectively, for 24 hr. CM was collected into 
15 mL falcon tubes and centrifuged 423 x g for 5 mins. The supernatant was collected 
and filtered using a 0.22 µm syringe filter and kept at 4 oC until prepared for mass 
spectrometry. 
 
Samples were prepared by Deborah Simpson, Centre for Proteome Research 
SILAC CM was dispensed into four replicate tubes with 2 mL of each individual label 
in each (6 mL of 1:1:1 mix). 1 mL of CM mix from each replicate was bound to 10 µL 
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of strataclean resin beads, the samples were vortexed for 1 min, centrifuged at 2000 
x g for 2 min and the depleted supernatant transferred to a fresh tube and retained. 1 
mL of CM was consecutively bound to the beads four times. The beads were washed 
three times with 1 mL of 25 mM ammonium bicarbonate and re-suspended in 80 µL 
of 25 mM ammonium bicarbonate and 5 µl of 1 % (w/v) Rapigest (Waters). 25 mM 
ammonium bicarbonate was added and the samples were heated at 80 oC for 10 min 
with shaking. Samples were reduced by the addition of 5 µL of 60 mM Dithiothreitol 
(DTT) in 25 mM ammonium bicarbonate and heated at 60 oC for 10 min. Samples 
were cooled and 5 µL of 180 mM iodoacetamide in 25 mM ammonium bicarbonate 
added and samples incubated at RT for 30 min in the dark. Trypsin (Porcine trypsin 
sequencing grade, Promega) (1 µg) was added and the samples incubated at 37 oC 
overnight on a rotary mixer. 
 
The following day, the digests were acidified to remove Rapigest surfactant by the 
addition of 1 %(v/v) Trifluoroacetic acid (TFA) (acidity checked using pH paper) and 
incubated at 37 oC for 45 min. Samples were then centrifuged at 17,000 x g for 30 
min and the clarified supernatants transferred to 0.5 mL low-bind tubes. Samples were 
centrifuged for a further 30 min and 10 µL transferred to total recovery vials for Liquid 
chromatography- high resolution mass spectrometry (LC-HRMS) analysis. 
 
2.17.1 SILAC mass spectrometry  
Samples were run by Deborah Simpson, Centre for Proteome Research 
Liquid chromatography- tandem mass spectrometry (LC-MSMS) analyses were 
conducted on a QExactive HF quadrupole-Orbitrap mass spectrometer coupled to a 
Dionex Ultimate 3000 RSLC nano-liquid chromatograph (Thermo Fisher).  The 
column was maintained at 40 oC, and the effluent introduced directly into the 
integrated nano-electrospray ionisation source operating in positive ion mode.  
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2.17.2 SILAC mass spectrometry analysis 
2.17.2.1 Maxquant SILAC analysis  
Mass spectrometry raw files from QExactive Orbitrap were analysed using Maxquant 
software (version 1.5.3.17) to perform peak picking, quantitative measuring and 
protein identification using incorporated Andromeda peptide search engine and 
UniprotKB database of Mus musculus (mouse) FASTA protein sequences. Group 
specific parameters selected for a multiplicity of 3 and trypsin digestion. Maxquant 
output ratios were filtered by the removal of identified contaminants and proteins not 
present in every replicate (NaN) or only identified by 1 peptide.  
 
2.17.2.2 LIMMA in R 
Statistical analysis was performed on sorted Maxquant output ratios using R studio 
(version 3.4.1) and LIMMA stats package (version 3.7), performing ANOVA statistical 
analysis with empirical Bayes distribution (Ritchie et al., 2015).  
 
2.17.2.3 Perseus principal component analysis (PCA) and Multiscatter plot  
Perseus software (version 1.5.8.5) was used to perform principal component analysis 
evaluating statistical significance of protein expression with a q-value of 0.05 for 
Benjamini-Hochberg false discovery rate (FDR) for each protein robustly identified in 
each replicate mass spectrometry run (Tyanova et al., 2016). A multiscatter plot was 
created based on gene ontology of biological processes with Pearson correlation 
coefficient calculated per comparison.  
 
2.17.2.4 SecretomeP, SignalP, TMHMM and Uniprot database analysis 
SecretomeP: FASTA sequences of identified proteins were analysed by SecretomeP 
2.0 server. Proteins with an NN_score score ≥0.6 without a SignalP positive 
identification was deemed to be non-classically secreted. 
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SignalP: FASTA sequences of identified proteins were analysed by SignalP 4.1 
server. Proteins with a positive D-score predicting the presence of a signal peptide 
associated with classical secretion.  
TMHMM: FASTA sequences of identified proteins were analysed by TMHMM v2.0 
server. Proteins predicted to contain transmembrane helices based in the amino acid 
sequence were deemed as spanning the cellular membrane. 
Uniprot: Used to identify gene ontology of associated cellular component  
 
2.18 Statistical Methods 
Statistical significance for in vitro assays and animal studies was assessed using 
unpaired two-tailed Student t test or one-way ANOVA coupled with Tukey’s post hoc 
tests or Bonferroni post hoc tests, and the GraphPad Prism 5 program. Proteomic 
data was assessed by one-way ANOVA, Multiscatter plots analysed with Pearson 
correlation and PCA analysis by Benjamini-Hochberg cut off (0.05 FDR) using R 
statistical package. 
 
2.19 Institutional approvals 
Experimental animals: Mice were maintained under specific pathogen-free conditions 
and experiments were performed under an approved project licence (reference 
number: 403725) as according to current UK legislation, at the Biomedical Science 
Unit at the University of Liverpool. All mice used were immunocompetent C57BL/6J 
6-8 week-old female mice.   
 
Human material: All studies involving blood collection were approved by the National 
Research Ethics (Research Integrity and Governance Ethics committee- Reference: 
RETH000807). All individuals provided informed consent for blood donation on 
approved institutional protocols. 
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Chemoresistance in pancreatic cancer is driven by 
stromal-derived insulin-like growth factors 
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3.1 INTRODUCTION 
3.1.1 Chemoresistance  
Drug resistance is one of the biggest challenges in cancer treatment and has been 
identified as the major cause of recurrence in the majority of cancer patients (Holohan 
et al., 2013, McMillin et al., 2013). Multiple factors can contribute to the development 
of therapy resistance thus allowing tumour progression. In solid tumours, extrinsic 
means of mediating chemoresistance is largely dominated by a rich pro-tumoural 
microenvironment (Noy and Pollard, 2014, Mantovani and Allavena, 2015, De Palma 
and Lewis, 2013, Junttila and de Sauvage, 2013). Although macrophages have the 
potential to remove cancer cells, it has been shown that polarised M2-like TAMs 
actually promote tumour initiation, progression and metastasis whilst also protecting 
tumours from cytotoxic agents (Lin et al., 2001, Qian et al., 2011, Qian et al., 2015, 
Schmid et al., 2011, Schmid et al., 2013, Shree et al., 2011, Bruchard et al., 2013, 
Weizman et al., 2014, DeNardo et al., 2011, Mitchem et al., 2013, Nielsen et al., 
2016). CAFs present in the TME have also been reported to protect against 
chemotherapeutic agents and promote further tumour growth (Zhang et al., 2017, 
Qiao et al., 2018). However, the precise molecular mechanisms utilised by TAMs and 
CAFs to support tumour progression are not completely understood, and the use of 
combination therapies which simultaneously target both pro-tumoural stromal cells 
and cancer cells are only beginning to emerge. 
 
3.1.2 PDAC 
Pancreatic cancer is a devastating disease with <7 % of patients surviving for 5 years 
after diagnosis (Siegel et al., 2017). This is largely due to the high occurrence of 
chemoresistance, especially to gemcitabine, the current standard of care (Kim and 
Gallick, 2008). The stromal compartment of PDAC is extremely rich with non-
malignant TAMs and CAFs abundantly present. Bi-directional interactions between 
stromal and PDAC cells are known to influence tumour cell behaviour including growth 
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and motility (Hanahan and Coussens, 2012, Quail and Joyce, 2013). This is largely 
mediated by secreted factors as TAMs and CAFs are not always in direct contact with 
tumour cells. However, the stromal signalling promoting chemoresistance in PDAC is 
only partially understood and requires further investigation.  
 
3.1.3 PDAC mouse models  
The use of immunocompetent preclinical mouse models which faithfully recapitulate 
the human disease is essential to elucidate stromal interactions as the majority of the 
stroma is comprised of infiltrating immune cells. Interestingly, orthotopic implantation 
of KPC-derived PDAC tumour cells into the tail of the pancreas of syngeneic recipient 
mice has been shown to develop PDAC with full penetrance (Jiang et al., 2014). The 
use of KPC-derived tumour cells orthotopically implanted into immunocompetent mice 
can therefore be used as a preclinical to investigate chemoresistance in vivo.  
 
3.1.4 Insulin and IGF signalling  
The IGF signalling axis uses three secreted ligands: insulin, IGF-1 and IGF-2. These 
bind to IGF-1R, IGF-2R and InsR with varying degrees of affinity (Bailyes et al., 1997). 
Upon ligand binding, the IGF-1R and InsR undergo autophosphorylation and 
subsequently phosphorylate and activate downstream insulin receptor substrate 1 or 
2 (IRS1, IRS2). IRS1 or IRS2 functions to increase and activate downstream 
phosphoinositide 3- kinase (PI3K) and subsequently protein kinase B (AKT) (Zha and 
Lackner, 2010). AKT activation prevents cell death, promotes glucose metabolism 
and activates protein synthesis (Baserga, 1999). The role of IGF signalling in PDAC 
is still limited and requires attention. 
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3.1.5 Hypothesis 
TAMs and CAFs present in the PDAC tumour microenvironment contribute to 
chemoresistance therefore tumour progression in preclinical mouse models.  
 
3.1.6 Aims 
 To identify TAMs and CAFs in the tumour microenvironment  
 To identify secreted factors which promote chemoresistance  
 Identify pro-survival signalling pathways in the tumour cells   
 Trial blocking antibodies in PDAC preclinical mouse model 
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3.2 RESULTS 
3.2.1 Macrophages can be differentiated from bone marrow monocytes in 
culture 
To cultivate primary murine macrophages in vitro, the hind legs of C57BL/6J mice 
were harvested post-mortem and bone marrow flushed from the femur and tibia to 
collect bone marrow monocytes. To promote differentiation into macrophages, the 
bone marrow monocytes were incubated with cell culture media supplemented with 
mCSF-1 for 5 days, which has been shown to differentiate macrophages towards an 
M2-like phenotype (Lawrence and Natoli, 2011) (Fig 3.1).  To collect macrophage-
secreted factors, the cells were incubated with serum free culture medium for use in 
further studies.  
 
  
 
 
 
 
 
Figure 3.1 Murine Bone marrow derived macrophages in culture  
Primary macrophages created by harvesting bone marrow from femur and tibia of 
C57BL/6J mice. Mononuclear cells isolated via density centrifugation and matured 
for 5 days in vitro using mCSF-1 (10 ng/mL) to create adherent M2-like 
macrophages. Scale bar, 50 µm. 
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3.2.2 Macrophage conditioned media (MCM) induces chemoresistance towards 
gemcitabine in PDAC cells in vitro. 
Chemoresistance is a major obstacle which arises during PDAC treatment. 
Macrophages are one of the most abundant cell types in the PDAC TME which may 
be implicated in the induction of chemoresistance. To investigate whether 
macrophage-secreted factors reduced cell death, mouse KPC-derived pancreatic 
cancer cells called KPC 3.5 were cultured in vitro and incubated with or without 
macrophage conditioned media (MCM) and in the presence or absence of the 
standard PDAC chemotherapeutic agent gemcitabine (200 nmol/L). FACS analysis of 
apoptosis/necrosis, by annexin V/propidium iodide (PI) staining, showed the addition 
of MCM reduced the levels of cell death in gemcitabine treated cells, whilst no effect 
was seen in untreated cells (Fig 3.2).  
 
 
 
Figure 3.2 MCM induces chemoresistance in PDAC cells treated with 
gemcitabine 
Mouse primary KPC-derived pancreatic cancer cells, KPC 3.5, were cultured in 
the presence or absence of conditioned media from mouse primary macrophages 
and treated with 200 nmol/L gemcitabine for 24 hr or left untreated. Percentage 
of cell death was quantified by flow cytometry annexin V/ PI staining. (Error bars, 
SD (n = 3 biological replicates); two-tailed unpaired t test; *, P ≤ 0.05.) 
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3.2.3 MCM activates the insulin receptor and insulin-like growth factor receptor 
on pancreatic cancer cells  
To determine which receptors were stimulated by MCM incubation and could 
therefore cause chemoresistance, human SUIT-2 pancreatic cancer cells were 
incubated with or without human MCM. The lysates from these cells were then 
analysed using a phospho-receptor tyrosine kinase (pRTK) array, identifying three 
activated RTKs: insulin receptor (InsR), AXL receptor and ephrin receptor (Fig 3.3). 
Of these receptors, insulin/IGF-1 receptor signalling has previously been reported to 
be involved in drug resistance in other cancer types (Denduluri et al., 2015).  However, 
a direct role of macrophage-derived IGF mediated chemoresistance in PDAC has yet 
to be elucidated.  
 
 
 
 
Figure 3.3 MCM causes phosphorylation of three RTKS on PDAC cells  
Human pancreatic cancer SUIT-2 cells were serum starved for 24 hr and exposed 
for 2 hr to human MCM or left unexposed. Protein lysates were subjected to a 
phospho-receptor tyrosine kinase (pRTK) array. RTK’s identified as activated: 1, 
phospho-insulin receptor; 2, phospho-AXL receptor; 3, phospho-Ephrin receptor. 
Performed by Dr. Mielgo. 
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3.2.4 Primary macrophages express and secrete IGF-1 and IGF-2  
The insulin receptor can be ligated and activated by three ligands: insulin, IGF-1, and 
IGF-2 (Pollak, 2012). Therefore, it was necessary to determine which of these ligands 
were expressed by macrophages and therefore activating the InsR on PDAC cells. 
qPCR analysis to elucidate expression levels of the three ligands in primary murine 
macrophages revealed the major ligands expressed as Igf-1 and Igf-2 but not Insulin 
(Fig 3.4).   
 
 
To confirm this result at the protein level, CM and cell lysates were collected from 
primary macrophages.  Cell lysates and proteins concentrated from the CM were 
immunoblotted for IGF-1 and IGF-2, revealing both to be expressed and secreted by 
primary murine macrophages (Fig 3.5). 
 
 
Figure 3.4 Igf-1 and Igf-2 genes are expressed by murine macrophages  
Primary isolated bone-marrow derived murine macrophages analysed by qPCR 
for quantification of Igf-1, Igf-2, and Insulin mRNA expression levels relative to 
GAPDH housekeeping gene levels. (Error bars, SEM, n=3 biological replicates).  
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These results show that MCM contained IGF-1 and IGF-2 which resulted in insulin 
receptor activation on PDAC tumour cells. However, it is also possibility that tumour 
cells themselves could produce and secrete IGF ligands which could act in an 
autocrine manner. To determine whether this was the case, mRNA expression levels 
of Igf-1, Igf-2 and Insulin were analysed in the KPC 3.5 pancreatic cancer cells. qPCR 
analysis showed tumour cells expressed Igf-1 but to a much lesser degree than 
macrophages (Fig 3.6) 
 
 
 
  
 
Figure 3.5 IGF-1 and IGF-2 proteins are both expressed intracellularly and 
secreted by primary macrophages 
Immunoblotting analysis of IGF-1 and IGF-2 ligand expression in primary isolated 
bone marrow-derived macrophage protein lysates and macrophage conditioned 
media (MCM) (2ml of CM bound to 10 µL strataclean beads to concentrate) with 
GAPDH loading control.  
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Thus, these findings suggest that activation of the insulin receptor on pancreatic 
cancer cells is triggered through paracrine macrophage-derived IGF-1/IGF-2 
signalling.  To confirm this finding, KPC 3.5 PDAC cells were stimulated with MCM or 
recombinant IGF (rec IGF). The lysates were then subject to immunoblotting for 
phosphorylated InsR (pInsR) detecting phosphorylation at Y1162/Y1163 but also for 
phosphorylated IGF-1 receptor (pIGF-1R) detecting phosphorylation at Y1135/Y1136 
as this can also be activated by IGF-1 and IGF-2 ligands. This revealed MCM and 
recIGF both caused activation of InsR and IGF-1R in PDAC cells (Fig 3.7 A). 
Densitometry analysis of the immunoblotting revealed KPC 3.5 cells increased 
pIns/IGF-1R levels when treated with MCM or rec IGF when compared to total insulin 
receptor or IGF-1 receptor expression (Fig 3.7 B).  
 
 
 
Figure 3.6 Macrophages produce higher levels of Igf-1 and Igf-2 than tumour 
cells 
Comparison of primary isolated bone marrow-derived macrophages and KPC 3.5 
tumour cells expression levels of Igf-1, Igf-2 and Insulin mRNA determine by qPCR 
gene expression quantification, relative to GAPDH (Error bars, SEM, n=3 biological 
replicates, 3 technical replicates per sample). 
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3.2.5 Blockade of macrophage-derived IGFs prevents Ins/IGF-1R activation 
Incubation of PDAC tumour cells with MCM has shown chemotherapy-induced cell 
death can be prevented in vitro (Fig 3.2) and it was also identified that InsR and IGF-
1R were activated in response MCM incubation (Fig 3.7). It was therefore important 
to determine whether IGF-1 and IGF-2 were responsible for the induction of 
chemoresistance.   
 
Figure 3.7 MCM and rec IGF activates Ins/IGF-1R signalling on PDAC cells 
A) Immunoblotting analysis of murine primary KPC 3.5 pancreatic cancer cells 
either serum starved, exposed to MCM, or exposed to recombinant IGF for 3 hr. 
Probed for phospho insulin/IGF-1 receptors, total insulin receptor, total IGF-1R 
receptor and tubulin loading control. B) Increase in pInsR/IGF-1R compared to 
total InsR (left) and total IGF-1R (right) relative to tubulin loading control quantified 
from 2 independent experiments by densitometry.   
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To address this question, we acquired an IGF-neutralizing antibody (ab9572) which 
specifically bound and inhibited IGF-1 activity, thus preventing ligation with either the 
InsR or IGF-1R.  Firstly, human SUIT-2 PDAC cells were incubated with or without 
MCM or with IGF blocking antibody (Ab). Interestingly, MCM stimulation alone 
significantly increased levels of pInsR/pIGF-1R and caused activation of downstream 
signalling components IRS1, IRS2, AKT and MEK (Fig 3.8 A and B). This activation 
was abrogated with the addition of the IGF blocking Ab (Fig 3.8 A and B).  
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Figure 3.8 Incubation of PDAC cells with IGF blocking Ab prevents Ins/IGF-
1R activation and downstream signalling 
A) Immunoblotting analysis of SUIT-2 cells untreated or treated with MCM or MCM 
with IGF-blocking antibody (ab9572) for 3 hr. Probed for phospho insulin/IGF-1 
receptors, total insulin receptor, phospho IRS1, total IRS1, phospho IRS2, total 
IRS2, phospho AKT, total AKT, phospho MEK, total MEK and tubulin loading 
control. Antibody heavy chains indicated. B) Quantification of western blot showing 
levels of p-insulin/IGF-1R compared to total Insulin receptor, p-IRS1 compared to 
total IRS1, p-IRS2 compared to total IRS2, p-AKT compared to AKT and p-MEK 
compared to total MEK, all relative to tubulin loading control. Error bars, SEM (n = 
3 biological replicates); **, p ≤ 0.001, *, p ≤ 0.01, ns, non=significant using one-
way ANOVA and Bonferroni post hoc test. 
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To investigate whether IGF signalling was directly responsible for induced 
chemoresistance in PDAC cells, KPC 3.5 cells were incubated with or without 
gemcitabine, MCM, IGF blocking Ab or rec IGF and cell death was measured using 
annexin V/PI staining. This confirmed the previous results that gemcitabine treatment 
alone induced significant cell death which was reduced with the addition of MCM (Fig 
3.9). However, the addition of an IGF blocking Ab prevented MCM-mediated 
chemoresistance, suggesting IGF ligands are responsible for promoting cell survival 
towards gemcitabine challenge (Fig 3.9). This is supported by the fact rec IGF alone 
was sufficient to mediate chemoresistance towards gemcitabine in PDAC cancer cells 
(Fig 3.9).  
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Figure 3.9 MCM and rec IGF promote chemoresistance in PDAC cells  
A) Quantification of annexin V/PI detected cell death by FACS in primary mouse KPC-
derived pancreatic cancer cells untreated or treated with gemcitabine (200 nmol/L), 
MCM, IGF blocking antibody (10 mg/mL), or recombinant IGF (100 ng/mL) for 24 hr. 
Error bars, SD. (n = 3 biological replicates); ***, p ≤ 0.005 using one-way ANOVA and 
Tukey post hoc test. B) Representative flow cytometry dot blots of KPC-derived cells 
exposed to gemcitabine, MCM, IGF-blocking antibody, and recombinant IGF. 
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To confirm the results seen by flow cytometry, levels of cell death were analysed by 
immunoblotting for cleaved caspase-3 in KPC 3.5 cells treated with gemcitabine 
alone, or combination with MCM or recIGF (Fig 3.10 A). The significant levels of cell 
death were induced by gemcitabine alone, however in accordance with annexin V/PI 
staining, cell death was reduced with addition of either MCM or rec IGF (Fig 3.10 A 
and B). 
 
 
 
 
 
 
 
Figure 3.10 MCM and rec IGF decrease levels of cleaved caspase 3 in PDAC 
cells 
A) Immunoblotting analysis for cell death of KPC 3.5 pancreatic cancer cells either 
untreated, treated with gemcitabine (200 nmol/L), MCM (2mL) with gemcitabine 
(200 nmol/L), or recombinant IGF (100 ng/mL) with gemcitabine (200 nmol/L) for 
24 hr. Probed for cleaved caspase-3 expression as a cell death marker and tubulin 
as loading control. B) Quantification of cleaved caspase-3 expression levels 
detected by western blotting in treated KPC 3.5 cells, compared to tubulin loading 
control. Error bars, SEM (n = 3 biological replicates); **, p ≤ 0.001, ns, non-
significant, using one-way ANOVA and Bonferroni post hoc test. 
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To further investigate this phenomenon, to determine whether IGF signalling 
promoted resistance to other chemotherapeutic agents used to treat PDAC patients. 
Therefore, KPC 3.5 cells were treated with nab-paclitaxel alone at 10 nM, 100 nM, 
1000 nM, or in combination with MCM or rec IGF and analysed by annexin V/PI 
staining. The addition of MCM or rec IGF significantly reduced cell death caused by 
nab-paclitaxel at all concentrations tested, although MCM reduced death to a slightly 
lesser extent than rec IGF (Fig 3.11) 
 
 
 
 
 
Figure 3.11 MCM and rec IGF promote chemoresistance towards Nab-
paclitaxel 
Quantification of cell death in KPC 3.5 cultured in the presence or absence of MCM 
or recombinant IGF and treated with 10, 100, or 1000 nmol/L nab-paclitaxel for 36 
hr and indicated by annexin V/PI staining and flow cytometry analysis. Error bars, 
SD (n = 3); ***, p ≤ 0.005; **, p ≤ 0.01 using one-way ANOVA and Tukey post hoc 
test. 
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As IGF ligand activation of InsR and IGF-1R had been seen to promote resistance to 
gemcitabine and nab-paclitaxel in KPC 3.5 pancreatic cancer cells in vitro, it was 
important to investigate this phenomenon further using other PDAC cell lines. Human 
SUIT-2, human MIA-PaCa-2 and murine KPC 3.5 PDAC cells were grown in vitro and 
incubated with either gemcitabine, paclitaxel or 5-FU in combination MCM or MCM 
with IGF blocking Ab. Quantification of annexin V/PI staining showed MCM reduced 
cell death incidence in all three cell lines, treated with any of the three 
chemotherapeutic agents (Fig 3.12 A, B and C). This protective effect provided by 
MCM was reversed in all cells and treatments with the addition of IGF blocking Ab, 
thereby confirming IGF ligands as responsible for the induction of chemoresistance 
in this model (Fig 3.12 A, B and C).  
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Figure 3.12 MCM enhances resistance of pancreatic cancer cells to 
gemcitabine, 5-FU and paclitaxel in an IGF-dependent manner. 
Quantification of annexin V/PI stain detected cell death in human SUIT-2, MIA-
PaCa-2 and murine KPC-derived pancreatic cancer cells. A) Treated with 
gemcitabine (200nmol/L), MCM and IGF blocking antibody (10 mg/mL) for 24 
hr. B) Treated with paclitaxel (200nmol/L), MCM and IGF blocking antibody (10 
mg/mL)  for 24 hr. C) Treated with 5-FU (100nmol/L), MCM and IGF blocking 
antibody (10 mg/mL) for 24 hr. Error bars represent SEM (n=3 biological 
replicates), *** p ≤ 0.005, ** p ≤ 0.01, * p ≤ 0.05 compared to control using one-
way ANOVA and Tukey’s post-hoc test. 
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The previous findings suggest an important role for macrophage-derived IGFs in the 
activation of the Ins/IGF-1R survival signalling in pancreatic cancer cells, thus 
enhancing resistance to chemotherapy. However, resistance was seen to be reduced 
with the addition of an IGF blocking antibody. Based on this data, IGF appears to be 
an attractive target in PDAC, deeming it necessary to determine whether the targeting 
of IGF ligands could have negative effects on cellular growth and survival in the 
absence of chemotherapy. To answer this question, KPC 3.5 cells were incubated 
with MCM, IGF-blocking Ab, or rec IGF alone to analyse perturbations in their cell 
cycle. This analysis showed incubation with either MCM, or rec IGF did not alter the 
survival or proliferation of cancer cells in the absence of chemotherapy (Fig 3.13).  
Importantly, incubation with an IGF blocking Ab did not have adverse effects of cell 
survival or proliferation suggesting it could be well tolerated in vivo (Fig 3.13). 
 
 
 
 
Figure 3.13 In the absence of chemotherapy, addition of MCM, IGF blockade 
or rec IGF does not affect proliferation or survival of pancreatic cancer cells. 
Cell cycle analysis of primary mouse KPC 3.5 cancer cells exposed to MCM, IGF 
blocking antibody (10 µg/mL) or recombinant IGF (100 ng/mL) for 3 hr. 
Quantification of propidium iodide incorporation into DNA detected by flow 
cytometry. 
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3.2.6 TAMS are a source of IGF ligands in the PDAC TME in vivo 
Macrophage-derived IGF ligands have been shown to induce resistance to 
chemotherapy in vitro. However, in vitro cell culture can induce abnormalities in cell 
signalling, consequently it was necessary to confirm activation of Ins/IGF-1R on 
tumour cells and TAMs as IGF sources in the pancreatic TME in vivo.  
 
To analyse IGF function in vivo an orthotopic PDAC mouse model was utilised using 
primary murine cancer cells derived from the KPC genetically engineered PDAC 
mouse model (Hingorani et al., 2005), These cells were surgically orthotopically 
implanted into the pancreas in syngeneic recipient mice and tumours grown for 29 
days and subsequently harvested (Fig 3.14 A). 
 
Hematoxylin and eosin (H&E) staining of the collected PDAC tissue revealed the 
orthotopic PDAC tumours had a distinctly altered ductal morphology compared to a 
naïve mouse pancreas, indicating the majority of tissue was PDAC (Fig 3.14 B). 
Immunohistochemical staining of the tumour tissue revealed infiltration by CD206+ 
M2-like macrophages and increased activation of Ins/IGF-1R on tumour cells 
compared to naïve pancreas (Fig 3.14 B).  
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Figure 3.14 Orthotopic PDAC tumours are infiltrated by macrophages and 
have active phosphorylated Ins/IGF-1R 
KPC-derived tumour cells were orthotopically implanted into the pancreas tail of 
syngeneic recipient mice. Pancreas from naïve mice and pancreatic tumours from 
implanted mice were harvested day 29 after implantation. Images show H&E, 
CD206, and phospho-insulin/IGF-1 receptor staining of naïve mouse pancreas and 
murine PDAC tissue samples, scale bar 50 µm. 
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Further characterisation of the tumours revealed an increased infiltration by CD68+ 
macrophages and the increased presence of cancer-associated fibrosis comprised of 
αSMA+ myofibroblasts (Fig 3.15 A and B). Immunofluorescent staining of the same 
tumour tissue for EpCAM+ tumour cells and αSMA+ CAFs confirmed the myofibroblast 
rich stromal surrounds the PDAC tumour cells (Fig 3.15 C), a phenomenon which is 
also seen in human PDAC as fibrosis can account for up to 80 % of the tumour mass 
(Gunderson et al., 2016, Zhu et al., 2014, Pylayeva-Gupta et al., 2016, Torres et al., 
2013). These results suggest the human PDAC disease phenotype was recapitulated 
in multiple orthotopically implanted mice. 
Chapter Three 
90 
 
 
 
Figure 3.15 Macrophages and CAFs infiltrate orthotopic PDAC tumours 
A) Immunohistochemical staining of αSMA and CD68 in paraffin embedded 
tissues from naïve mouse pancreas and orthotopic mouse pancreatic tumours. 
Scale bar, 50 µm. B) Quantification of immunohistochemical staining of αSMA+ 
myofibroblasts and CD68+ macrophages in naïve pancreas and PDAC tumour-
bearing mice. Error bars, SEM (n=3 images per mouse). C) Immunofluorescent 
staining of EpCAM (green), αSMA (red) and nuclei (blue) in frozen tissues from 
naïve mouse pancreas and orthotopic mouse pancreatic tumours. Scale bar, 100 
µm. 
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Therefore, to determine whether the in vitro findings of macrophage-derived IGF 
induced chemoresistance was also recapitulated in vivo, F4/80+ TAMs and F4/80- 
cells were FACS sorted from the tumour tissue. qPCR analysis revealed F4/80+ TAMs 
expressed higher levels of both Igf-1 and Igf-2 compared to F4/80- cells, suggesting 
macrophages are still sources of IGF ligands in vivo (Fig 3.16).   
 
To confirm this result, a second KPC-derived cell line stably transfected with zsGreen 
reporter gene, FC1242 luc/zsGreen, were orthotopically implanted into the pancreas 
of syngeneic recipient C57BL/6J mice and tumours were harvested 23 days after 
implantation (Fig 3.17 A). The harvested tumours were stained and FACS sorted for 
tumour cells (Sytox-, CD45-, zsGreen+), non-immune stromal cells (Sytox-, CD45-, 
zsGreen-), M1-like macrophages (Sytox-, CD45+, F4/80+, CD206-) and M2-like 
macrophages (Sytox-, CD45+, F4/80+, CD206+) (Fig 3.17 B). Knowing that 
myofibroblasts can account for up to 80 % of the tumour mass, the sorted non-immune 
stromal cells were analysed by qPCR which revealed high levels of αSMA expression 
typical of activated fibroblasts (Fig 3.17 C). 
 
Figure 3.16 F4/80+ TAMs express high levels of Igf-1 and Igf-2 
Quantification of Igf-1 (left) and Igf-2 (right) mRNA expression levels in F4/80+ 
macrophages and F4/80- mixed cell population, FACS sorted from digested murine 
orthotopic pancreatic tumours. Error bars, SD (n = 3 technical replicates). 
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Figure 3.17 FACS sorted non-immune stromal cells express high levels of 
αSMA myofibroblast marker  
A) KPC-derived tumour cells, FC1242 luc/zsGreen, were orthotopically implanted 
into the pancreas of syngeneic recipient (C57BL/6J) mice. Tumours were harvested 
and digested at day 23 after implantation and tumour cells, non-immune stromal cells, 
M1-like and M2-like macrophages were sorted by flow cytometry. B) Gating strategy 
used to sort CD45-/zsGreen+ KPC-derived tumour cells, CD45-/zsGreen- non-
immune stromal cells, CD45+/F4/80+/CD206- M1-like macrophages and 
CD45+/F4/80+/CD206+ M2-like macrophages from mouse pancreatic tumours. C) 
Quantification of αSMA mRNA expression levels in the FACS sorted populations 
isolated from pancreatic tumours (n=3 technical replicates). 
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To confirm macrophages as a source of IGF ligands in the new orthotopic mouse 
model TME, the FACS sorted populations were analysed by qPCR. M2-like 
macrophages and αSMA+ myofibroblasts were shown to be sources of Igf-1 and Igf-
2 expression in the orthotopic model (Fig 3.18).  
 
 
 
 
 
3.2.7 αSMA+ myofibroblasts are also stromal producers of IGF-1 and IGF-2  
It was interesting to find αSMA+ non-immune stromal cells also expressed a high level 
of Igf-1 and Igf-2. Both myofibroblasts and macrophages are abundant in the PDAC 
TME and CAFs may also be responsible for activation of the InsR and IGF-1R on 
PDAC tumour cells. To confirm this, pancreatic stellate cells (PaSCs) were isolated 
from naïve mouse pancreas and cultured on plastic to induce activation confirmed by 
αSMA expression (Fig 3.19).  
 
 
Figure 3.18 M2-like TAMs and αSMA+ stromal cells express the high levels 
of Igf-1 and Igf-2 
Quantification of Igf-1 (left) and Igf-2 (right) mRNA expression levels in 
CD45+/F4/80+/CD206- M1-like macrophages, CD45+/F4/80+/CD206+ M2-like 
macrophages, CD45+/zsGreen+ non-immune stromal cells, and CD45+/zsGreen+ 
tumour cells isolated from murine pancreatic tumours. Error bars, SD (n = 3 
technical replicates). 
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To create CAFs, freshly isolated and activated PaSCs were incubated with tumour 
conditioned media (TCM). qPCR analysis showed myofibroblasts expressed both Igf-
1 and Igf-2 under basal conditions (Fig 3.20 A). However, the addition of TCM to the 
culture enhanced expression levels of both Igf-1 and Igf-2 (Fig 3.20 A). Myofibroblast 
conditioned media (MyoCM) and cell lysates confirmed the qPCR results, detecting 
IGF-1 and IGF-2 as both expressed and secreted (Fig 3.20 B).  
 
 
 
 
 
 
 
 
 
Figure 3.19 PaSCs express αSMA when activated  
Left, Light microscopy image of primary isolated, activated murine PaSCs in 
culture. Scale bar 100 μm. Right, immunoblotting of αSMA and GAPDH as loading 
control of primary mouse activated PaSCs. 
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Figure 3.20 Myofibroblasts express IGF-1 and IGF-2   
A) Quantification of Igf-1 (left) and Igf-2 (right) mRNA expression levels in 
pancreatic myofibroblasts exposed or unexposed to KPC-derived tumour 
conditioned media (TCM). Error bars, SEM (n = 3 biological replicates each with 3 
technical replicates) *** p-value ≤ 0.0001 using unpaired t test. B) Immunoblotting 
analysis of IGF-1 and IGF-2 ligands in pancreatic myofibroblast conditioned media 
(MyoCM) and myofibroblast lysates. GAPDH loading control.  
*** ***
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Previously, MCM was used to promote chemoresistance in tumour cells when 
challenged with gemcitabine, paclitaxel or 5-FU in vitro (Fig 3.12). After discovering 
myofibroblasts as another stromal source of IGFs, it was necessary to investigate 
whether IGFs in MyoCM could reproduce this phenomenon. Therefore, PDAC tumour 
cells were incubated with either gemcitabine, paclitaxel or 5-FU alone or with MyoCM 
and/or IGF blocking Ab to assess changes in cell survival. Quantification of annexin 
V/PI staining revealed all the chemotherapeutic agents significantly induced tumour 
cell death (Fig 3.21). Yet, the addition of MyoCM reduced levels cell death levels in 
all treatments which was reversed with the addition of IGF blocking antibody (Fig 
3.21).  
 
 
 
 
Figure 3.21 MyoCM confers resistance to neoplastic agents which is alleviated 
by addition of IGF blocking Ab  
Quantification of annexin V/PI detected cell death in KPC-derived pancreatic cancer 
cells treated with gemcitabine, paclitaxel or 5-FU, myofibroblast conditioned media 
(MyoCM) or IGF blocking antibody for 24 hr. Error bars represent SEM (n=3 
biological replicates), *** p ≤ 0.005, ** p ≤ 0.01, * p ≤ 0.05 compared to control using 
one-way ANOVA and Tukey’s post-hoc test. 
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3.2.8 Blockade of IGFs improves response to gemcitabine in a preclinical model 
of PDAC 
Macrophages and myofibroblasts are the most abundant non-malignant stromal cells 
within the TME in PDAC (Feig et al., 2012).  The previous results had shown TAMs 
and CAFs from the orthotopic PDAC TME expressed and secreted IGF-1 and IGF-2. 
These ligands induced resistance to chemotherapy in PDAC cells treated in vitro, 
which was reversed with the addition of an IGF blocking Ab.  
 
To test whether this phenomenon was seen in the in vivo preclinical model, mice were 
orthotopically implanted with FC1242 luc/zsGreen KPC-derived tumour cells and 
treated with isotope control IgG antibody (n=6), gemcitabine alone (n=6), xentuzumab 
IGF-1/2 blocking Ab alone (n=6) or gemcitabine in combination with xentuzumab 
(n=6) (Fig 3.22 A).   
 
Size and weight of the harvested tumours revealed gemcitabine treatment alone had 
little effect on primary tumour growth in this model (Fig 3.22 B). Xentuzumab IGF-
blocking Ab (Boehringer Ingelheim) treatment alone showed only a modest effect on 
restricting tumour growth, however when used in combination with gemcitabine, 
tumour size was significantly reduced compared to gemcitabine alone (Fig 3.22 B) 
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Figure 3.22 Combination Tx of xentuzumab with gemcitabine reduces tumour 
size 
A) FC1242 luc/zsGreen-derived pancreatic tumour cells were orthotopically implanted 
into the pancreas of syngeneic C57BL/6J recipient mice. Starting at day 7 after 
implantation, mice were treated bi-weekly by intraperitoneal injection with either 
control IgG antibody, gemcitabine (100 mg/kg), IGF-blocking antibody xentuzumab 
(100 mg/kg), or a combination of gemcitabine with xentuzumab. B) Representative 
images of tumours at harvest and tumour weights (n = 6 mice per group); *, p ≤ 0.05 
using one-way ANOVA and Tukey post hoc test. 
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Immunohistochemical staining of the harvested tumour tissue confirmed xentuzumab 
treatment alone and in combination with gemcitabine reduced activation of Ins/IGF-
1R on PDAC cells by preventing stimulation by IGF ligands (Fig 3.23 A).  
 
To interpret how combination xentuzumab with gemcitabine treatment reduced 
tumour size, the tissues were also stained for cleaved caspase-3 as a marker of cell 
death (Fig 3.23 A). Quantification of cleaved caspase-3 revealed significantly higher 
levels of cell death in combination gemcitabine and xentuzumab treated tumours 
compared to control IgG, gemcitabine alone, or xentuzumab alone (Fig 3.23 B).  
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Figure 3.23 Xentuzumab with gemcitabine treatment increases levels of 
tumour cell death       
A) Immunohistochemical staining of phospho-Ins/IGF-1R and cleaved caspase-3 
in pancreatic tumours treated with IgG (control), gemcitabine, xentuzumab IGF-
blocking antibody, or gemcitabine with xentuzumab. B) Quantification of cleaved 
caspase-3 positive dead cells in tumours treated with IgG (control), gemcitabine, 
xentuzumab IGF-blocking antibody, or gemcitabine with xentuzumab (8–11 fields 
counted/ mouse tumour); ***, p ≤ 0.005 compared with other treatment groups, 
using one-way ANOVA and Tukey post hoc test.  
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To confirm the results of the in vivo experiment, it was repeated but instead using a 
commercially available IGF blocking Ab (ab9572, Abcam) which was previously used 
in vitro. Tumours were grown for 21 days and treated three times with either control 
IgG, gemcitabine alone or gemcitabine in combination with ab9572 IGF blocking Ab 
by intraperitoneal injection (Fig 3.24 A). Tumours harvested 30 days after implantation 
again revealed a significant decrease in size in the combination gemcitabine with 
ab9572 IGF blocking Ab treated mice compared to control IgG and gemcitabine alone 
treatments (Fig 3.24 B).  
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Figure 3.24 Gemcitabine treatment in combination with IGF-blocking Ab 
decreases tumour growth 
A) FC1242 luc/zsGreen pancreatic cancer cells were orthotopically implanted in the 
pancreas of syngeneic recipient mice. Mice were treated by intraperitoneal injection 
twice a week with IgG antibody, gemcitabine alone, or gemcitabine with an IGF-
blocking antibody (ab9572). Tumours were harvested at day 30 and representative 
images are shown. B) Tumour weights are shown (n = 9–12 mice per group). **, p ≤ 
0.01; *, p ≤ 0.05 using one-way ANOVA and Tukey post hoc test. 
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Immunohistochemical staining for pInsR and pIGF-1R revealed the ab9572 IGF-
blocking antibody reduced activation of InsR and IGF-1R to a similar extent as 
xentuzumab (Fig 3.25).  
 
 
 
Staining of pIns/IGF-1R confirmed receptor activation in IgG and gemcitabine treated 
tissues (Fig 3.26 A).To confirm a reduction in tumour size was due to increase 
gemcitabine efficacy and therefore increased cell death, tissues were stained for 
cleaved caspase-3 (Fig 3.26 A). Cleaved caspase-3 levels were confirmed as 
significantly higher in mice treated with gemcitabine and ab9572 IGF-blocking Ab (Fig 
3.26 B). 
 
 
Figure 3.25 IGF blockade decreases activation of InsR and IGF-1R in murine 
pancreatic tumours 
Comparison of insulin and IGF-1 receptor activation in control treated, xentuzumab 
IGF blocking Ab treated or ab9572 IGF blocking Ab treated mice. 
Immunohistochemical staining of phospho-Insulin receptor (top) and phospho-IGF-
1 receptor (bottom) in control (IgG) treated mouse pancreatic tumours, and tumours 
treated with IGF blocking antibodies xentuzumab and ab9572 (n=1 mouse per 
stain). Scale bar, 50 µm. 
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Figure 3.26 Combination treatment gemcitabine with ab9572 IGF-blocking Ab 
increases cell death  
A) Immunohistochemical staining of phospho-insulin/IGF-1R, and cleaved 
caspase-3 in pancreatic tumours treated with IgG, gemcitabine, or gemcitabine with 
IGF-blocking antibody ab9572. B) Quantification of cleaved caspase-3 positive 
dead cells in pancreatic tumours from mice treated with IgG control antibody, 
gemcitabine, or gemcitabine with ab9572 IGF-blocking antibody (6–8 fields 
counted/mouse tumour), **, p ≤ 0.01 using one-way ANOVA and Tukey post hoc 
test. 
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3.2.9 Paclitaxel or 5-FU in combination with xentuzumab increases levels of cell 
death 
 
Although gemcitabine is the current standard of care for PDAC patients, it is not the 
only chemotherapy used for patient treatment. As previously shown in vitro, MCM and 
MyoCM confer resistance to tumour cells when challenged with gemcitabine, 5-FU or 
paclitaxel (Fig 3.12 and Fig 3.21). This trait was confirmed in PDAC in vivo models 
treated with gemcitabine. Therefore, it was also important to investigate whether IGF 
signalling promoted chemoresistance against 5-FU and paclitaxel in vivo. 
 
To determine whether 5-FU or paclitaxel would have a similar synergy with 
xentuzumab treatment, FC1242 luc/zsGreen cells were implanted into C57BL/6J mice 
and divided into the treatment groups; control IgG (n=6), 5-FU (n=6), 5-FU with 
xentuzumab (n=6), paclitaxel (n=6) and paclitaxel with xentuzumab (n=6) for a total 
of 5 treatments (Fig 3.27 A). The weights of the harvested tumours revealed the 
combination treatments of 5-FU with xentuzumab and paclitaxel with xentuzumab 
both caused a slight decrease in tumour growth in this model (Fig 3.27 B). 
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Figure 3.27 5-FU and paclitaxel with xentuzumab modestly reduces tumour 
size 
A) FC1242 luc/zsGreen derived pancreatic tumour cells were orthotopically 
implanted into the pancreas of syngeneic C57BL/6J recipient mice, and mice were 
treated, starting at day 6 after tumour implantation, bi-weekly i.p., with either control 
IgG antibody, 5-FU (50 mg/kg), paclitaxel (10 mg/kg), a combination of 5-FU with 
xentuzumab (100 mg/kg) or a combination of paclitaxel with xentuzumab. B) 
Tumour weights (n=6 mice per group); p values obtained using unpaired two tailed 
T-test.  
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Levels of cleaved caspase-3 showed an increase in cell death in both combination 
treatment groups, however not by a large margin (Fig 3.28). Taken together, these 
findings indicate that functional blockade of IGFs significantly increases the response 
of pancreatic tumours to mainly gemcitabine in vivo. 
 
 
 
 
 
 
 
 
Figure 3.28 Combination of 5-FU and paclitaxel with xentuzumab 
significantly increased levels of cell death 
A) Immunohistochemical staining of phospho-Ins/IGF-1R and cleaved caspase-3 
in pancreatic tumours treated with IgG (control), 5-FU, 5-FU with xentuzumab, 
paclitaxel, and paclitaxel with xentuzumab. Scale bar, 50 µm. B) Quantification of 
cleaved caspase-3 positive dead cells in tumours treated with IgG (control), 5-FU, 
5-FU with xentuzumab, paclitaxel, and paclitaxel with xentuzumab (3-5 fields 
counted/ tumour tissues from 5-6 mice per treatment group), * p ≤ 0.05 using 
unpaired two tailed T-test. 
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3.3 DISCUSSION 
The findings described in this chapter indicate that stromal-derived IGF-1 and IGF-2 
from TAMs and CAFs are inducers of chemoresistance in KPC-derived PDAC cells in 
vitro and in vivo against gemcitabine administration. The results obtained using an 
orthotopic preclinical PDAC model suggest the use of IGF-blocking antibodies in 
combination with chemotherapy, specifically gemcitabine, may increase effectiveness 
of gemcitabine treatment of pancreatic cancer patients.  
 
The role of the TME in response to chemotherapy has been subject to speculation 
due to the TME’s bi-directional signalling with tumour cells which can influence many 
aspects of tumour progression. Based on the findings in this chapter, TAMs and 
CAFs, the most abundant cells in the PDAC TME, appear to play a direct role in the 
induction of chemoresistance in pancreatic cancer cells against gemcitabine. TAM 
and CAF-secreted IGFs participate in a paracrine signalling loop which bind and 
activate the InsR and IGF-1R on tumour cells activating survival pathways thereby 
reducing the response of pancreatic cancer cells to chemotherapy, specifically 
gemcitabine.  
 
 In agreement with the findings described here, a recent study using a proteomic 
approach has reported fibroblasts secrete IGF after exposure to KPC-pancreatic 
tumour cells, promoting cancer cell survival and increased proliferation in vitro (Tape 
et al., 2016). In this chapter, it has further been confirmed that IGF production by both 
fibroblasts and macrophages in the TME occurs in PDAC tumours in vivo and 
contributes towards tumour cell survival. 
 
Chemoresistance is a large obstacle in effective PDAC treatment, it has routinely 
been shown that gemcitabine administration has little effect in PDAC patients 
(Mitchem et al., 2013, Gunderson et al., 2016, Zhu et al., 2014). Our preclinical PDAC 
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model mimicked this modest response and has further shown that IGF signalling 
induced resistance towards gemcitabine in this model. Thus revealing the therapeutic 
opportunity of combining IGF inhibition, with gemcitabine, the current standard 
chemotherapeutic for PDAC. In orthotopic preclinical models of PDAC used here, 
inhibition of IGFs increased PDAC sensitivity to gemcitabine shown by a reduction in 
tumour size and increased levels of cell death within the primary tumour mass. 
However, further studies should be undertaken to elucidate the exact mechanism 
behind IGF’s effect on gemcitabine efficacy. Such as whether increased amounts of 
gemcitabine are taken up in response to IGF blockade or whether downstream 
effectors of gemcitabine metabolism are affected.   
 
So far IGF-1R inhibitors have been unsuccessful in PDAC in the clinic, often due to 
aberrations in metabolism (Zha et al., 2010, Guha, 2013, King et al., 2014, Gradishar 
et al., 2016). However, IGF blocking Ab’s, such as xentuzumab used here, are being 
developed to bind IGF ligands and prevent proliferative but not metabolic signalling. 
Two IGF-blocking antibodies, MEDI-573 and xentuzumab, are currently being 
evaluated in phase II clinical trials for metastatic breast cancer (MEDI-573), and 
metastatic breast cancer and castration-resistant prostate cancer (xentuzumab; 
Clinicaltrials.gov identifiers: NCT02204072, NCT01446159, NCT02123823). 
However, clinical trials are currently lacking for PDAC, and our pre-clinical model work 
would support future investigations.  
 
The stromal compartment of PDAC is comprised of a variety of non-malignant cells 
and extra-cellular matrix proteins which function to support tumour initiation, 
progression and drug resistance. This could explain the limited effectiveness of the 
recent therapies developed for PDAC, which only exert a modest effect as they 
specifically target tumour cells. Current therapies have not significantly improved 
patient outcome and thus, therapies which target both the neoplastic cells and the 
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pro-tumourigenic functions of the stromal compartment will likely achieve a better 
therapeutic response. 
 
Overall the studies in this chapter suggest that in PDAC, stromal-derived IGFs can 
reduce response to chemotherapy via an IGF ligand - Ins/IGF-1R paracrine signalling 
axis and provide the rationale for further investigation into the combination of 
gemcitabine with IGF signalling blockade in pancreatic cancer treatment (Ireland et 
al. 2016). 
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Chapter Four:  
Blockade of insulin-like growth factors increases 
efficacy of paclitaxel in metastatic breast cancer 
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4.1 INTRODUCTION 
4.1.1 Triple negative breast cancer (TNBC)  
Breast cancer is a solid tumour which is currently the leading cause of cancer death 
in females worldwide (Siegel et al., 2017). TNBC is a highly metastatic subtype of 
breast cancer that accounts for ~ 20 % of all breast cancer cases, but has limited 
efficacious treatment options (Wahba and El-Hadaad, 2015). The current standard of 
care for metastatic TNBC includes radiotherapy and chemotherapy such as paclitaxel 
the standard agent, however, these treatments lack specificity due to the deficiency 
of targets such as hormone or HER2 receptors which are found in other breast cancer 
subtypes (Rakha et al., 2007, Schneider et al., 2008). Based on this, the TNBC 
subtype has the poorest survival rate, due to the absence of specific targeted therapy 
and its biology being comparatively less understood compared to other subtypes 
(Bauer et al., 2007).  
 
Breast cancer has a propensity to give rise to metastasis at distant sites such as 
lungs, bone and brain which can present up to 10 years after treatment (Weigelt et 
al., 2005). Patients with metastatic breast cancer ultimately become resistant to 
chemotherapy treatment and as a result account for >90 % of breast cancer deaths 
(Marquette and Nabell, 2012), highlighting the need for new therapeutic targets to 
treat metastatic burden more effectively. 
 
4.1.2 TNBC TME and chemoresistance 
A tumours response to therapy can be influenced by its surrounding TME (Klemm and 
Joyce, 2015, Fantozzi and Christofori, 2006). Macrophages are  the most abundant 
leukocytes in the breast TME (Williams et al., 2016) and an increased TAM presence 
has been shown to correlate with a poorer prognosis (Bingle et al., 2002, Campbell et 
al., 2011, Leek et al., 1996). TNBC also possesses a rich desmoplastic reaction 
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surrounding the tumour which comprises of several subtypes of activated CAF, which 
perform subtype-dependent functions (Costa et al., 2018). 
 
Chapter 3 of this thesis describes the role of IGF signalling in PDAC chemotherapy 
resistance. The tumour stroma of PDAC and breast cancer share similar 
characteristics in that they both exhibit infiltrating macrophages and the presence of 
dense fibrosis. The IGF signalling axis has been implicated in promoting cancer 
progression in several tumour types including breast cancer (Zhang et al., 2011, 
Denduluri et al., 2015, Pollak, 2008). IGF signalling has also been implicated in breast 
cancer resistance to estrogen and HER2 receptor inhibition (Zhang et al., 2011, Lu et 
al., 2001, Massarweh et al., 2008, Farabaugh et al., 2015). However, the role of IGF 
signalling in chemoresistance in TNBC breast cancer is not yet completely understood 
(Farabaugh et al., 2015).  
 
4.1.3 TNBC mouse models  
To fully investigate the role of IGF signalling in TNBC chemoresistance it was 
necessary to utilise immunogenic preclinical models which recapitulate the human 
disease. MMTV-PyMT mice have been shown to develop breast cancer which is 
recapitulative of human TNBC, with tumour cells lacking expression of hormone 
receptors and low expression of HER2 (Guy et al., 1992, Davie et al., 2007). Py230 
cells isolated from this model can be orthotopically implanted into recipient mice to 
create TNBC-like tumours (Maglione et al., 2001). 4T1 cells isolated from a 
spontaneously arising tumour in BALB/cfC3H mice (Dexter et al., 1978) also create a 
breast tumour along with pulmonary metastasis when orthotopically implanted into 
BALB/c mice (Pulaski and Ostrand-Rosenberg, 1998) 
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4.1.4 Hypothesis 
Stromal TAMs and CAFs play an active role in IGF signalling in TNBC tumours and 
influence chemoresistance in this setting. 
 
4.1.5 Aims 
 Creation of preclinical TNBC mouse model  
 Identify TAMs and CAFs as sources of IGF in primary tumour 
 Investigate pulmonary metastasis in mouse model  
 Analyse the stroma at the metastatic site and presence of IGF 
 Block IGF signalling in vivo to assess effect on tumour progression in 
combination with chemotherapy treatment 
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4.2 RESULTS 
 
4.2.1 TAMs and CAFs are the main sources of IGF-1 and IGF-2 in primary 
tumours in Py230 invasive breast cancer mouse model 
Due to the previous findings in the PDAC mouse model described in chapter 3 and 
the similarities between PDAC and breast cancer TME, we investigated the effect of 
Ins/IGF-1R activation in the promotion of chemoresistance in TNBC.  
 
To analyse this, Py230 luc/zsGreen (HR-, Her2 low) murine breast cancer cells from 
MMTV-PyMT genetically engineered spontaneous breast cancer model were 
orthotopically implanted into the mammary fat pad of isogenic immunocompetent 
recipient C57BL/6J mice. Tumours were harvested 42 days after implantation and 
processed for FACS sorting of TAMs, CAFs and tumours cells (Fig 4.1 A).  
 
TAM infiltration into the tumour tissue was characterised by immunofluorescent 
staining which showed high levels of F4/80+ macrophage infiltration surrounding 
actively proliferating Ki67+ tumour cells (Fig 4.1 B). Immunohistochemical staining of 
the same tissue showed the tumour mass had active InsR and IGF-1R signalling and 
these tumour cells were surrounded by M2-like (CD68+, CD206+) macrophages (Fig 
4.1 C).  
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As the murine TNBC tissue showed activated Ins/IGF-1R it was important to identify 
the stromal source(s) of the IGF-1 and IGF-2 ligands in the TME. Tumour cells (CD45-
, zsGreen+), non-immune stromal cells (CD45-, zsGreen-) and TAMs (CD45+, F4/80+) 
were FACS sorted from the Py230 tissue (Fig 4.2 A) and analysed by qPCR. Non-
immune stromal cells were shown to highly express αSMA, indicating the majority of 
cell population were αSMA+ CAFs (Fig 4.2 B). 
 
 
Figure 4.1 Murine TNBC tumours have activated Ins/IGF-1 receptors and are 
infiltrated by macrophages 
A) Py230 tumour cells were subcutaneously implanted into the third mammary 
gland of syngeneic recipient mice. B) Images show immunofluorescent staining 
for F4/80 (green), Ki67 (red), and nuclei (blue) in murine breast cancer tissue 
harvested at day 42 after tumour implantation, scale bar 50 μm. C) Serial sections 
of immunohistochemical staining for CD68, CD206 and phospho-Ins/IGF-1 
receptor in murine breast tumours. Scale bar 50 μm. 
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Figure 4.2 Gating strategy for FACS-sorting tumour cells, macrophages and 
non-immune stromal cells. 
A) Gating strategy used to FACS sort alive (Sytox-), CD45- (APC-Cy7) /zsGreen+ 
Py230 breast cancer cells, CD45-(APC-Cy7)/zsGreen- non-immune stromal cells, 
CD45+(APC-Cy7)/F4/80+(APC) macrophages from day 42 harvested mouse Py230 
primary orthotopic breast tumours. B) qPCR quantification of αSMA mRNA 
expression levels indicative of activated myofibroblasts in tumour cells, non-immune 
stromal cells and macrophages FACS sorted from primary breast tumours (n=3 
technical replicates). 
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To determine which of the sorted cell populations expressed IGF ligands and were 
therefore responsible for activating Ins/IGF-1 receptors on tumour cells, qPCR 
analysis was performed for Igf-1 and Igf-2 ligand expression. Macrophages expressed 
the highest levels of Igf-1 (Fig 4.3 A), whereas both TAMs and CAFs were both shown 
to be the major sources of Igf-2 expression in the primary site TME (Fig 4.3 B).  
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Macrophages and non-immune stromal cells express Igf-1 and Igf-2 
in the primary TME   
Quantified mRNA expression levels in tumour cells, non-immune stromal cells and 
tumour-associated macrophages FACS sorted from murine breast cancer tumours. 
A) Igf-1 expression, B) Igf-2 expression. Error bars represent SEM (n = 3 technical 
replicates), * p value ≤ 0.05 using one-way ANOVA and Bonferroni post hoc test. 
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To determine the location of the CAF stromal cells in relation to the tumour cells, 
tissues were immunofluorescently stained revealing αSMA+ CAFs surrounded 
actively dividing Ki67+ tumour cells in the primary breast cancer tissue (Fig 4.4).  
 
  
 
 
4.2.2 Metastasis-associated macrophages and fibroblasts remain sources of 
IGF-1 and IGF-2 in pulmonary metastatic lesions 
 
Human TNBC breast cancer is a highly invasive disease which usually metastasizes 
to the lung. To analyse if this was also seen the Py230 TNBC-like orthotopic 
syngeneic model, metastatic foci in lungs were confirmed by bioluminescence ex vivo 
imaging using IVIS technology to detect Py230 luc/zsGreen cells, and foci were 
subsequently detected in sectioned lung tissue via hematoxylin and eosin (H&E) 
staining (Fig. 4.5).  
 
 
 
 
Figure 4.4 αSMA+ CAFs cells surround actively dividing breast tumour cells  
Immunofluorescently stained primary orthotopic PY230 breast tumour tissue 
harvested day 42 after implantation. αSMA+ (green) cancer-associated fibroblast 
are seen surrounding actively dividing tumour cells (Ki67+, red), and nuclei (blue) 
in primary breast tumours. Scale bar 50 μm. 
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Lung sections which were identified as having metastatic foci by serial sectioning and 
H&E staining, were immunofluorescently stained for macrophages (F4/80+), 
myofibroblasts (αSMA+) and proliferating tumour cells (Ki67+). This staining showed, 
similar to the primary tumour, metastatic lesions had actively proliferating tumour cells 
surrounded by macrophages and myofibroblasts in the stroma (Fig 4.6).  
 
 
 
 
 
Figure 4.5 Lung metastatic foci are formed in Py230 orthotopically implanted 
mice  
Left, identification of metastatic tumour lesions in the lung by bioluminescent imaging 
technique to detect Py230 luc/zsGreen breast cancer cells. Right, images show H&E 
staining of metastatic foci in the lungs. Arrows indicate metastatic foci, scale bars 
200 μm, 100μm, and 50 μm. 
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As TAMs and CAFs in the primary TME were stromal sources of IGF-1 and IGF-2 
ligands it was logical to investigate whether this phenomenon was also seen the 
pulmonary metastatic foci. To address this question, metastatic tumour cells (CD45-, 
zsGreen+), non-immune stromal cells (CD45-, zsGreen-) and metastasis associated-
macrophages (MAMs) (CD45+, F4/80+) were FACS sorted from the collected lungs 
(Fig 4.7 A). Again, to confirm the presence of myofibroblasts, qPCR analysis showed 
the non-immune stromal cells from metastatic foci expressed the highest levels of 
αSMA indicating the majority of the cells were CAFs (Fig 4.7 B) 
 
 
Figure 4.6 Macrophages and myofibroblasts surround dividing tumour cells 
in pulmonary metastatic foci.  
Immunofluorescent staining of Py230 metastatic foci in lungs harvested 42 days 
after primary site implantation. Confirmed presence of F4/80+ (green) metastasis 
associated macrophages (top), αSMA+ (green) metastasis associated fibroblasts 
(bottom) surrounding actively dividing Ki67+ (red) cells, and nuclei (blue). Scale 
bar 50 μm. 
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Figure 4.7 FACS gating strategy to sort for tumour cells, myofibroblasts and 
macrophages  
A) Gating strategy used to FACS sort CD45-/zsGreen+ metastatic Py230 breast 
cancer cells, CD45-/zsGreen- non-immune stromal cells, CD45+F4/80+ 
macrophages from mouse lung metastatic foci harvested 43 days after primary 
site implantation B) Quantification of αSMA mRNA expression levels in the 
different cell populations isolated from lung metastatic foci using flow cytometry 
(n=3 technical replicates). 
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The FACS sorted populations were analysed by qPCR for Igf-1 and Igf-2 expression. 
Similar to the observation at the primary site, MAMs and metastasis-associated 
fibroblasts (MAFs) expressed high levels of Igf-1 and Igf-2, whereas disseminated 
breast cancer cells do not express these ligands (Fig. 4.8 A and B). Together, these 
findings provide evidence that macrophages and fibroblasts are the sources of IGF-1 
and IGF-2 both at the primary and the metastatic site in the Py230 invasive breast 
cancer model. 
 
 
 
 
 
 
 
 
 
Figure 4.8 Expression of Igf-1 and Igf-2 in tumour cells, non-immune stromal 
cells and macrophages from lung metastasis.  
Quantification of mRNA expression levels in metastatic tumour cells, metastasis-
associated non-immune stromal cells and metastasis-associated macrophages 
isolated from pulmonary metastasis by FACS sorting. A) Igf-1 expression, B) Igf-2 
expression. Error bars represent SEM (n = 3 technical replicates), * p-value ≤ 0.05, 
*** p-value ≤ 0.0001, using one-way ANOVA and Bonferroni post hoc test. 
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4.2.3 Combination treatment with paclitaxel and IGF blocking antibody reduces 
tumour cell proliferation and metastasis in an orthotopic Py230 model 
 
Based on the findings in chapter 3 of this thesis, IGF signalling may also affect breast 
cancer progression and metastasis when challenged with paclitaxel, a standard agent 
used in the treatment of breast cancer. To test this, mice were orthotopically implanted 
with Py230 luc/zsGreen TNBC-like cells and treated with isotype control IgG antibody 
(n=8), xentuzumab IGF-1/2 blocking antibody (n=8), paclitaxel (n=8), or a combination 
of xentuzumab with paclitaxel (n=8) (Fig. 4.9 A). 
 
To determine the effectiveness of xentuzumab IGF blocking Ab in the Py230 breast 
cancer model, tumours were harvested and stained by immunohistochemistry for 
pIns/IGF-1R. Control IgG and paclitaxel treated mice showed high levels of Ins/IGF-
1R activation in the primary tumours (Fig 4.9 B and C). Xentuzumab treatment as a 
single agent and in combination with paclitaxel markedly reduced activation levels of 
Ins/IGF-1R, confirming that xentuzumab had reached the tumour and blocked IGF 
signalling (Fig 4.9 B and C). 
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Figure 4.9 Py230 orthotopic breast cancer model treated with xentuzumab 
shows a reduction in Ins/IGF-1R activation 
A) Py230 luc/zsGreen cells were orthotopically implanted into the third mammary 
fatpad of syngeneic C57BL/6J recipient mice. Treatment was started when tumours 
reached between 5–8mm2, twice a week i.p., with control IgG antibody, IGF blocking 
antibody xentuzumab (100 mg/kg), paclitaxel (100 mg/kg), or a combination of 
xentuzumab with paclitaxel (n = 8 mice per group). B) Immunohistochemical 
staining of phospho-insulin/IGF-1R in breast tumours treated with IgG (control), 
paclitaxel, xentuzumab or paclitaxel with xentuzumab. Scale bars 100 μm and 50 
μm. C) Quantification of immunohistochemical staining of pInsR/IGF-1R. Error bars 
represent SEM (4 fields counted/mouse tumour, n =4 mice per treatment group). Ns 
non-significant, ** p-value ≤ 0.001, using one-way ANOVA and Bonferroni post hoc 
test. 
Chapter Four 
127 
 
 
To determine when to begin treatment of the mice and to monitor tumour progress 
throughout the experiment, the growth of the primary tumours was measured bi-
weekly using calipers. These measurements revealed no differences in primary 
tumour growth throughout the course of treatment (Fig 4.10 A). Despite this, treatment 
could still have an effect on tumour composition, therefore, the tissues were 
immunofluorescently stained for Ki67 to determine the levels of proliferating tumour 
cells. These levels were shown to be modestly reduced by both paclitaxel and 
xentuzumab single treatments and significantly reduced by the combination treatment 
of xentuzumab with paclitaxel compared to control IgG (Fig 4.10 B and C). 
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Figure 4.10 Tumour cell proliferation is significantly decreased with 
paclitaxel and xentuzumab combination treatment  
A) Tumour mean diameter (mm2) measured by calipers before and during 
treatment with IgG control, xentuzumab, paclitaxel and paclitaxel with 
xentuzumab. B) Immunofluorescent staining of Ki67 in primary tumours treated 
with IgG (control), paclitaxel, xentuzumab, or paclitaxel with xentuzumab, scale 
bar 50 μm. C) Quantification of Ki67 staining. Error bars represent SEM (3–5 
fields counted/mouse tumour, n = 3–4 mice per treatment group), * p ≤ 0.05 
using one-way ANOVA and Bonferroni post hoc test. 
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TAM infiltration into the primary tumour was analysed by flow cytometry analysis of 
the CD45+/F4/80+ macrophage population (Fig 4.11 A). Quantification of the F4/80+ 
macrophage population among CD45+ cells revealed no significant difference 
between the percentage of macrophages found infiltrating the primary tumour mass 
in any treatment groups (Fig 4.11 B).  
 
 
Figure 4.11 No significant differences are seen in TAM infiltration in any 
treatment groups 
A) Flow cytometry gating strategy to analyse Sytox-/CD45+/F4/80+ macrophages 
in the digested tumour. B) Quantification of F4/80+ macrophages among CD45+ 
immune cells in control IgG, paclitaxel, xentuzumab and paclitaxel with 
xentuzumab treated tumours (n=3 technical replicates). Error bars represent SEM, 
(n= 3 biological replicates), ns, non-significant.  
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The Py230 orthotopic mouse model recapitulates metastasis to the lung, therefore we 
were also able to investigate whether treatment effected pulmonary metastatic 
burden. Firstly, mice with metastatic foci were identified by IVIS imaging and H&E 
staining of the lung foci. This revealed 7/8 mice in each of the control IgG, paclitaxel 
and xentuzumab treatment groups mice with metastatic foci (Fig 4.12 A). However, 
the combination treatment of xentuzumab with paclitaxel showed a reduction of lung 
metastasis incidence, with only 5/8 mice possessing detectable lesions (Fig 4.12 A). 
However, statistical analysis revealed the incidence of metastatic lesions was not 
significantly associated with their treatment received (Fig 4.12 B).  
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The reduction of metastatic incidence could be due to an overall decrease in 
disseminated tumour cells seeding in the lung. To investigate this, the average 
number of foci per 100 mm2 was quantified through H&E staining of the entire lung 
and identification by light microscopy. This analysis did not reveal significant changes 
in the average number of lesions in any treatment group (Fig 4.13). Interestingly, 
paclitaxel treated mice showed a slight increase in the number of foci compared to 
the other treatment groups (Fig 4.13).  
 
 
Figure 4.12 Quantification of mice with pulmonary metastatic foci 
A) Percentage of mice presenting with lung metastatic foci per treatment group 
detected by IVIS imaging and H&E staining. (n = 8 mice/group). B) 
Contingency table and results from statistical analysis showing no significant 
correlation between treatment and presence of lung metastasis. Chi-square = 
2.46; p = 0.48. 
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As significant differences were not seen in the seeding of disseminated tumour cells, 
it was possible the outgrowth of foci was affected by treatment, ultimately reducing 
metastatic burden. The average metastatic lesion size was calculated for each 
treatment group by measuring foci sizes throughout the entire lung. Paclitaxel 
treatment alone and xentuzumab alone modestly reduced the average lesion size 
compared to control IgG treated mice, but not by a significant margin (Fig 4.14 A and 
B). Interestingly, mice which received the combination treatment of paclitaxel with 
xentuzumab showed a bigger yet still modest reduction in foci lesion size compared 
to control IgG treated mice (Fig 4.14 A and B).  
 
Figure 4.13 Paclitaxel treated mice show a slight increase in average number 
of foci per 100 mm2   
Quantification of number of lung metastatic foci per 100 mm2 in whole lung H&E 
stained sections of mice treated with control IgG, paclitaxel, xentuzumab, or 
paclitaxel with xentuzumab, (n=4 lungs per group) ns, non-significant differences 
using one-way ANOVA and Bonferroni post hoc test. 
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Figure 4.14 Combination treatment of paclitaxel with xentuzumab 
significantly reduced average metastatic lesion size   
A) Average size of pulmonary metastatic lesions (mm2) in whole sectioned lungs 
stained by H&E mice treated with control IgG, paclitaxel, xentuzumab, or 
paclitaxel with xentuzumab, (n=4 per group) * p ≤ 0.05, using one-way ANOVA 
and Bonferroni post hoc test. B) Representative H&E staining of lung metastatic 
foci (outlined by dashed line) in mice treated with control IgG, paclitaxel, 
xentuzumab, or paclitaxel with xentuzumab. Scale bar 50 μm. 
Chapter Four 
134 
 
The combination of foci size and frequency provided a measure of total metastatic 
burden, which was calculated for each treatment group. Paclitaxel treatment and 
xentuzumab treatment alone reduced metastatic burden in the Py230 orthotopic 
TNBC-like mouse model, which was further modestly reduced by combination 
treatment of paclitaxel and xentuzumab (Fig 4.15). These data suggest that treatment 
with either paclitaxel or xentuzumab or in combination likely impairs outgrowth of 
disseminated breast cancer cells in metastatic foci. 
 
 
 
 
 
 
 
 
 
Figure 4.15 Combination paclitaxel with xentuzumab treatment significantly 
reduces total metastatic burden 
Total metastatic burden (mm2) in whole lungs stained by H&E of mice treated with 
control isotype IgG antibody, paclitaxel, xentuzumab, and paclitaxel with 
xentuzumab, (n=4 per group) * p ≤ 0.05, using one-way ANOVA and Bonferroni 
post hoc test 
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4.2.4 Paclitaxel and IGF blocking antibody combination treatment reduces 
tumour cell proliferation and metastasis in a syngeneic orthotopic 4T1 model 
 
To confirm the results seen in the Py230 model, 4T1 (HR-, HER2-) luc/zsGreen cells 
were implanted into the mammary fatpad of syngeneic BALB/c mice and treated with 
IgG control antibody (n=8), paclitaxel (n=9), xentuzumab (n=8), or paclitaxel with 
xentuzumab (n=9) (Fig. 4.16 A). To determine whether xentuzumab treatment was 
also effective in this model, tumours were immunohistochemically stained for 
pIns/IGF-1R.  In accordance with the previous model, Ins/IGF-1R activation was 
significantly reduced in mice treated with xentuzumab alone and paclitaxel with 
xentuzumab combination (Fig. 4.16 B and C). 
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Figure 4.16 4T1 breast cancer cells possess active insulin and IGF-1 
receptor signalling. A) 4T1 luc/zsGreen cells were orthotopically implanted 
into the third mammary fatpad of syngeneic Balb/c recipient mice and were 
treated when tumours reached ~ 5 mm2 mean diameter, over 2 weeks the 
mice received four treatments by i.p. with control human IgG antibody (10 
mg/kg) (n = 8 mice), xentuzumab IGF blocking antibody (100 mg/kg) (n = 8 
mice), paclitaxel (100 mg/kg) (n = 9 mice) or combination of xentuzumab with 
paclitaxel (n = 9 mice). B) Immunohistochemical staining of phospho-Ins/IGF-
1R in 4T1 breast tumours. Scale bar 100 μm. C) Quantification of 
immunohistochemical staining of pInsR/IGF-1R. Error bars represent SEM (3 
fields counted/mouse tumour, n =8 mice per treatment group). Ns non-
significant, *** p-value ≤ 0.001, **** p-value ≤ 0.0001 using one-way ANOVA 
and Bonferroni post hoc test. 
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As with the previous model, tumour growth was measured bi-weekly using calipers to 
determine when to begin treatment and to continuously monitor the effect of treatment 
on primary tumour growth. Interestingly in this breast cancer model, primary tumour 
growth was significantly reduced by paclitaxel treatment and further significantly 
reduced by the combination treatment of paclitaxel with xentuzumab (Fig. 4.17). 
 
 
 
 
 
 
 
 
Figure 4.17 Primary tumour growth is retarded by paclitaxel and 
combination paclitaxel with xentuzumab treatment   
Graph showing tumour mean diameter (mm2) measured by calipers before and 
during treatment with isotype IgG control, xentuzumab, paclitaxel, and paclitaxel 
with xentuzumab. Error bars represent SEM (IgG antibody and xentuzumab n = 8, 
paclitaxel and paclitaxel with xentuzumab n = 9), * p-value ≤ 0.05, ** p-value ≤ 
0.01 using two-way ANOVA and Bonferroni post hoc test. 
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Again intrinsic changes were seen in tumour composition, paclitaxel treated mice 
exhibited a significant reduction in Ki67+ cells compared to control IgG treated mice 
(Fig 4.18 A and B). However a more significant decrease was caused by combination 
paclitaxel with xentuzumab treatment (Fig 4.18 A and B).  
 
 
 
 
Figure 4.18 Paclitaxel alone and combination treatment significantly 
reduces Ki67+ cells in the primary tumour 
A) Immunofluorescent staining of Ki67 in primary tumours treated with IgG 
(control), paclitaxel, xentuzumab, or paclitaxel with xentuzumab. Scale bar 50 μm. 
B) Quantification of Ki67 staining. A total of 3–5 fields counted/mouse tumour, n = 
8–9 mice per treatment group, ns, non-significant differences, ** p ≤ 0.01, *** ≤ 
0.0001 p using one-way ANOVA and Bonferroni post hoc test.  
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The presence of pulmonary metastasis was analysed in the 4T1 breast cancer model, 
revealing xentuzumab alone or in combination with paclitaxel treatment reduced the 
number of mice presenting with pulmonary metastasis (Fig 4.19 A). To analyse 
changes in tumour cell seeding, the average number of metastatic foci per 100 mm2 
was calculated. Paclitaxel alone and in combination with xentuzumab treatment both 
significantly reduced the average number of metastatic foci per 100 mm2 compared 
to control IgG treated mice (Fig 4.19 B). 
 
 
Figure 4.19 Paclitaxel and paclitaxel with xentuzumab treatment reduced 
metastatic incidence and reduced average number of foci 
A) Percentage of mice presenting with lung metastasis per treatment group. B) 
Quantification of number of lung metastatic foci per 100mm2 in mice treated with 
control IgG (n=7), paclitaxel (n=9), xentuzumab (n=8), or paclitaxel with 
xentuzumab (n=9). Error bars represent SEM, ns, non-significant differences, * p 
value ≤ 0.05, using one-way ANOVA and Bonferroni post hoc test. 
Chapter Four 
140 
 
Average metastatic foci size was calculated to indicate changes in metastatic 
outgrowth. This analysis revealed the combination treatment of paclitaxel with 
xentuzumab significantly reduced the average metastatic lesion size compared to 
control IgG treated mice (Fig 4.20 A and B).  
 
 
Figure 4.20 Combination treatment paclitaxel with xentuzumab significantly 
reduces metastatic lesion size 
A) Average size of pulmonary metastatic lesions (mm2) in whole lungs of mice 
treated with control IgG, paclitaxel, xentuzumab, or paclitaxel with xentuzumab. 
Error bars represent SEM. (n=7-9 lungs per treatment group), ns, non-significant 
differences, ** p ≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. B) 
Representative H&E staining of lung metastatic foci in treatment group, indicated 
by dashed line. Scale bar 50 μm 
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Foci size and frequency were combined in order to calculate total metastatic burden; 
which revealed the combination treatment of paclitaxel with xentuzumab significantly 
reduced overall metastatic burden of 4T1 implanted mice compare to IgG treated 
control, although paclitaxel alone and xentuzumab alone both reduced burden, 
suggesting an additive effect (Fig 4.21). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21 Combination treatment paclitaxel with xentuzumab significantly 
reduced total metastatic burden 
Total metastatic burden (mm2) in whole lungs of mice treated with control IgG, 
paclitaxel, xentuzumab, and paclitaxel with xentuzumab (n=7–9 lungs per 
treatment group). Error bars represent SEM., ns, non-significant differences, ** p 
≤ 0.01, using one-way ANOVA and Bonferroni post hoc test. 
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4.3 DISCUSSION 
Breast cancer, and in particular TNBC, are highly metastatic and potentially lethal 
diseases which require identification of specific molecular targets and development of 
more effective therapies (Schneider et al., 2008, Bauer et al., 2007). IGF signalling 
been reported to support the progression of HR+ and HER2+ breast cancer along 
with conferring resistance to established therapies (Zhang et al., 2011, Lu et al., 2001, 
Massarweh et al., 2008, Farabaugh et al., 2015).  However, the precise role of IGF in 
TNBC had remained elusive (Farabaugh et al., 2015).  
 
In the invasive TNBC models used here, it was found that TAMs and CAFs secrete 
IGF-1 and IGF-2 at both the primary tumour site and pulmonary metastatic site. Zhang 
et al., previously reported CAF-derived IGF-1 primes breast cancer cells for bone 
metastasis (Zhang et al., 2013). This study in combination with the data shown here 
suggest stromal-derived IGF from TAMs and CAFs may play an important role in the 
metastatic process of breast cancer and in this particular case may promote 
dissemination to the lungs or at least support outgrowth in the lungs. 
 
To investigate the therapeutic potential of blocking IGF signalling in invasive breast 
cancer xentuzumab, an IGF-1/2 blocking antibody developed by Boehringer 
Ingelheim, was tested in two preclinical mouse models of invasive TNBC breast 
cancer, which metastasized to the lungs. In both models, however more significantly 
in the 4T1 model, combination treatment of xentuzumab with paclitaxel reduced 
incidence of metastasis, as well as a reduction of tumour cell proliferation compared 
to monotherapy of either agent. In agreement with these findings, Gooch et al., 
previously showed that IGF-1 promotes proliferation of paclitaxel treated cells in vitro 
(Gooch et al., 1999). Interestingly, in this study administration of xentuzumab was 
shown to increase the efficacy of paclitaxel the commonly used chemotherapeutic 
agent for the treatment of invasive breast cancer; decreasing pulmonary metastatic 
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lesion size however not the number of foci suggesting that the combination treatment 
likely affects outgrowth of metastatic tumour cells rather than metastatic seeding. 
 
IGF-1R inhibitors have been assessed in clinical trials for metastatic HR+ breast 
cancer, as well as TNBC, but have shown limited success (Robertson et al., 2013, 
Ma et al., 2013, Jones et al., 2015, Gradishar et al., 2016, Guha, 2013, Lodhia et al., 
2015). Two IGF ligand blocking antibodies, xentuzumab and MEDI-573, are currently 
being evaluated in clinical trials in HR+ metastatic breast cancer patients in 
combination with everolimus and exemestane (NCT02123823) and in hormone 
sensitive metastatic breast cancer in combination with letrozole (NCT01446159), 
respectively. In contrast to IGF-1R antibodies, IGF blocking antibodies neutralize both 
ligands IGF-1 and IGF-2 and thereby inhibit proliferative signalling through both 
insulin and IGF-1 receptors without affecting insulin metabolic signalling (Friedbichler 
et al., 2014). 
 
Breast cancer cells survive poorly in isolation and participate in a complex relationship 
with surrounding stromal and immune cells in the TME, which can support tumour cell 
survival, proliferation and dissemination to other organs (Qian et al., 2015, Shree et 
al., 2011, DeNardo et al., 2011, Lin et al., 2001, Zhang et al., 2013). CAFs and TAMs 
are the most abundant stromal cells in solid cancers, including breast cancer. 
However, different populations of CAFs and TAMs with both pro- and anti-
tumourigenic functions co-exist (Ohlund et al., 2017, Mills et al., 2016, Augsten, 2014). 
Therefore, therapies aiming to specifically inhibit tumour supporting functions of 
stromal cells, without affecting their anti-tumourigenic functions, may be more 
effective than ablation therapies in restraining tumour progression (Quail and Joyce, 
2013, Aslakson and Miller, 1992). The findings in this chapter suggest IGF blockade 
in combination with paclitaxel, reduces tumour cell proliferation levels, also reducing 
pulmonary metastasis without affecting macrophage infiltration. In conclusion, this 
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study suggests that stromal-derived IGFs may support breast cancer pulmonary 
metastasis outgrowth and may modulate tumour cell response to paclitaxel (Ireland 
et al. 2018). 
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Chapter Five: 
PDAC tumours with varying metastatic 
potential express differing secretome 
profiles  
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Five 
146 
 
CONTENTS 
5.1 INTRODUCTION…………………………………………………………………….147 
5.1.1 PDAC……………………………………………………………………………147 
5.1.2 Mesothelin………………………………………………………………………147 
5.1.3 Mesothelin in cancer …………………………………………………………..148 
5.1.4 Hypothesis………………………………………………………………………149 
5.1.5 Aims………………………………………………………………………. ……149 
5.2 RESULTS …………………………………………………………………….......... 150 
5.2.1 Orthotopically implanted FC1242, FC1245 and FC1199 cells  
        create tumours with varied aggressiveness…………………………………150 
5.2.2 FC1245 tumours show a slight decrease in vasculature and  
        collagen deposition compared to FC1199 and FC1242 tumours…………156 
5.2.3 Rationale for a proteomic approach to determine secretome  
         differences between FC1199, FC1242 and FC1245 cells…………………158 
5.2.4 SILAC mass spectrometry approach for secreted factors ………………...159 
5.2.5 Reliability of SILAC mass spectrometry data……………………………….160 
5.2.6 Identification of significantly differentially abundant proteins  
in FC1245 samples ………………………………………………………………..…163    
5.2.7 Mesothelin expression in FC1245 cells ……………………………………..168 
5.2.8 Mesothelin expression in FC1245, FC1242 and FC1199 cells…………...171 
5.3 DISCUSSION………………………………………………………………………..175
  
 
 
 
 
Chapter Five 
147 
 
5.1 INTRODUCTION 
5.1.1 PDAC  
Pancreatic cancer is a highly metastatic disease which infiltrates into the peritoneum 
and uses the lymphatic and vascular system to spread into the liver and lungs 
(Humphris et al., 2014, Pandol et al., 2009). Patients are usually described as being 
asymptomatic until metastasis impedes bodily function resulting in jaundice or 
breathing difficulty due to blockage of the common bile duct or growth in the lung 
respectively (Claire et al., 2016).  
 
Although most cancer patients succumb due to cachexia, a high metastatic burden 
significantly effects the quality of a patient’s life. Tumours grow as a tissue, with cells 
possessing varying genetic mutations performing different functions. This genetic 
heterogeneity can create tumours with varying propensity for metastatic outgrowth 
(Meacham and Morrison, 2013). This means PDAC is not uniform among patients 
and some will experience a more aggressive disease than others.  
 
Chapter 3 of this thesis utilised an orthotopic mouse model of PDAC. PDAC tumour 
cells from the KPC GEMM were implanted into the tail of the pancreas creating a 
PDAC tumour mass with ductal structures, but also developed the associated rich 
TME with infiltrating macrophages and desmoplasia of activated fibroblasts. However, 
metastasis was not investigated in this orthotopic model and cells isolated from the 
KPC GEMM may also have varying metastatic potential. Metastatic potential and 
disease progression can be mediated by many factors but in particular, by secreted 
proteins which interact with surrounding cells to promote movement and invasion. 
 
5.1.2 Mesothelin  
In healthy tissues, mesothelin expression is limited to mesothelial cells which line the 
pleura, peritoneum and pericardium (Hassan et al., 2004).  Mesothelin exists as a 71 
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kDa precursor protein which is proteolytically cleaved by the endoprotease furin to 
create two protein products: N-terminus megakaryocyte potentiating factor (MPF) and 
C-terminus mature mesothelin (mMSLN) (Chang and Pastan, 1996). MPF is a 31 kDa 
protein secreted from cells and functions as a cytokine to stimulate colony formation 
of bone marrow megakaryocytes through IL-3 stimulation in the bone marrow 
(Yamaguchi et al., 1994). mMSLN is a 40 kDa glycoprotein which can remain 
membrane bound through a glycophosphatidylinositol (GPI) anchor or shed from the 
cell via cleavage by TNF-α converting enzyme (Chang and Pastan, 1996, Zhang et 
al., 2011, Dangaj et al., 2011).  The exact function of mMSLN is not known but it may 
function as a cell surface adhesion protein (Kojima et al., 1995, Chang and Pastan, 
1996).  
 
5.1.3 Mesothelin in cancer  
Mesothelin has been identified as a tumour antigen in neoplasia arising in mesothelial 
cells. However, it has also been confirmed as aberrantly expressed in other cancers 
including pancreatic, ovarian, lung, stomach cholangiocarcinoma and TNBC (Hassan 
et al., 2004, Ho et al., 2007, Tchou et al., 2012, Argani et al., 2001). It has been shown 
in tumours that mMSLN can bind to mucin 16 (Muc16) which has been associated 
with progression of mesothelioma and ovarian cancer into the peritoneum (Rump et 
al., 2004). Due to the secreted nature of mesothelin, it has been found at elevated 
levels in the serum of breast and lung cancer patients compared to healthy volunteers 
(Robinson et al., 2003). Although mesothelin as a blood biomarker for  PDAC patients 
has currently been unsuccessful (Sharon et al., 2012). One important finding in 
ovarian cancer has shown that mMSLN cleaved from the cell can engage with the 
mannose receptor of TAMs, promoting an immunosuppressive phenotype and 
therefore tumour progression (Dangaj et al., 2011).  
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5.1.4 Hypothesis 
Tumour cells can influence their own progression through the secretion of specific 
factors. These secreted factors differ between tumour cells of differential metastatic 
potential.  
 
5.1.5 Aims 
 To identify tumour cells with differing metastatic potential using a preclinical 
orthotopic mouse model 
 To SILAC label tumour cells and analyse secreted factors by mass 
spectrometry 
 Bioinformatic analysis of SILAC mass spectrometry data 
 Identification of differing factors secreted by KPC-derived PDAC cell lines 
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5.2 RESULTS 
5.2.1 Orthotopically implanted FC1242, FC1245 and FC1199 cells create 
tumours with varied aggressiveness  
Human PDAC disease and the KPC genetic PDAC mouse model are known to 
metastasise to the liver and lungs (Humphris et al., 2014, Pandol et al., 2009, 
Hingorani et al., 2003). As shown in chapter 3 of this thesis, orthotopic implantation 
of KPC-derived PDAC tumour cells into the tail of the pancreas creates a tumour mass 
recapitulative of the human disease. This posed the question as to whether the 
orthotopic implantation model also recapitulated metastasis to the liver and lungs after 
an extended period of tumour growth (Fig 5.1 A). 
 
To investigate this in our model, three KPC-derived cell lines, FC1199 luc/zsGreen, 
FC1242 luc/zsGreen and FC1245 luc/zsGreen were each implanted into the pancreas 
of syngeneic C57BL/6J recipient mice (n=3 per cell line) to determine which cell line 
created the largest metastatic burden (Fig 5.1 B). To maximise the potential of 
metastasis occurring, the mice were maintained until they met humane endpoint as 
dictated by project license restrictions. To monitor welfare, the mice were checked 
three times a week to supervise weight loss, restrictions in movement, dehydration 
and loss of appetite.  
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Unexpectedly, the three FC1245 tumour-bearing mice met humane endpoint at 19, 
22 and 25 days after implantation due to 20 % weight loss and restriction of movement 
and were culled via a schedule one method in accordance with project license 
restrictions (Fig 5.2 A). One FC1242 tumour bearing mouse was culled at 51 days 
after implantation meeting endpoint description due to 20 % weight loss, however, the 
remaining FC1242 (n=2) and FC1199 (n=3) tumour bearing mice were culled on day 
56 after implantation due to deterioration of their general condition (Fig 5.2 A).   
 
Figure 5.1 Schematic of orthotopic implantation into pancreas and metastasis 
to liver and lungs    
A) Cells isolated from the KrasG12D/+; p53R172H/+; Pdx1-Cre genetic PDAC mouse 
model were orthotopically implanted into the tail of the pancreas of syngeneic 
recipient C57BL/6J mice. PDAC cells penetrate the peritoneum and colonise the 
liver and lungs creating metastatic foci. B) KPC-derived cell lines FC1199 
luc/zsGreen, FC1242 luc/zsGreen and FC1245 luc/zsGreen were implanted into the 
pancreas of C57BL/6J mice (n=3 mice per cell line). 
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At the time of harvesting, primary PDAC tumour, liver and lungs were resected. 
Interestingly, FC1245 tumours showed no significant differences in size compared to 
FC1242 or FC1199 tumours despite being harvested around 30 days earlier (Fig 5.2 
B).  
 
 
 
 
 
Figure 5.2 FC1245-tumour bearing mice exhibit reduced survival but no 
significant change in tumour size  
A) Survival percentage of FC1199, FC1242 and FC1245 tumour bearing mice 
over the course of the experiment (n=3 mice per cell line). B) Representative 
images of harvested tumours and tumour weights at time of harvesting for 
FC1199, FC1242 and FC1245 tumours (n=3 tumours per cell line). n.s = non-
significant p = 0.5995 using one-way ANOVA and Tukey post hoc test 
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Before sacrifice, two mice from each cell implantation group (FC1199 mice Cage (Cg) 
1.1 and Cg1.3, FC1242 mice Cg2.2 and Cg2.3 and FC1245 mice Cg3.1 and Cg4.2) 
were imaged using IVIS technology to detect in vivo signal from luc/zsGreen tumour 
cells. A high signal was detected in the abdomen, approximately in the location of the 
pancreas, in all mice imaged (representative images Fig 5.3). Post mortem ex vivo 
IVIS imaging of resected primary tumour, liver and lungs confirmed solid PDAC 
tumours were formed and liver and lung metastasis was established by all cell lines 
(Fig 5.3).  
 
 
 
 
 
 
 
Figure 5.3 In vivo and ex vivo IVIS imaging confirms the presence of liver 
and lung metastasis   
IVIS imaging of in vivo FC1199 luc/zsGreen, FC1242 luc/zsGreen and FC1245 
luc/zsGreen tumour bearing mice, 1 minute exposure. Ex vivo IVIS imaging of 
primary PDAC tumour, liver and lungs to detect zsGreen+ tumour cells, 1 minute 
exposure.  
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IVIS analysis of the ex vivo PDAC tumours revealed, aside from the Cg1.1 FC1199 
tumour, all tumours collected on day 56 had very similar levels of luciferase activity 
indicating the tumours have grown to a similar extent (Fig 5.4 A). Interestingly, the 
FC1245 tumours had comparatively higher luciferase activity at days 19 and 22 after 
implantation than the majority of tumours harvested at day 56, despite the non-
significant changes in tumour mass (Fig 5.4 A).  
 
Liver metastasis was confirmed by analysis of ex vivo IVIS readings. FC1245 livers 
exhibited high levels of luciferase activity (total flux per second) indicative of higher 
numbers of luc/zsGreen tumour cells at days 19 and 22 after implantation (Fig 5.4 B).  
FC1199 Cg1.1 mouse liver exhibited the highest luciferase activity (total flux per 
second) (Fig 5.4 B). FC1242 livers harvested at day 56 exhibited the lowest levels of 
liver metastasis among the three cell lines. (Fig 5.4 B). 
 
Ex vivo lung metastasis imaging revealed FC1199 lungs again showed mouse Cg1.1 
had the highest levels of total flux indicating more tumour cells (Fig 5.4 C).  FC1245 
lungs possessed metastasis, although mouse Cg3.1 harvested at day 22 had signal 
similar to or higher than day 56 lungs, excluding FC1199 Cg1.1 (Fig 5.4 C).  Overall, 
the levels of total flux detected in FC1245 livers and lungs were higher than the 
majority of livers and lungs harvested at day 56, indicating metastasis had occurred 
sooner or more successfully with this cell line compared to FC1199 and FC1242 cell 
lines (Fig 5.4 B and C). 
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Figure 5.4 FC1245 tumours exhibit metastasis to liver and lungs by day 19 
Quantification of ex vivo IVIS imaging detecting luciferase activity (total flux per 
second) of FC1199 mice Cg1.1 and Cg1.3, FC1242 mice Cg2.2 and Cg2.3 and 
FC1245 mice Cg3.1 and Cg4.2. A) Primary PDAC tumours, B) Liver metastasis, C) 
Lung metastasis. Day of harvesting indicated for each tumour. 
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5.2.2 FC1245 tumours show a slight decrease in vasculature and collagen 
deposition compared to FC1199 and FC1242 tumours.   
Due to the differences seen in metastatic potential and the severe decrease in life 
expectancy with FC1245 implanted mice, it was important to investigate whether any 
major differences were obvious within the primary tumour itself. Therefore, the primary 
PDAC tumours were serially sectioned and immunohistochemically stained for CD31 
vasculature marker, CD3 T cell marker, αSMA myofibroblast marker and picrosirius 
red staining for collagen deposition (Fig 5.5 A). Quantification of CD31 staining for 
endothelial cells revealed a tendency of FC1245 tumours to possess reduced 
vasculature, although this was not significantly decreased (Fig 5.5 B).  Presence of 
CD3 T cells showed no significant differences between the tumours, although FC1199 
showed a slight decrease in T cell infiltration (Fig 5.5 B). As previously mentioned, 
CAFs are an abundant cell type in the TME which has been reported to both restrain 
and support tumour growth.  Identification of αSMA+ CAFs in the tumours showed 
variable results across all tumours of FC1199, FC1242 and FC1245 origin and 
ultimately showed no significant difference among the tumour types (Fig 5.5 B). 
Perturbations in collagen deposition can affect the migration of tumour cells and 
therefore influence metastasis. Quantification of picrosirius red staining revealed no 
significant differences, however, FC1245 tumours showed a slight decrease 
compared to FC1199 and FC1242 primary tumours (Fig 5.5 B).  
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Figure 5.5 FC1199, FC1242 and FC1245 tumours show no significant 
differences in primary tumour composition   
A) Immunohistochemical staining of serial sections of FC1199, FC1242 and 
FC1245 tumours for CD31 vascular marker, CD3 T cell marker, αSMA CAF 
marker and picrosirius red collagen deposition, scale bar 7 mm. B) Quantification 
of CD31 positive staining n.s. = non-significant p=0.5147, CD3- positive cells 
p=0.4844, αSMA-positive stain p=0.6771 and picrosirius red stain p=0.3040, 
using one-way ANOVA and Tukey post hoc test in FC1199, FC1242 and FC1245 
tumours (n=3 tissues stained per marker).  
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5.2.3 Rationale for a proteomic approach to determine secretome differences 
between FC1199, FC1242 and FC1245 cells  
It is known that the tumour and the TME partake in a bi-directional cross-talk which 
can influence tumour progression (Hanahan and Coussens, 2012). Therefore, 
FC1245 tumour cells may produce an altered secretome profile to support their 
increased metastatic potential. Although not significant, the tissue stainings revealed 
a slight decrease in vasculature and collagen deposition which could also be mediated 
by secreted factors. These reasons provided the rationale to investigate the 
secretome profiles of the FC1199, FC1242 and FC1245 tumour cells to determine 
any altered secreted factors which could influence tumour progression and metastasis 
(Fig 5.6).  
 
 
 
 
Figure 5.6 Proteomic experimental rationale to investigate FC1199, FC1242 
and FC1245 cells 
A schematic to depict the rationale behind a proteomic approach to determine 
secretome profile of FC1199, FC1242 and FC1245 primary murine PDAC tumour 
cells generated from the KPC GEMM of PDAC. To investigate differences in 
tumour secretome profile which may identify factors which signal to immune cells 
and mediate fibroblast activation in the tumour microenvironment altering the 
tumour progression.  
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5.2.4 SILAC mass spectrometry approach for secreted factors  
Stable isotope labelling with amino acids in cells culture (SILAC) mass spectrometry 
is an attractive proteomic approach in this case as it enables quantitative analysis of 
proteins rather than qualitative identification. FC1199, FC1242 and FC1245 tumour 
cells may secrete the same factors but their expression levels of the proteins may be 
altered influencing TME interactions.  
 
The FC1245, FC11199 and FC1242 tumour cells were incubated with light, medium 
and heavy SILAC media respectively, to allow incorporation of carbon 13 and nitrogen 
15 labelled amino acids into proteins. The CM was collected and subjected to a triplex 
liquid chromatography tandem mass spectrometry (LC-MS/MS) to identify 
quantitative changes in secreted proteins (Fig 5.7).  
 
 
 
 
Figure 5.7 SILAC mass spectrometry experimental design   
PDAC tumour cells incubated with serum free non-phenol red SILAC media: 
FC1245 cells with light R0K0 12C SILAC media, FC1199 cells with medium R6K6 
13C media and FC1242 cells with heavy R10K8 13C and 15N media in vitro. Media 
was collected after 24 hr incubation and mixed 1:1:1 and analysed by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) (n=4 biological 
replicates).  
Mixed 1:1:1 and 
subjected to LC-
MS/MS
Triplex experimental set up:  
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5.2.5 Reliability of SILAC mass spectrometry data   
The raw files from LC-MS/MS were run through Maxquant software to perform peak 
picking and create ratios for the quantitative measure of secreted proteins. Due to the 
nature of Maxquant SILAC sample analysis, the output created ratios of Heavy/Light 
(FC1242/FC1245), Medium/Light (FC1199/FC1245) and Heavy/Medium 
(FC1242/FC1199) labelled samples for each replicate (n=4). Principal component 
analysis (PCA) was performed by means of quality control on the four triplex 
replicates. FC1242/FC1245, FC1199/FC1245 and FC1242/FC1199 ratios perfectly 
separated, with the replicates each building a segregated cluster confirming 
reproducibility (Fig 5.8).  
 
 
 
Figure 5.8 Principal component analysis of SILAC replicates shows a high 
degree of similarity 
Principal component analysis (PCA) of triplex secretome SILAC mass spectrometry 
replicates analysed by Perseus software. PCA based on gene ontology of biological 
processes annotation using Benjamini-Hochberg cut off (FDR=0.05). Replicates of 
triplex samples were processed into FC1199/FC1245, FC1242/FC1245 and 
FC1242/FC1199 ratios which cluster independently.  
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To further investigate the relationship between individual replicates, the linear 
correlation between individual samples was calculated to identify any replicates which 
should be regarded as outliers. Direct comparisons of replicates all resulted in a 
Pearson correlation coefficient of ≥0.9 indicating a high similarity between replicates 
(Fig 5.9) 
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Figure 5.9 Pearson correlation shows sample replicates are highly comparable 
Comparison of SILAC samples by multiscatter plot showing linear correlation of 
proteins detected in each replicate FC1199/FC1245, FC1242/FC1245 and 
FC1242/FC1245 created by Perseus software. Pearson correlation coefficient 
calculated for every sample comparison and shown in blue at top left of each graph.  
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5.2.6 Identification of significantly differentially abundant proteins in FC1245 
samples  
To identify proteins with differing abundance between FC1199, FC1242 and FC1245 
cell lines, analysis of variance (ANOVA) statistical analysis was performed using the 
LIMMA statistical package in R. The results were visualised by volcano plots in which 
p value (-log10) was plotted against fold change (log2) allowing significantly abundant 
proteins to be identified (p ≤ 0.01). A comparison of FC1245 and FC1199 samples 
revealed 32 significantly enriched proteins secreted by FC1245 cells compared to 44 
significantly enriched proteins secreted by FC1199 cells (Fig 5.10 A, Sup. Table 1A). 
Comparison of FC1245 and FC1242 samples revealed 47 significantly enriched 
proteins secreted by FC1245 cells compared to 33 significantly enriched proteins 
secreted by FC1242 cells (Fig 5.10 B, Sup. Table 1B).  
 
 
 
Figure 5.10 Volcano plots reveal significantly differentially regulated proteins 
in each sample 
Volcano plots depicting ANOVA statistical analysis of protein abundance (-log10) 
against protein fold change (log2) identifying significantly enriched proteins in each 
sample above p ≤ 0.01 using ANOVA (indicated by dashed red line). A) FC1245 vs 
FC1199 B) FC1245 vs FC1242. 
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FC1245 tumours grew more aggressively in vivo compared to both FC1199 and 
FC1242 tumours, resulting in reduced life expectancy (Fig 5.2). Potential candidate 
proteins which influence FC1245’s increased progression are likely to be present at 
increased abundance compared to both FC1199 and FC1242 secretion levels. 
Comparison of FC1245, FC1242 and FC1199 samples allowed the identification of 
consistently significantly enriched proteins secreted by FC1245 samples compared to 
FC1199 (Fig 5.11 A) and FC1242 (Fig 5.11 B).   
 
 
Figure 5.11 Significantly upregulated proteins secreted by FC1245 tumour 
cells 
Identification of proteins secreted at significantly increased abundance by FC1245 
tumour cells, p ≤ 0.01 using ANOVA. Gene names indicated, shown against 
ANOVA p value (-log2).  A) FC1245 tumour cells compared to FC1199 tumour 
cells (32 proteins present at significantly increased abundance). B) FC1245 
tumour cells compared to FC1242 tumour cells (47 proteins present at significantly 
increased abundance). 
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A two-way comparison of the significantly differentially secreted proteins in each 
sample revealed 19 proteins were consistently present at significant abundance in 
FC1245 cells compared to both FC1199 and FC1242 cells (Fig 5.12, Sup. Table 1 A-
C).  
 
 
 
 
 
 
Figure 5.12 Nineteen proteins are consistently significantly secreted by 
FC1245 
Venn diagram identifying 19 proteins consistently enriched in FC1245 samples 
compared to both FC1199 and FC1242. 5 proteins were consistently enriched in 
FC1242 samples compared to both FC1245 and FC1199. 11 proteins were 
identified as consistently enriched in FC1199 samples compared to both FC1245 
and FC1242 samples. 14 proteins were identified as consistently increased in both 
FC1199 and FC1245 samples, 9 proteins were expressed by both FC1245 and 
FC1242 and 23 proteins both expressed by FC1199 and FC1242. 4 proteins were 
significantly expressed by all cell lines. 
FC1199 FC1245
FC1242
19
5
11
9
14
23
4
Increased abundance
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It was important to confirm that the nineteen proteins of increased abundance from 
FC1245 cells were truly secreted. Each protein identified by Maxquant was searched 
in SecretomeP, SignalP and TMHMM databases along with Uniprot gene ontology 
(GO) to identify secretion characteristics (Table 5.1). From this analysis, eleven 
proteins were identified as either classically or non-classically secreted (Table 5.1, 
shown in red).  Of these eleven enriched secreted proteins, mesothelin was identified 
as a protein of interest due to its identification in 60 samples of resected primary 
human PDAC and its ability to regulate growth and apoptosis in PDAC (Argani et al., 
2001).  
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5.2.7 Mesothelin expression in FC1245 cells   
SILAC mass spectrometry was performed on in vitro samples, therefore it was 
important to confirm the findings using in vivo tissue. Mass spectrometry identified 
mesothelin as abundant in FC1245 cells, however this detected sequence 
encompasses both MPF and mMSLN (Fig 5.13 A). We decided to focus these studies 
on mMSLN due to its implications in interacting with TAMs in ovarian cancer (Dangaj 
et al., 2011). To confirm whether mMSLN was differentially expressed in FC1245, 
FC1242 and FC1199 cells, it was necessary to use an antibody which bound 
specifically to the 40 kDa C-terminus portion of mesothelin. The mesothelin antibody 
Orb14370 (Biorbyt) binds specifically to the C-terminus region of precursor 
mesothelin (sequence: GLGLQGGIPNGYLVL) and therefore to cleaved 40 kDa 
mMSLN (Fig 5.13 B).  
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Figure 5.13 Mesothelin Ab Orb14370 binds to the C-terminus portion of 
mesothelin 
A) Schematic showing the maturation of mesothelin protein. Precursor 71 kDa 
protein mesothelin is synthesized with a potential signal peptide (SP) and the 
glycosylphosphatidyl inositol anchor signal sequence (GASS) are predicted at the 
NH2 terminus and the COOH terminus, respectively. The precursor protein has a 
furin cleavage site (RR). Cleavage at the furin site generates membrane-bound 
mature mesothelin (green) and the secretory protein megakaryocyte-potentiating 
factor (red). (Hassan et al., 2004). B) Identification of mesothelin antibody 
Orb14370 binding site on full length mesothelin, highlighted in yellow. From 
UniprotKB mesothelin FASTA amino acid sequence (ref: Q61468 
MSLN_MOUSE). 
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To confirm the presence of mesothelin in the in vivo setting, FC1245 tumours and 
naïve murine pancreas were immunohistochemically stained revealing a lack of 
mesothelin in healthy tissue but high expression in FC1245 tumour tissue (Fig 5.14 A 
and B). 
 
 
 
Figure 5.14 Mesothelin is detected in FC1245 tumour tissues and not in 
healthy pancreas 
A) Immunohistochemical staining of mesothelin in healthy mouse pancreas and 
FC1245 murine tumour. Scale bars 100 μm and 50 μm. B) Quantification of 
immunohistochemical staining of mesothelin in naïve murine pancreas and FC1245 
PDAC tumour. Error bars represent SEM (3 fields counted/mouse, n =3 mice per 
group). *** p-value ≤ 0.001, using one-way ANOVA and Bonferroni post hoc test. 
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To confirm the secretion of mMSLN by the FC1245 tumour cells, CM was 
concentrated and analysed by immunoblotting. FC1245 protein lysate showed a full 
length precursor mesothelin, whereas CM highly expressed mMSLN and distinctly 
lacks the full length precursor protein (Fig 5.15).  
 
 
5.2.8 Mesothelin expression in FC1245, FC1242 and FC1199 cells   
As the presence of precursor mesothelin was detected in FC1245 lysates and 
mMSLN was secreted by FC1245 tumour cells, it was important to confirm the results 
of the SILAC mass spectrometry analysis comparing expression against FC1199 and 
FC1242 cells. Firstly, all three cell lines expressed Msln, although surprisingly 
FC1199 cells expressed significantly more than FC1242 cells (Fig 5.16). 
 
 
 
 
 
 
Figure 5.15 FC1245 tumour cells secrete 40 kDa mMSLN 
Immunoblotting of FC1245 cell lysate and FC1245 concentrated conditioned 
media for the presence of mesothelin. Arrows indicate 71 kDa precursor 
mesothelin protein and cleaved 40 kDa mMSLN protein detected.  
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However, mRNA expression levels do not always correlate with protein expression 
levels. Therefore, immunohistochemical staining of all FC1245, FC1242 and FC1199 
tumours and naïve pancreas was performed for mesothelin. This again showed no 
positive staining in the healthy pancreas (Fig 5.17 A). All tumours showed positive 
staining for mesothelin however, FC1199 tumours possessed much weaker staining 
and FC1245 tissues expressed significantly higher levels of mesothelin (Fig 5.17A 
and B).  
 
 
 
 
 
Figure 5.16 FC1199, FC1242 and FC1245 cell lines express Msln 
Msln mRNA expression levels quantified in murine PDAC FC1199, FC1242 and 
FC145 tumour cells relative to GAPDH housekeeping gene.  Error bars represent 
SEM (n = 3 technical replicates), ** p ≤ 0.01 using one-way ANOVA and Tukey 
post hoc test. 
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Figure 5.17 Mesothelin expression is limited to tumour tissue but at varying 
extents 
A) Immunohistochemical staining of mesothelin in healthy pancreas, FC1199 
PDAC, FC1242 PDAC and FC1245 PDAC. Scale bars 100 μm and 50 μm. B) 
Quantification of immunohistochemical staining of mesothelin in naïve murine 
pancreas, FC1199 PDAC, FC1242 PDAC and FC1245 PDAC tumour tissue. Error 
bars represent SEM (3 fields counted/mouse, n =3 mice per group). ** p-value ≤ 
0.01, *** p-value ≤ 0.001, using one-way ANOVA and Bonferroni post hoc test. 
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To confirm that the FC1245 tumour cells secrete mesothelin at higher levels than 
FC1199 and FC1242 cells, CM was collected from all three cell lines and analysed 
by immunoblotting. This confirmed the results of the IHC and SILAC mass 
spectrometry that FC1245 cells secrete mMSLN at higher levels than FC1199 and 
FC1242 cells (Fig 5.18).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18 FC1245 cells secrete the highest levels of mMSLN 
Immunoblotting of concentrated conditioned media collected from murine PDAC 
cells: FC1199, FC1242 and FC1245 for secreted mesothelin.  Arrow indicates 
presence cleaved 40kDa mMSLN. 
Chapter Five 
175 
 
5.3 DISCUSSION 
The work in this chapter has revealed cells from the KPC PDAC genetic mouse model 
can create tumours with varying aggressiveness when orthotopically implanted into 
syngeneic mice. Orthotopic implantation of FC1245 cells resulted in mice with 
reduced life expectancy and an increased propensity for liver and lung metastasis 
compared to FC1242 and FC1199 implanted cells. 
 
Staining of the different tumour tissues revealed no significant changes in 
desmoplasia, T cell infiltration or αSMA+ myofibroblasts. Instead, only slight 
decreases in collagen deposition and CD31 vascular cells were seen in the FC1245 
tumours compared to the FC1199 and FC1242 tumours. As major differences in 
tumour composition were not apparent, these results suggested differences 
governing tumour cell dissemination may be due to secreted factors.  
 
Human PDAC patients possess genetic heterogeneity and varying levels of disease 
aggressiveness (Claire et al., 2016). Tumours are known to secrete factors which 
interact with the surrounding tumour stroma and neighbouring tumour cells to support 
outgrowth (Hanahan and Coussens, 2012). The use of SILAC mass spectrometry to 
quantitatively analyse the differences in tumour secretome between the three cell 
lines revealed nineteen consistently significantly enriched proteins secreted by the 
FC1245 cells compared to both FC1199 and FC1242 cell lines.  
 
Mesothelin was identified as a protein of interest as it was enriched in FC1245 cells 
in the SILAC proteomic approach and has previously been reported in PDAC. 
Investigation into the function of mesothelin in PDAC proliferation and migration has 
so far shown conflicting results (Zheng et al., 2012, Zervos et al., 2016, Bharadwaj et 
al., 2011). In vitro analysis using qPCR, immunoblotting and IHC confirmed the 
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FC1245 cell line released higher levels of mMSLN expression compared to FC1199 
and FC1242 cells.  
 
Research into mesothelin as a blood biomarker to aid tumour diagnosis has been 
unsuccessful in PDAC patients despite tumour cells highly expressing mesothelin on 
their surface (Sharon et al., 2012). This is interesting as it has been detected in the 
serum of lung and breast cancer patients (Robinson et al., 2003). These results could 
be explained by the involvement of the rich PDAC TME restricting its release into the 
circulatory system, although these studies are currently lacking. In ovarian cancer, it 
has been shown that cleaved mMSLN can engage with CD206 receptors on TAMs 
and induce an immune suppressive phenotype (Dangaj et al., 2011). However, 
interactions of mMSLN with other stromal components and in different tumours has 
not been explored (Fig 5.19).  
 
Mesothelin has been identified as a tumour antigen and has received attention as a 
suitable target in cancer therapy. Amatuximab (MORAb-009) is a high-affinity 
chimeric (mouse/human) monoclonal IgG1/k antibody with high affinity and specificity 
for mesothelin and has been developed and recently trialled for efficacy in PDAC 
patients in combination with gemcitabine treatment. The phase 2 trial of Amatuximab 
with gemcitabine (NCT00570713) failed to show any advantage over gemcitabine as 
a single agent. Amatuximab has been reported to bind specifically to the N-terminal 
fragment of mesothelin which binds to Muc16 receptor  and therefore reduces 
metastasis (Ma et al., 2012). However, C-terminal cleaved mMSLN would still be free 
to function and this may explain the lack of success seen in the clinical trial, 
interestingly this is the proportion identified as upregulated in PDAC in this work. 
Overall, mMSLN warrants further exploration in PDAC due its detection in the more 
aggressive FC1245 tumours.  
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Figure 5.19 Functions of mesothelin in PDAC  
Mesothelin is cleaved into N-terminal megakaryocyte potentiating factor (MPF) and C- 
terminal mature mesothelin (mMSLN). MPF interacts with IL-6 and potentiates 
megakaryocyte colony formation. mMSLN may bind to CD206 receptor on TAMs 
promoting M2 polarisation or mediate fibroblast activation or other immune cell actions. 
Protease 
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6.1 INTRODUCTION 
Chemoresistance and metastatic spread and are the major causes of mortality in 
cancer patients. PDAC and TNBC are two solid cancers which exhibit high levels of 
metastatic spread and resistance against their respective standard agents of care 
(Humphris et al., 2014, Pandol et al., 2009, Kim and Gallick, 2008, Weigelt et al., 
2005, Marquette and Nabell, 2012). The TME of both invasive breast cancer and 
PDAC are rich with non-malignant stromal cells recruited to the tumour, the most 
abundant of which being macrophages and myofibroblasts. These TAMs and CAFs 
have been implicated in the promotion of tumour progression and survival (Paulus et 
al., 2006, Wyckoff et al., 2007, Bergers et al., 2000, Bonde et al., 2012, Costa et al., 
2018). The current treatments available for both types of cancer exclusively target 
neoplastic cells which ultimately leads to patients acquiring resistance to the drug. 
Investigation into the role of the TME in chemoresistance and identification of new 
therapeutic targets which mediate resistance are therefore required. High levels of 
metastasis and advanced stage of disease reduce quality of life for cancer patients. 
Identification of tumour-released factors which mediate progression and 
aggressiveness may also provide future therapeutic targets. 
 
6.2 SUMMARY OF THE WORK IN THIS THESIS  
This thesis set out to elucidate how the TME in solid tumours, PDAC and TNBC, 
influences response to chemotherapeutic intervention, along with identifying factors 
that mediate tumour progression. Specifically, studies within this thesis were 
designed to explore secreted factors from macrophages and myofibroblasts, to 
identify ligands responsible for enhancing tumour cell survival when challenged with 
chemotherapy and testing signalling blockade in preclinical mouse models of 
neoplasia. Moreover, this thesis set out to determine variations in PDAC tumour 
progression in vivo using KPC-derived cell lines and to identify variable factors 
produced by the tumour cells. The objectives of this thesis have been met as IGF 
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signalling has been identified to enhance chemoresistance in both PDAC and 
invasive breast cancer (Fig 6.1 and 6.2) and the identification of increased abundance 
of mesothelin in advanced PDAC tumours. 
 
The first experimental chapter of this thesis investigated PDAC resistance to 
gemcitabine treatment. Human and murine PDAC cell lines tested in vitro showed 
MCM and MyoCM increased tumour cell survival after gemcitabine chemotherapy 
administration. Investigation into stromal-derived factors identified IGF-1 and IGF-2 
as some factors responsible for promoting survival of tumour cells. Further to these 
findings, preclinical PDAC mouse models treated with IGF blocking antibody in 
combination with gemcitabine exhibited higher levels of cell death within the primary 
tumour (Fig 6.1). These results suggest that IGF blockade is well tolerated in mice 
and may have future therapeutic potential in the clinic.  
 
 
Figure 6.1 IGF signalling promotes chemoresistance in PDAC  
The role of stroma-derived IGF in activation of the insulin/IGF-1R signalling survival 
pathway and in mediating chemoresistance of pancreatic cancer cells. TAMs and 
CAFs in the TME secreted IGF-1/2 which activate Insulin/IGF-1 receptors on tumour 
cells promoting resistance. IGF blockade in combination with gemcitabine resulted 
in increased levels of cell death.  
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The second experimental chapter in this thesis investigated the phenomenon of IGF-
mediated chemoresistance in TNBC-like invasive breast cancer. Preclinical models 
of implanted breast cancer cells were shown to recapitulate the human TNBC primary 
disease, including development of pulmonary metastasis. TAMs and CAFs were 
identified as stromal sources of IGF-1 and IGF-2 in both the primary tumour site and 
metastatic foci. The administration of IGF blocking antibody in combination with 
paclitaxel, the standard agent of care, reduced primary tumour growth in the 4T1-
mouse model and reduced overall metastatic burden in both preclinical models (Fig 
6.2).  
 
 
 
 
 
Figure 6.2 IGF signalling promotes chemoresistance in TNBC-like breast 
cancer 
The role of stroma-derived IGF-1 and IGF-2 in regulating the response of 
metastatic breast cancer to paclitaxel. TAMs and CAFs in the breast TME secreted 
IGF-1/2 which activate Insulin/IGF-1 receptors on breast tumour cells promoting 
resistance. IGF blockade in combination with paclitaxel resulted reduced tumour 
cell proliferation at the primary site and reduced pulmonary metastatic burden. 
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The third experimental chapter of this thesis set out to analyse spontaneous 
metastasis in the preclinical orthotopic PDAC model. Implantation of three KPC-
derived cell lines, FC1199, FC1242 and FC1245, revealed variance in their 
aggressive nature and metastatic potential. The FC1245 tumour bearing mice 
experienced a severely reduced life expectancy and early onset of metastasis 
compared to both FC1199 and FC1242 tumour bearing mice. SILAC proteomic 
analysis identified secreted proteins from the three cell lines. Nineteen proteins were 
identified as consistently enriched from FC1245 cells compared to FC1199 and 
FC1242 cells. Of these proteins, mesothelin was identified as a protein of interest due 
to the action of C-terminus mMSLN in TAM polarisation in ovarian cancer but 
unexplored functions in PDAC progression and interaction with the TME. In vitro 
validation of the SILAC mass spectrometry confirmed FC1245 cells secreted higher 
levels of mMSLN. 
 
6.3 Limitations of experimental studies 
6.3.1 Limitations of animal studies   
As with any scientific study, the data presented herein must be interpreted within the 
context and limitations of the experimental framework. The preclinical orthotopic 
PDAC mouse model used is subject to project licence restrictions which limit the size 
of tumours grown and animal welfare deterioration. This is limiting as PDAC patients 
are often at an advanced disease stage when diagnosed and their treatment initiated. 
Comparatively, tumours are implanted in the mouse model and treated soon 
afterwards. Another caveat to consider is the administration of chemotherapy. 
Patients are given gemcitabine in a specific weekly dosing schedule comprising of 
eight weeks, which is not feasible in this preclinical model due to the previously 
outlined restrictions.  
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The orthotopic preclinical breast cancer model was also subject to limitations. 
According to project licence restrictions, primary tumours were limited to 1.5 cm2 and 
visible ulceration defined as an endpoint. Breast cancer patients may develop lesions 
at larger sizes which could influence the effectiveness of treatment. Although the mice 
developed pulmonary metastasis which occurred within the time frame of the 
experiment, breast cancer patients can experience metastasis up to 10 years after 
treatment, which cannot be mimicked in this model. Again, chemotherapy 
administration was adapted for the mouse model and was therefore given in a shorter 
space of time, whereas TNBC patients are administered paclitaxel every 3 weeks.  
 
6.3.2 Limitations of proteomic analysis  
Although SILAC mass spectrometry is a sensitive detection system, analysis of the 
data required a triage approach to recognise robustly identified proteins present in 
each replicate and those that are truly secreted. Therefore, any proteins which were 
not detected in every replicate (represented by NaN) or were only identified by 1 
peptide by Andromeda peptide search engine were removed from analysis. This 
decision was taken to maintain robust analysis and minimise mis-identified proteins. 
Confirmation of secreted protein characteristics were identified by SignalP, 
SecretomeP, TMHMM, Uniprot database searching for classical and non-classical 
secretion. Proteins deemed as non-secreted by these databases may still be released 
from cells packaged in exosomes, vesicles, or by other means not currently known. 
Exclusion of any of these proteins may have resulted in particular proteins or 
expression changes being overlooked. Identification of mesothelin as a protein of 
interest was based on statistical analysis and literature searching. The other 
upregulated proteins identified may still be implicated in conferring to tumour 
progression and may be the focus of future studies.  
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6.4 Future directions 
6.4.1 IGF blockade in cancer   
The work in this thesis has shown that IGF blockade promotes efficacy of gemcitabine 
and paclitaxel chemotherapeutic agents in our preclinical mouse models of PDAC 
and TNBC-like breast cancer respectively. Future directions for these studies would 
require testing of other commonly used chemotherapeutic agents in vivo along with 
the completion of clinical trials using both xentuzumab and Medi-573 IGF-1/2 blocking 
antibodies to reveal whether the combination has efficacy in patients. 
 
IGF blocking antibodies are not currently in clinical trials for PDAC. However, IGF-1R 
antagonists have been assessed in PDAC trials in combination with chemotherapy 
but all studies were prematurely terminated due to a lack of improved survival (Kindler 
et al., 2012, Fuchs et al., 2015, Tabernero et al., 2015). In contrast to IGF-1R 
inhibition, IGF blocking antibodies neutralize both IGF-1 and IGF-2 ligands and 
thereby inhibit proliferative signalling through both insulin and IGF-1 receptors without 
affecting metabolic insulin signalling (Friedbichler et al., 2014). This may provide a 
more beneficial outcome and should be investigated in PDAC. 
 
In breast cancer, Medi-573 is currently being assessed in hormone sensitive HER2- 
metastatic breast cancer in combination with letrozole (NCT01446159). Xentuzumab 
is being trialled in HR+ metastatic breast cancer patients in combination with 
everolimus and exemestane (NCT02123823). These trials are still currently active but 
have not published any interim results to date. TNBC trials have not been established 
but may show promising results.  
 
Future directions should also encompass investigating the effect of IGF blockade in 
patients with obesity. Obesity is associated with an increased risk of the cancer 
development including pancreatic and post-menopausal breast cancer (Vainio et al., 
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2002).  Importantly, it is hypothesised hyperinsulinemia can promote cancer 
development through the reduction of IGF binding protein 1, thus increasing levels of 
active IGF-1 (Giovannucci, 2003, Calle and Kaaks, 2004). This hypothesis would fit 
the data presented in this thesis and therefore warrants further investigation into the 
role of macrophage and myofibroblast-derived IGFs during tumour initiation. As the 
development of diabetes mellitus often precedes a PDAC diagnosis, investigation into 
the administration of IGF blocking antibodies to newly diagnosed diabetic patients 
may prevent PDAC tumour development.  
 
6.4.2 Investigation into mesothelin in PDAC  
Chapter 5 of this thesis identified mMSLN as a protein of interest in PDAC progression 
due its previous implications as a tumour antigen and its polarising activity on TAMs 
previously seen in ovarian cancer (Argani et al., 2001, Dangaj et al., 2011). 
Interestingly, mesothelin has been detected in the serum of lung and breast cancer 
patients but not in PDAC patients despite its high expression at the cellular level 
(Robinson et al., 2003, Sharon et al., 2012). This phenomenon may be due to the 
dense stromal compartment surrounding PDAC, in which stromal cells may be 
interacting with mesothelin preventing it from entering the circulation. Therefore, 
future work should investigate the interactions of mMSLN with stromal components 
such as macrophages and fibroblast. mMSLN can bind to Mucin16 in the peritoneum 
(Rump et al., 2004), however the presence of this receptor on fibroblasts and 
macrophages is not yet known. Reciprocally, mMSLN still bound to tumour cells by 
their GPI anchor may still interact with surrounding stromal cells or other tumour cells 
and therefore elucidation of activated downstream signalling of mMSLN should also 
be included. This thesis has shown cleaved mMSLN is upregulated in murine PDAC 
tissue, however further investigation of mesothelin in PDAC progression should also 
encompass cleaved MPF by investigating its secretion by in vitro techniques.  
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6.5 CONCLUDING REMARKS 
In summary, the key findings presented in this thesis are: 
 TAM and CAF-derived IGF-1 and IGF-2 in the orthotopic PDAC TME enhance 
chemoresistance to gemcitabine.  
 Combination treatment of IGF blocking antibody and gemcitabine increased 
cell death in our preclinical mouse models of PDAC. 
 TAM and CAF-derived IGF-1 and IGF-2 enhanced chemoresistance to 
paclitaxel in TNBC at both the primary site and pulmonary metastatic site in 
our orthotopic model. 
 Combination treatment of IGF blocking antibody and paclitaxel reduced 
metastatic burden and primary tumour size in 4T1 preclinical mouse model. 
 KPC GEMM- derived PDAC cell lines vary in aggressiveness when 
orthotopically implanted into syngeneic recipient mice. 
 mMSLN is highly expressed by FC1245 KPC cells which may correlate with 
increased metastatic potential.  
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SUPPLEMENTARY DATA 
Supplementary Table 1A, LIMMA output from FC1245 R0K0 compared to FC1199 
R6K6 mass spectrometry Maxquant data. ANOVA analysis of FC1245:FC1199 mass 
spectrometry using expression ratios and Medium and Light intensities quantified by 
Maxquant software. Significant proteins shown in red (p ≤ 0.01). 
 
Cell line Majority 
Protein IDs 
Protein names Gene 
names 
logFC adj.P.Val 
FC1245 Q3UPN1;P2
9533 
Vascular cell adhesion 
protein 1 
Vcam1 -1.57705 9.6E-06 
FC1245 Q3TJ52;P54
728 
UV excision repair 
protein RAD23 
homolog B 
Rad23b -1.26901 1.62E-05 
FC1245 Q91XA2;G3
X8U4 
Golgi membrane 
protein 1 
Golm1 -1.23814 1.62E-05 
FC1245 E9PZ16;B1B
0C7 
Basement membrane-
specific heparan 
sulfate proteoglycan 
core protein 
Hspg2 -1.00994 3.33E-05 
FC1245 Q01853 Transitional 
endoplasmic reticulum 
ATPase 
Vcp -1.32117 7.24E-05 
FC1245 P50580;D3Y
VH7 
Proliferation-
associated protein 
2G4 
Pa2g4 -1.21518 7.24E-05 
FC1245 P10923;F8W
IP8 
Osteopontin Spp1 -1.0556 7.24E-05 
FC1245 P18760;F8W
GL3;E9Q1T2 
Cofilin-1 Cfl1 -0.72634 7.24E-05 
FC1245 Q3U9N4;P28
798 
Granulins;Acrogranin;
Granulin-1;Granulin-
2;Granulin-3;Granulin-
4;Granulin-5;Granulin-
6;Granulin-7 
Grn -0.72359 7.42E-05 
FC1245 P40142 Transketolase Tkt -0.67822 7.42E-05 
FC1245 P06797 Cathepsin 
L1;Cathepsin L1 heavy 
chain;Cathepsin L1 
light chain 
Ctsl -1.04641 0.000149 
FC1245 Q61753 D-3-phosphoglycerate 
dehydrogenase 
Phgdh -0.76386 0.000195 
FC1245 Q8C483;P26
638;A2AFS0 
Serine--tRNA ligase, 
cytoplasmic 
Sars -0.59395 0.000209 
FC1245 Q6PI17;P257
85;B1AQJ3 
Metalloproteinase 
inhibitor 2 
Timp2 -0.65571 0.00021 
FC1245 E9Q2Q0;P97
821 
Dipeptidyl peptidase 1 Ctsc -0.97258 0.000315 
FC1245 Q3TGL4;G5
E8B3;P3788
9-2;P37889 
Fibulin-2 Fbln2 -0.70687 0.000315 
FC1245 Q9D0R2 Threonine--tRNA 
ligase, cytoplasmic 
Tars -0.90048 0.000329 
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FC1245 P40124 Adenylyl cyclase-
associated protein 1 
Cap1 -0.41298 0.000411 
FC1245 Q99MN1;Q8
R2P8 
Lysine--tRNA ligase Kars -0.85075 0.000426 
FC1245 E9QN70;P02
469 
Laminin subunit beta-1 Lamb1 -0.64716 0.000481 
FC1245 Q61081 Hsp90 co-chaperone 
Cdc37 
Cdc37 -0.35924 0.000485 
FC1245 Q91YJ2 Sorting nexin-4 Snx4 -0.33938 0.000662 
FC1245 P16045 Galectin-1 Lgals1 -0.3965 0.000747 
FC1245 Q61468 Mesothelin;Megakaryo
cyte-potentiating 
factor;Mesothelin, 
cleaved form 
Msln -0.62716 0.000829 
FC1245 E9QMZ5 Plectin Plec -0.33665 0.000889 
FC1245 Q06890 Clusterin Clu -0.36837 0.000915 
FC1245 G5E8M2;G5
E8B8;P1127
6 
Fibronectin;Anastellin Fn1 -0.27675 0.001188 
FC1245 P35979 60S ribosomal protein 
L12 
Rpl12 -0.43427 0.001532 
FC1245 Q3UQ28 Peroxidasin homolog Pxdn -0.96555 0.001994 
FC1245 A2ASQ1-
3;A2ASQ1-
2;A2ASQ1 
Agrin Agrn -1.13266 0.004468 
FC1245 E9PXE7;P62
281;D3Z3M6 
40S ribosomal protein 
S11 
Rps11 -0.32376 0.006046 
FC1245 F8VQJ3;P02
468 
Laminin subunit 
gamma-1 
Lamc1 -0.2721 0.00787 
FC1245 Q93092 Transaldolase Taldo1 -0.32117 0.010453 
FC1245 P21107-
2;D3Z2H9;Q
8K0Z5;E9Q5
J9 
Tropomyosin alpha-3 
chain 
Tpm3;T
pm3-rs7 
-0.1779 0.011359 
FC1245 Q9WUM4 Coronin-1C Coro1c -0.2439 0.014121 
FC1245 Q8C243;P18
242;F6Y6L6 
Cathepsin D Ctsd -0.27769 0.018997 
FC1245 P26041 Moesin Msn -0.15141 0.026739 
FC1245 G3UYZ1;Q8
R366 
Immunoglobulin 
superfamily member 8 
Igsf8 -0.14463 0.035178 
FC1245 Q6IRU2 Tropomyosin alpha-4 
chain 
Tpm4 -0.14239 0.037014 
FC1245 Q80X90 Filamin-B Flnb -0.2923 0.044019 
FC1245 Q61171;D3Z
4A4 
Peroxiredoxin-2 Prdx2 -0.10946 0.05802 
FC1245 P35700;B1A
XW5;B1AXW
6;G3UW54;B
1AXW4 
Peroxiredoxin-1 Prdx1 -0.12486 0.059668 
FC1245 P62908;D3Y
V43 
40S ribosomal protein 
S3 
Rps3 -0.26898 0.090546 
FC1245 Q61937;Q9D
AY9;Q5SQB
0;Q5SQB5;E
9Q5T3 
Nucleophosmin Npm1;G
m5611 
-0.16736 0.099656 
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FC1245 O88342 WD repeat-containing 
protein 1 
Wdr1 -0.10977 0.099656 
FC1245 P28352 DNA-(apurinic or 
apyrimidinic site) lyase 
Apex1 -0.14166 0.131287 
FC1245 Q61001 Laminin subunit alpha-
5 
Lama5 -0.17471 0.133063 
FC1245 Q02053 Ubiquitin-like modifier-
activating enzyme 1 
Uba1 -0.12232 0.214518 
FC1245 P13020-
2;P13020 
Gelsolin Gsn -0.22338 0.473448 
FC1245 F8WH23;Q6
1581;E9Q5D
9;F8WII5 
Insulin-like growth 
factor-binding protein 7 
Igfbp7 -0.0441 0.473448 
FC1245 P58252 Elongation factor 2 Eef2 -0.03224 0.478386 
FC1245 Q6NZM2;E9
QQ01;P9806
3 
Bone morphogenetic 
protein 1 
Bmp1 -0.06357 0.561655 
FC1245 E9QLA4;E9
QLA3;E9QK
04;P97798-
5;P97798-
2;P97798-
3;P97798-
4;P97798 
Neogenin Neo1 -0.0858 0.617598 
FC1245 P48678;P48
678-
2;P48678-3 
Prelamin-A/C;Lamin-
A/C 
Lmna -0.03121 0.704455 
FC1245 P52480 Pyruvate kinase PKM Pkm -0.00096 0.985531 
FC1199 P62806 Histone H4 Hist1h4
a 
1.575865 9.6E-06 
FC1199 P30681 High mobility group 
protein B2 
Hmgb2 1.088066 1.62E-05 
FC1199 Q8CBB6 Histone H2B Hist1h2
br 
1.769042 2.31E-05 
FC1199 P27773 Protein disulfide-
isomerase A3 
Pdia3 1.215077 3.27E-05 
FC1199 E9Q0A1;Q3
UL54;Q8BVY
0 
Ribosomal L1 domain-
containing protein 1 
Rsl1d1 1.074888 4.57E-05 
FC1199 P07356;B0V
2N7;B0V2N8 
Annexin A2;Annexin Anxa2 1.132839 7.24E-05 
FC1199 E9Q616;F7B
RM2 
Ahnak Ahnak 0.862002 7.42E-05 
FC1199 Q60817; Nascent polypeptide-
associated complex 
subunit alpha 
Naca 0.945263 7.87E-05 
FC1199 P52927;Q6N
SP9 
High mobility group 
protein HMGI-C 
Hmga2 0.844229 0.00011 
FC1199 A2AGN7;B7
ZCF1;O8868
5;F6Q2E3 
26S protease 
regulatory subunit 6A 
Psmc3 0.757826 0.000111 
FC1199 P63158;D3Z
351;D3YZ18;
D3YVC6 
High mobility group 
protein B1 
Hmgb1 0.700392 0.000113 
FC1199 P17918;E9Q
7Z3 
Proliferating cell 
nuclear antigen 
Pcna 0.70027 0.000114 
FC1199 B8JJN0;F6V
QX8;B8JJM5
Complement factor 
B;Complement factor 
Gm2054
7;Cfb 
2.28959 0.000114 
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;P04186;B8J
JM6 
B Ba 
fragment;Complement 
factor B Bb fragment 
FC1199 O89093-
2;O89093;F8
WHA7 
C-C motif chemokine 
20;C-C motif 
chemokine 
Ccl20 1.171771 0.000146 
FC1199 P11499;E9Q
3D6 
Heat shock protein 
HSP 90-beta 
Hsp90a
b1 
0.618305 0.000199 
FC1199 G3XA10;Q8
VEK3 
Heterogeneous 
nuclear 
ribonucleoprotein U 
Gm2806
2;Hnrnp
u 
0.659748 0.000201 
FC1199 E9PZV5;P20
152 
Vimentin Vim 0.719226 0.000201 
FC1199 D3Z3R0;D3Y
XT4;D3YVE6
;F6TJZ4;P12
970;D3YU93;
F6YI27;F6U2
H0;F6ZVW4 
60S ribosomal protein 
L7a 
Rpl7a 0.840763 0.000201 
FC1199 Q91UZ6 DNA segment, Chr 17, 
human D6S56E 5, 
isoform CRA_c 
D17H6S
56E-5 
1.272456 0.000201 
FC1199 P17095 High mobility group 
protein HMG-I/HMG-Y 
Hmga1 0.868685 0.000202 
FC1199 Q9R0P5 Destrin Dstn 0.993266 0.000209 
FC1199 P51859;E0C
XA0;E0CYW
7 
Hepatoma-derived 
growth factor 
Hdgf 0.442787 0.00021 
FC1199 G5E839;P80
315 
T-complex protein 1 
subunit delta 
Cct4 0.638982 0.000221 
FC1199 Q8K3I3;P502
28 
C-X-C motif 
chemokine 5;GCP-2(1-
78);GCP-2(9-78) 
Cxcl5 0.432256 0.00027 
FC1199 E9Q2Z4;A3K
GL9;B7ZCQ
3;F6W687;P
09602;Q5XK
38 
Non-histone 
chromosomal protein 
HMG-17 
Gm1649
4;Hmgn
2 
0.470609 0.00027 
FC1199 P62960 Nuclease-sensitive 
element-binding 
protein 1 
Ybx1 0.884219 0.000304 
FC1199 P26040 Ezrin Ezr 0.694497 0.000355 
FC1199 P54227;D3Z
1Z8;D3Z5N2 
Stathmin Stmn1 0.54579 0.000411 
FC1199 Q8BMJ3;Q6
0872;Q3UTA
4;Q3TQZ4;E
9Q5G6 
Eukaryotic translation 
initiation factor 1A, X-
chromosomal;Eukaryot
ic translation initiation 
factor 1A 
Eif1ax;E
if1a;Gm
8300;G
m2016 
0.451531 0.000426 
FC1199 P14148;D3Z
6N4;F6XI62 
60S ribosomal protein 
L7 
Rpl7 1.032597 0.000467 
FC1199 P63242;Q8B
GY2 
Eukaryotic translation 
initiation factor 5A-
1;Eukaryotic 
translation initiation 
factor 5A-2 
Eif5a;Eif
5a2 
0.353793 0.000706 
FC1199 P60710;F8W
I82;E9Q1F2;
E9Q5F4 
Actin, cytoplasmic 
1;Actin, cytoplasmic 1, 
N-terminally processed 
Actb 0.370697 0.000743 
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FC1199 P97467;E9Q
704 
Peptidyl-glycine alpha-
amidating 
monooxygenase 
Pam 0.370419 0.000861 
FC1199 P10126;D3Y
Z68;D3Z3I8;
B7ZBW3;P6
2631 
Elongation factor 1-
alpha 1;Elongation 
factor 1-alpha 2 
Eef1a1;
Eef1a2 
0.989749 0.001087 
FC1199 Q62266 Cornifin-A Sprr1a 0.462172 0.001532 
FC1199 Q6PDM2;Q6
PDM2-
3;Q6PDM2-2 
Serine/arginine-rich 
splicing factor 1 
Srsf1 0.270404 0.001636 
FC1199 P17742 Peptidyl-prolyl cis-
trans isomerase A 
Ppia 0.264907 0.001994 
FC1199 B7FAV1;B7F
AU9;Q8BTM
8 
Filamin-A Flna 0.26162 0.002204 
FC1199 Q8BJW6 Eukaryotic translation 
initiation factor 2A 
Eif2a 0.336042 0.002572 
FC1199 Q9CY58-
3;Q9CY58-
2;Q9CY58;Q
9CY58-4 
Plasminogen activator 
inhibitor 1 RNA-
binding protein 
Serbp1 0.427715 0.00351 
FC1199 Q9Z2U0 Proteasome subunit 
alpha type-7 
Psma7 0.29337 0.003942 
FC1199 P09405 Nucleolin Ncl 0.28685 0.004468 
FC1199 P08249 Malate 
dehydrogenase, 
mitochondrial 
Mdh2 0.446215 0.005828 
FC1199 Q78PY7;Q3T
J56 
Staphylococcal 
nuclease domain-
containing protein 1 
Snd1 0.283516 0.006046 
FC1199 P09411 Phosphoglycerate 
kinase 1 
Pgk1 0.192588 0.010095 
FC1199 O08553 Dihydropyrimidinase-
related protein 2 
Dpysl2 1.130453 0.01103 
FC1199 P20029 78 kDa glucose-
regulated protein 
Hspa5 0.195957 0.012043 
FC1199 Q02819;D3Z
7D7 
Nucleobindin-1 Nucb1 0.143749 0.018468 
FC1199 Q3U111;P26
043;Q7TSG6 
Radixin Rdx 0.152075 0.018997 
FC1199 Q9EPL2-
2;Q9EPL2 
Calsyntenin-1;Soluble 
Alc-alpha;CTF1-alpha 
Clstn1 0.176588 0.025368 
FC1199 E9PX72 Glyceraldehyde-3-
phosphate 
dehydrogenase 
Gapdh;
Gm7293 
0.578934 0.026739 
FC1199 Q9CR16 Peptidyl-prolyl cis-
trans isomerase D 
Ppid 0.11569 0.040451 
FC1199 O70475;D3Z
3F7 
UDP-glucose 6-
dehydrogenase 
Ugdh 0.494024 0.043138 
FC1199 P17182;Q6P
HC1 
Alpha-enolase Eno1 0.163742 0.060053 
FC1199 P30416;F7C
AT1; 
Peptidyl-prolyl cis-
trans isomerase 
FKBP4 
Fkbp4 0.106386 0.090013 
FC1199 Q9D8N0 Elongation factor 1-
gamma 
Eef1g 0.084608 0.189551 
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FC1199 Q60864 Stress-induced-
phosphoprotein 1 
Stip1 0.0617 0.247624 
FC1199 P24369 Peptidyl-prolyl cis-
trans isomerase B 
Ppib 0.066101 0.247624 
FC1199 E9PYL7;F2Z
4A3 
FAT atypical cadherin 
1 
Fat1 0.443347 0.294436 
FC1199 Q60709;Q61
482;Q06335-
2;Q06335 
Amyloid-like protein 2 Aplp2 0.101062 0.367465 
FC1199 Q8CGC7 Bifunctional 
glutamate/proline--
tRNA 
ligase;Glutamate--
tRNA ligase;Proline--
tRNA ligase 
Eprs 0.100679 0.475322 
FC1199 P63017;Q50
4P4 
Heat shock cognate 71 
kDa protein 
Hspa8 0.037336 0.617598 
FC1199 P62983;E9Q
9J0 
Ubiquitin-40S 
ribosomal protein 
S27a 
Rps27a 0.048031 0.65055 
FC1199 P63005;P63
005-2 
Platelet-activating 
factor acetylhydrolase 
IB subunit alpha 
Pafah1b
1 
0.023912 0.83535 
FC1199 Q8VDD5 Myosin-9 Myh9 0.012274 0.941623 
FC1199 O70251 Elongation factor 1-
beta 
Eef1b 0.001377 0.985531 
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Supplementary Table 1B LIMMA output from FC1245 R0K0 compared to FC1242 
R10K8 mass spectrometry Maxquant data. ANOVA analysis of FC1245:FC1242 
mass spectrometry using expression ratios and Heavy and Light intensities quantified 
by Maxquant software. Significant proteins shown in red (p ≤ 0.01). 
Cell line Majority 
protein IDs 
Protein names Gene names logFC adj.P.Val 
FC1245 G5E8M2;G5
E8B8;P1127
6 
Fibronectin;Anast
ellin 
Fn1 -2.80087 8.25E-10 
FC1245 P10923;F8W
IP8 
Osteopontin Spp1 -3.70079 1.22E-09 
FC1245 Q3TJ52;P54
728 
UV excision repair 
protein RAD23 
homolog B 
Rad23b -1.26126 1.52E-07 
FC1245 P06797 Cathepsin L1 Ctsl -1.23366 1.60E-07 
FC1245 G3UYZ1;Q8
R366 
Immunoglobulin 
superfamily 
member 8 
Igsf8 -1.86141 2.37E-07 
FC1245 A2ASQ1-
3;A2ASQ1-2 
Agrin;Agrin N-
terminal 110 kDa 
subunit 
Agrn -1.68244 2.37E-07 
FC1245 Q01853 Transitional 
endoplasmic 
reticulum ATPase 
Vcp -1.2109 2.37E-07 
FC1245 Q61937;Q9D
AY9;Q5SQB
0 
Nucleophosmin Npm1 -0.90464 9.21E-07 
FC1245 P50580;D3Y
VH7 
Proliferation-
associated protein 
2G4 
Pa2g4 -0.91267 1.09E-06 
FC1245 Q6IRU2 Tropomyosin 
alpha-4 chain 
Tpm4 -0.81534 1.26E-06 
FC1245 Q3U9N4;P28
798 
Granulins;Acrogra
nin;Granulin-
1;Granulin-
2;Granulin-
3;Granulin-
4;Granulin-
5;Granulin-
6;Granulin-7 
Grn -1.0038 1.95E-06 
FC1245 Q61753 D-3-
phosphoglycerate 
dehydrogenase 
Phgdh -0.90583 2.52E-06 
FC1245 Q6PI17;P257
85;B1AQJ3 
Metalloproteinase 
inhibitor 2 
Timp2 -0.89034 2.52E-06 
FC1245 Q3UQ28 Peroxidasin 
homolog 
Pxdn -0.71549 2.91E-06 
FC1245 Q9D0R2 Threonine--tRNA 
ligase, 
cytoplasmic 
Tars -0.85869 3.37E-06 
FC1245 P16045 Galectin-1 Lgals1 -0.76099 3.49E-06 
FC1245 E9QN70;P02
469 
Laminin subunit 
beta-1 
Lamb1 -0.75978 4.56E-06 
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FC1245 Q91XA2;G3
X8U4 
Golgi membrane 
protein 1 
Golm1 -0.66451 4.57E-06 
FC1245 P18760;F8W
GL3;E9Q1T2 
Cofilin-1 Cfl1 -0.68713 5.42E-06 
FC1245 E9Q2Q0;P97
821 
Dipeptidyl 
peptidase 1; 
Ctsc -0.96287 6.87E-06 
FC1245 E9PZ16;B1B
0C7 
Basement 
membrane-
specific heparan 
sulfate 
proteoglycan core 
protein 
Hspg2 -1.52466 1.20E-05 
FC1245 P52927;Q6N
SP9 
High mobility 
group protein 
HMGI-C 
Hmga2 -0.56555 1.24E-05 
FC1245 P26041 Moesin Msn -0.54871 1.68E-05 
FC1245 Q8C483;P26
638;A2AFS0 
Serine--tRNA 
ligase, 
cytoplasmic 
Sars -0.56404 2.72E-05 
FC1245 Q61081 Hsp90 co-
chaperone Cdc37  
Cdc37 -0.53819 2.75E-05 
FC1245 P35979 60S ribosomal 
protein L12 
Rpl12 -0.54703 3.16E-05 
FC1245 Q3UPN1;P2
9533 
Vascular cell 
adhesion protein 
1 
Vcam1 -0.43866 4.58E-05 
FC1245 E9QLA4;E9
QLA3 
Neogenin Neo1 -0.47729 6.43E-05 
FC1245 Q3TGL4;G5
E8B3;P3788
9-2;P37889 
Fibulin-2 Fbln2 -0.84742 7.22E-05 
FC1245 Q99MN1;Q8
R2P8 
Lysine--tRNA 
ligase 
Kars -0.57258 0.000143 
FC1245 Q61171;D3Z
4A4 
Peroxiredoxin-2 Prdx2 -0.33466 0.00032 
FC1245 Q61468 Mesothelin;Megak
aryocyte-
potentiating 
factor;Mesothelin, 
cleaved form 
Msln -0.4962 0.000384 
FC1245 P54227;D3Z
1Z8;D3Z5N2 
Stathmin Stmn1 -0.40234 0.000509 
FC1245 Q8C243;P18
242;F6Y6L6 
Cathepsin D Ctsd -0.41798 0.000561 
FC1245 Q9WUM4 Coronin-1C Coro1c -0.32693 0.000561 
FC1245 P17742;E9Q
1E3 
Peptidyl-prolyl cis-
trans isomerase A 
Ppia -0.36615 0.000632 
FC1245 P40124 Adenylyl cyclase-
associated protein 
1 
Cap1 -0.47172 0.000844 
FC1245 Q93092 Transaldolase Taldo1 -0.32449 0.00102 
FC1245 F8WH23;Q6
1581;E9Q5D
9;F8WII5 
Insulin-like growth 
factor-binding 
protein 7 
Igfbp7 -0.27566 0.001321 
FC1245 P48678;P48
678-
2;P48678-3 
Prelamin-
A/C;Lamin-A/C 
Lmna -0.50724 0.001344 
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FC1245 D3Z3R0;D3Y
XT4;D3YVE6
;F6TJZ4 
60S ribosomal 
protein L7a 
Rpl7a -0.23181 0.002151 
FC1245 Q6NZM2;E9
QQ01;P9806
3 
Bone 
morphogenetic 
protein 1 
Bmp1 -0.28504 0.002809 
FC1245 Q9EPL2-
2;Q9EPL2 
Calsyntenin-
1;Soluble Alc-
alpha;CTF1-alpha 
Clstn1 -0.33716 0.003977 
FC1245 P21107-
2;D3Z2H9;Q
8K0Z5;E9Q5
J9 
Tropomyosin 
alpha-3 chain 
Tpm3;Tpm3-rs7 -0.21228 0.005037 
FC1245 E9QMZ5;Q9
QXS1-
3;E9Q3W4 
Plectin Plec -0.28867 0.005267 
FC1245 P63005;P63
005-2 
Platelet-activating 
factor 
acetylhydrolase 
IB subunit alpha 
Pafah1b1 -0.2143 0.007441 
FC1245 Q9CR16 Peptidyl-prolyl cis-
trans isomerase D 
Ppid -0.25327 0.009311 
FC1245 Q8BJW6;Q8
BJW6-2 
Eukaryotic 
translation 
initiation factor 2A 
Eif2a -0.20897 0.010103 
FC1245 Q8VDD5 Myosin-9 Myh9 -0.31319 0.011777 
FC1245 P17182;Q6P
HC1 
Alpha-enolase Eno1 -0.2169 0.011829 
FC1245 P13020-
2;P13020 
Gelsolin Gsn -0.89472 0.012067 
FC1245 Q61001 Laminin subunit 
alpha-5 
Lama5 -0.18148 0.012067 
FC1245 P20029 78 kDa glucose-
regulated protein 
Hspa5 -0.3097 0.013955 
FC1245 P35700;B1A
XW5;B1AXW
6;G3UW54;B
1AXW4 
Peroxiredoxin-1 Prdx1 -0.16195 0.014675 
FC1245 P62908;D3Y
V43 
40S ribosomal 
protein S3 
Rps3 -0.15 0.032336 
FC1245 Q9CY58-
3;Q9CY58-
2;Q9CY58;Q
9CY58-4 
Plasminogen 
activator inhibitor 
1 RNA-binding 
protein 
Serbp1 -0.26031 0.044811 
FC1245 P17095 High mobility 
group protein 
HMG-I/HMG-Y 
Hmga1 -0.14337 0.044811 
FC1245 P62983;E9Q
9J0;E9Q0Z8;
E9Q4P0;E9
Q5F6 
Ubiquitin-40S 
ribosomal protein 
S27a 
Rps27a;Uba52;
Kxd1;Ubc;Ubb 
-0.18922 0.04608 
FC1245 E9PXE7;P62
281;D3Z3M6 
40S ribosomal 
protein S11 
Rps11 -0.18984 0.060841 
FC1245 O88342 WD repeat-
containing protein 
1 
Wdr1 -0.16954 0.08002 
FC1245 F8VQJ3;P02
468 
Laminin subunit 
gamma-1 
Lamc1 -0.10146 0.113711 
FC1245 P40142 Transketolase Tkt -0.08705 0.115524 
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FC1245 Q02053 Ubiquitin-like 
modifier-activating 
enzyme 1 
Uba1 -0.11483 0.120128 
FC1245 P51859;E0C
XA0;E0CYW
7 
Hepatoma-
derived growth 
factor 
Hdgf -0.0935 0.232554 
FC1245 Q9Z2U0 Proteasome 
subunit alpha 
type-7 
Psma7 -0.06746 0.232554 
FC1245 O70251 Elongation factor 
1-beta 
Eef1b -0.07579 0.287538 
FC1245 A3KGL9;B7Z
CQ3;F6W68
7;P09602;Q5
XK38 
Non-histone 
chromosomal 
protein HMG-17 
Hmgn2 -0.06705 0.304888 
FC1245 P63017;Q50
4P4 
Heat shock 
cognate 71 kDa 
protein 
Hspa8 -0.04689 0.387982 
FC1245 P09405 Nucleolin Ncl -0.06925 0.46963 
FC1245 P24369 Peptidyl-prolyl cis-
trans isomerase B 
Ppib -0.03444 0.520284 
FC1245 Q8CGC7 Bifunctional 
glutamate/proline-
-tRNA ligase 
Eprs -0.03614 0.752289 
FC1245 Q60864 Stress-induced-
phosphoprotein 1 
Stip1 -0.01595 0.752289 
FC1242 Q8K3I3;P502
28 
C-X-C motif 
chemokine 
5;GCP-2(1-
78);GCP-2(9-78) 
Cxcl5 3.088823 7.92E-10 
FC1242 B8JJN0;F6V
QX8;B8JJM5 
Complement 
factor B 
Cfb 1.847933 3.20E-08 
FC1242 E9Q616;F7B
RM2 
Ahnak Ahnak 1.292232 2.37E-07 
FC1242 P62806 Histone H4 Hist1h4a 1.198726 3.65E-07 
FC1242 Q91UZ6 DNA segment, 
Chr 17, human 
D6S56E 5, 
isoform CRA_c 
D17H6S56E-5 1.243566 4.45E-07 
FC1242 Q8CBB6;Q9
21L4;Q8CGP
2;Q8CGP1;Q
6ZWY9 
Histone H2B Hist1h2br 1.278259 5.45E-07 
FC1242 Q9R0P5 Destrin Dstn 1.067895 1.09E-06 
FC1242 P26040 Ezrin Ezr 0.867968 1.26E-06 
FC1242 P10126;D3Y
Z68 
Elongation factor 
1-alpha 1 
Eef1a1;Eef1a2 0.997776 1.64E-06 
FC1242 P07356;B0V
2N7;B0V2N8 
Annexin 
A2;Annexin 
Anxa2 0.852984 2.52E-06 
FC1242 Q60817;P70
670 
Nascent 
polypeptide-
associated 
complex subunit 
alpha 
Naca 0.733319 2.91E-06 
FC1242 P97467;E9Q
704 
Peptidyl-glycine 
alpha-amidating 
monooxygenase 
Pam 0.621469 5.55E-06 
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FC1242 A2AGN7;B7
ZCF1;O8868
5;F6Q2E3 
26S protease 
regulatory subunit 
6A 
Psmc3 0.61582 7.07E-06 
FC1242 Q91YJ2 Sorting nexin-4 Snx4 0.62148 1.24E-05 
FC1242 P30681 High mobility 
group protein B2 
Hmgb2 0.571297 1.40E-05 
FC1242 Q06890;E9P
UU2;E9PXG
5;E9Q8Y5;E
9Q9B8 
Clusterin;Clusteri
n beta 
chain;Clusterin 
alpha chain 
Clu 0.614143 1.75E-05 
FC1242 O08553 Dihydropyrimidina
se-related protein 
2 
Dpysl2 0.617449 2.41E-05 
FC1242 E9PX72;E9P
X42;P16858;
E9PZH9;E9
QAC7;E9Q9
E5 
Glyceraldehyde-
3-phosphate 
dehydrogenase 
Gapdh 1.130828 3.76E-05 
FC1242 Q60709;Q61
482;Q06335-
2;Q06335 
Amyloid-like 
protein 2 
Aplp2 1.010859 6.43E-05 
FC1242 P63158;D3Z
351;D3YZ18;
D3YVC6 
High mobility 
group protein B1 
Hmgb1 0.465768 7.42E-05 
FC1242 P30416;F7C
AT1;D6RDE
2 
Peptidyl-prolyl cis-
trans isomerase 
FKBP4 
Fkbp4 0.416924 8.15E-05 
FC1242 Q9D8N0 Elongation factor 
1-gamma 
Eef1g 0.376768 0.000258 
FC1242 O89093-
2;O89093;F8
WHA7 
C-C motif 
chemokine 20;C-
C motif 
chemokine 
Ccl20 0.382655 0.000258 
FC1242 G5E839;P80
315 
T-complex protein 
1 subunit delta 
Cct4 0.413234 0.001159 
FC1242 E9Q0A1;Q3
UL54;Q8BVY
0 
Ribosomal L1 
domain-
containing protein 
1 
Rsl1d1 0.302226 0.001333 
FC1242 O70475;D3Z
3F7 
UDP-glucose 6-
dehydrogenase 
Ugdh 0.344839 0.001421 
FC1242 P27773 Protein disulfide-
isomerase A3 
Pdia3 0.27173 0.001773 
FC1242 P11499;E9Q
3D6 
Heat shock 
protein HSP 90-
beta 
Hsp90ab1 0.519432 0.001929 
FC1242 Q02819;D3Z
7D7 
Nucleobindin-1 Nucb1 0.231744 0.002151 
FC1242 P52480 Pyruvate kinase 
PKM 
Pkm 0.253271 0.003118 
FC1242 P60710;F8W
I82;E9Q1F2 
Actin, cytoplasmic 
1 
Actb 0.259922 0.003298 
FC1242 Q78PY7;Q3T
J56 
Staphylococcal 
nuclease domain-
containing protein 
1 
Snd1 0.250211 0.004043 
FC1242 E9PZV5;P20
152 
Vimentin Vim 0.225792 0.006919 
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FC1242 E9PYL7;F2Z
4A3 
FAT atypical 
cadherin 1 
Fat1 0.212877 0.011777 
FC1242 P58252 Elongation factor 
2 
Eef2 0.138426 0.030846 
FC1242 P62960 Nuclease-
sensitive element-
binding protein 1 
Ybx1 0.182924 0.032336 
FC1242 P28352;F6Q
A74; 
DNA-(apurinic or 
apyrimidinic site) 
lyase 
Apex1 0.198437 0.032336 
FC1242 P17918;E9Q
7Z3 
Proliferating cell 
nuclear antigen 
Pcna 0.171484 0.035194 
FC1242 G3XA10;Q8
VEK3 
Heterogeneous 
nuclear 
ribonucleoprotein 
U 
Hnrnpu 0.166215 0.044811 
FC1242 Q8BMJ3;Q6
0872;Q3UTA
4;Q3TQZ4;E
9Q5G6 
Eukaryotic 
translation 
initiation factor 
1A,  
Eif1ax;Eif1a;Gm
8300;Gm2016 
0.146768 0.047767 
FC1242 P09411 Phosphoglycerate 
kinase 1 
Pgk1 0.143672 0.057394 
FC1242 P08249 Malate 
dehydrogenase, 
mitochondrial 
Mdh2 0.120376 0.060354 
FC1242 Q80X90 Filamin-B Flnb 0.106402 0.062385 
FC1242 B7FAV1;B7F
AU9;Q8BTM
8 
Filamin-A Flna 0.094025 0.099433 
FC1242 P63242;Q8B
GY2 
Eukaryotic 
translation 
initiation factor 
5A-1;Eukaryotic 
translation 
initiation factor 
5A-2 
Eif5a;Eif5a2 0.095452 0.131436 
FC1242 Q6PDM2;Q6
PDM2-
3;Q6PDM2-2 
Serine/arginine-
rich splicing factor 
1 
Srsf1 0.07773 0.217206 
FC1242 Q62266 Cornifin-A Sprr1a 0.074576 0.287538 
FC1242 Q3U111;P26
043;Q7TSG6 
Radixin Rdx 0.042234 0.55012 
FC1242 P14148;D3Z
6N4;F6XI62 
60S ribosomal 
protein L7 
Rpl7 0.036295 0.688329 
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Supplementary Table 1C LIMMA output from FC1242 vs FC1199 mass 
spectrometry Maxquant data. ANOVA analysis of FC1242:FC1199 mass 
spectrometry using expression ratios and Heavy and Medium intensities quantified 
by Maxquant software. Significant proteins shown in red (p ≤ 0.01). 
Cell line Majority 
protein IDs 
Protein names Gene 
names 
logFC adj.P.Val 
FC1199 P10923;F8W
IP8 
Osteopontin Spp1 -2.42602 1.45E-06 
FC1199 G5E8M2;G5
E8B8;P1127
6 
Fibronectin;Anastellin Fn1 -2.39562 1.45E-06 
FC1199 P52927;Q6N
SP9 
High mobility group 
protein HMGI-C 
Hmga2 -1.34208 4.25E-06 
FC1199 G3UYZ1;Q8
R366 
Immunoglobulin 
superfamily member 8 
Igsf8 -1.44674 5.93E-06 
FC1199 O89093-
2;O89093;F8
WHA7 
C-C motif chemokine 
20;C-C motif 
chemokine 
Ccl20 -1.05329 1.08E-05 
FC1199 D3Z3R0;D3Y
XT4;D3YVE6
;F6TJZ4 
60S ribosomal protein 
L7a 
Rpl7a -0.85429 1.50E-05 
FC1199 P27773 Protein disulfide-
isomerase A3 
Pdia3 -0.76807 3.53E-05 
FC1199 P17095 High mobility group 
protein HMG-I/HMG-Y 
Hmga1 -0.86322 3.94E-05 
FC1199 P54227;D3Z
1Z8;D3Z5N2 
Stathmin Stmn1 -0.71649 8.77E-05 
FC1199 P14148;D3Z
6N4;F6XI62 
60S ribosomal protein 
L7 
Rpl7 -0.83958 0.000137 
FC1199 P17742;E9Q
1E3 
Peptidyl-prolyl cis-
trans isomerase A 
Ppia -0.49525 0.000197 
FC1199 Q9CY58-
3;Q9CY58-
2;Q9CY58;Q
9CY58-4 
Plasminogen activator 
inhibitor 1 RNA-binding 
protein 
Serbp1 -0.61616 0.000285 
FC1199 E9Q2Z4;A3K
GL9;B7ZCQ
3;F6W687;P
09602;Q5XK
38 
Non-histone 
chromosomal protein 
HMG-17 
Hmgn2 -0.45761 0.000412 
FC1199 B8JJN0;F6V
QX8;B8JJM5 
Complement factor B Cfb -0.62541 0.000495 
FC1199 Q61937;Q9D
AY9;Q5SQB
0;Q5SQB5;E
9Q5T3 
Nucleophosmin Npm1 -0.88183 0.000731 
FC1199 E9PZV5;P20
152 
Vimentin Vim -0.31713 0.001006 
FC1199 Q6IRU2 Tropomyosin alpha-4 
chain 
Tpm4 -0.51413 0.001016 
FC1199 G3XA10;Q8
VEK3 
Heterogeneous 
nuclear 
ribonucleoprotein U 
Gm28062;
Hnrnpu 
-0.46637 0.001016 
Supplementary Data 
202 
 
FC1199 Q8BJW6;Q8
BJW6-2 
Eukaryotic translation 
initiation factor 2A 
Eif2a -0.57362 0.001268 
FC1199 Q62266 Cornifin-A Sprr1a -0.40019 0.001338 
FC1199 P62960 Nuclease-sensitive 
element-binding 
protein 1 
Ybx1 -0.48932 0.001518 
FC1199 P48678;P48
678-
2;P48678-3 
Prelamin-A/C;Lamin-
A/C 
Lmna -0.38443 0.001518 
FC1199 Q9Z2U0 Proteasome subunit 
alpha type-7 
Psma7 -0.27819 0.001518 
FC1199 P62806 Histone H4 Hist1h4a -0.41523 0.002312 
FC1199 Q8VDD5 Myosin-9 Myh9 -0.24081 0.002808 
FC1199 E9PZ16;B1B
0C7;E9QL02
;Q05793;Q3
UHH3 
Basement membrane-
specific heparan 
sulfate proteoglycan 
core protein 
Hspg2 -0.62196 0.00315 
FC1199 P17918;E9Q
7Z3 
Proliferating cell 
nuclear antigen 
Pcna -0.47466 0.00315 
FC1199 P30681 High mobility group 
protein B2 
Hmgb2 -0.42387 0.00315 
FC1199 Q8CBB6 Histone H2B Hist1h2br -0.36339 0.003329 
FC1199 P51859;E0C
XA0;E0CYW
7 
Hepatoma-derived 
growth factor 
Hdgf -0.37508 0.00407 
FC1199 P13020-
2;P13020 
Gelsolin Gsn -0.67147 0.004262 
FC1199 Q61171;D3Z
4A4 
Peroxiredoxin-2 Prdx2 -0.2592 0.004682 
FC1199 P17182;Q6P
HC1 
Alpha-enolase Eno1 -0.255 0.004815 
FC1199 Q9EPL2-
2;Q9EPL2 
Calsyntenin-1;Soluble 
Alc-alpha;CTF1-alpha 
Clstn1 -0.48908 0.005425 
FC1199 Q6NZM2;E9
QQ01;P9806
3 
Bone morphogenetic 
protein 1 
Bmp1 -0.18966 0.005425 
FC1199 E9Q0A1;Q3
UL54;Q8BVY
0 
Ribosomal L1 domain-
containing protein 1 
Rsl1d1 -0.47449 0.007483 
FC1199 Q3U9N4;P28
798 
Granulins;Acrogranin;
Granulin-1;Granulin-
2;Granulin-3;Granulin-
4;Granulin-5;Granulin-
6;Granulin-7 
Grn -0.34951 0.013024 
FC1199 P20029 78 kDa glucose-
regulated protein 
Hspa5 -0.54535 0.014803 
FC1199 P09405 Nucleolin Ncl -0.421 0.014803 
FC1199 P63005;P63
005-2 
Platelet-activating 
factor acetylhydrolase 
IB subunit alpha 
Pafah1b1 -0.26076 0.014803 
FC1199 Q9CR16 Peptidyl-prolyl cis-
trans isomerase D 
Ppid -0.19412 0.018073 
FC1199 P35979 60S ribosomal protein 
L12 
Rpl12 -0.25286 0.018324 
FC1199 Q6PDM2;Q6
PDM2-
3;Q6PDM2-2 
Serine/arginine-rich 
splicing factor 1 
Srsf1 -0.21259 0.020134 
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FC1199 P11499;E9Q
3D6 
Heat shock protein 
HSP 90-beta 
Hsp90ab1 -0.17572 0.024521 
FC1199 F8WH23;Q6
1581;E9Q5D
9;F8WII5 
Insulin-like growth 
factor-binding protein 7 
Igfbp7 -0.12006 0.036359 
FC1199 P16045 Galectin-1 Lgals1 -0.12564 0.039333 
FC1199 Q8BMJ3;Q6
0872;Q3UTA
4 
Eukaryotic translation 
initiation factor 1A,  
Eif1ax;Eif1
a; 
-0.09496 0.052159 
FC1199 E9PXE7;P62
281;D3Z3M6 
40S ribosomal protein 
S11 
Rps11 -0.16785 0.060628 
FC1199 Q60817;P70
670 
Nascent polypeptide-
associated complex 
subunit alpha 
Naca -0.15119 0.065443 
FC1199 P63242;Q8B
GY2 
Eukaryotic translation 
initiation factor 5A-
1;Eukaryotic 
translation initiation 
factor 5A-2 
Eif5a;Eif5a
2 
-0.10443 0.067892 
FC1199 B7FAV1;B7F
AU9;Q8BTM
8 
Filamin-A Flna -0.07195 0.118528 
FC1199 E9QN70;P02
469 
Laminin subunit beta-1 Lamb1 -0.12968 0.201804 
FC1199 P35700;B1A
XW5;B1AXW
6;G3UW54;B
1AXW4 
Peroxiredoxin-1 Prdx1 -0.10212 0.2326 
FC1199 Q9WUM4 Coronin-1C Coro1c -0.04755 0.258745 
FC1199 P26041 Moesin Msn -0.0884 0.283482 
FC1199 P63158;D3Z
351;D3YZ18;
D3YVC6 
High mobility group 
protein B1 
Hmgb1 -0.05437 0.292983 
FC1199 Q8CGC7 Bifunctional 
glutamate/proline--
tRNA ligase 
Eprs -0.04271 0.294598 
FC1199 P40124 Adenylyl cyclase-
associated protein 1 
Cap1 -0.10043 0.410992 
FC1199 E9QLA4;E9
QLA3 
Neogenin Neo1 -0.30266 0.433635 
FC1199 O08553 Dihydropyrimidinase-
related protein 2 
Dpysl2 -0.30762 0.449134 
FC1199 P62983;E9Q
9J0;E9Q0Z8;
E9Q4P0 
Ubiquitin-40S 
ribosomal protein S27a 
Rps27a;Ub
a52;Kxd1;U
bc;Ubb 
-0.13696 0.459137 
FC1199 Q6PI17;P257
85;B1AQJ3 
Metalloproteinase 
inhibitor 2 
Timp2 -0.03388 0.460015 
FC1199 P24369 Peptidyl-prolyl cis-
trans isomerase B 
Ppib -0.01741 0.711622 
FC1199 E9PYL7;F2Z
4A3 
FAT atypical cadherin 
1 
Fat1 -0.16301 0.73757 
FC1199 Q93092 Transaldolase Taldo1 -0.00811 0.879176 
FC1199 P09411 Phosphoglycerate 
kinase 1 
Pgk1 -0.00845 0.880232 
FC1199 P06797 Cathepsin 
L1;Cathepsin L1 heavy 
chain;Cathepsin L1 
light chain 
Ctsl -0.0083 0.891117 
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FC1199 A2ASQ1-
3;A2ASQ1-
2;A2ASQ1 
Agrin;Agrin N-terminal 
110 kDa subunit 
Agrn -0.03733 0.901895 
FC1199 O70251 Elongation factor 1-
beta 
Eef1b -0.00488 0.92655 
FC1199 O70475;D3Z
3F7 
UDP-glucose 6-
dehydrogenase 
Ugdh -0.00841 0.9698 
FC1199 P63017;Q50
4P4 
Heat shock cognate 71 
kDa protein 
Hspa8 -0.00068 0.985578 
FC1242 Q8K3I3;P502
28 
C-X-C motif 
chemokine 5;GCP-2(1-
78); 
Cxcl5 2.87775 2.99E-07 
FC1242 Q06890;E9P
UU2;E9PXG
5;E9Q8Y5;E
9Q9B8 
Clusterin;Clusterin 
beta chain;Clusterin 
alpha chain 
Clu 1.223041 4.25E-06 
FC1242 Q3UPN1;P2
9533 
Vascular cell adhesion 
protein 1 
Vcam1 1.172848 1.50E-05 
FC1242 Q91YJ2 Sorting nexin-4 Snx4 1.152415 1.54E-05 
FC1242 P40142 Transketolase Tkt 0.669876 3.94E-05 
FC1242 Q91XA2;G3
X8U4 
Golgi membrane 
protein 1 
Golm1 0.700457 5.05E-05 
FC1242 Q9D8N0 Elongation factor 1-
gamma 
Eef1g 0.456302 0.000187 
FC1242 P26040 Ezrin Ezr 0.420667 0.000282 
FC1242 Q80X90 Filamin-B Flnb 0.558398 0.000285 
FC1242 Q60709;Q61
482;Q06335-
2;Q06335 
Amyloid-like protein 2 Aplp2 0.903753 0.000322 
FC1242 Q78PY7;Q3T
J56 
Staphylococcal 
nuclease domain-
containing protein 1 
Snd1 0.360601 0.000602 
FC1242 P52480 Pyruvate kinase PKM Pkm 0.450165 0.000689 
FC1242 E9Q616;F7B
RM2 
Ahnak Ahnak 0.420107 0.001094 
FC1242 P58252 Elongation factor 2 Eef2 0.398648 0.001268 
FC1242 P97467;E9Q
704;F8VQA4
;E9Q8R9 
Peptidyl-glycine alpha-
amidating 
monooxygenase 
Pam 0.27673 0.001361 
FC1242 Q02053 Ubiquitin-like modifier-
activating enzyme 1 
Uba1 0.307965 0.001518 
FC1242 P28352;F6Q
A74;D3Z124 
DNA-(apurinic or 
apyrimidinic site) 
lyase;DNA-(apurinic or 
apyrimidinic site) 
lyase, mitochondrial 
Apex1 0.448494 0.001518 
FC1242 E9QMZ5;Q9
QXS1-3 
Plectin Plec 0.313411 0.002249 
FC1242 Q3UQ28 Peroxidasin homolog Pxdn 0.611725 0.002316 
FC1242 F8VQJ3;P02
468 
Laminin subunit 
gamma-1 
Lamc1 0.328677 0.002576 
FC1242 Q02819;D3Z
7D7 
Nucleobindin-1 Nucb1 0.411369 0.002846 
FC1242 P60710;F8W
I82 
Actin, cytoplasmic 1 Actb 0.216162 0.003779 
FC1242 Q61001 Laminin subunit alpha-
5 
Lama5 0.28965 0.003857 
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FC1242 P30416;F7C
AT1;D6RDE
2 
Peptidyl-prolyl cis-
trans isomerase 
FKBP4 
Fkbp4 0.356235 0.00407 
FC1242 P18760;F8W
GL3;E9Q1T2 
Cofilin-1 Cfl1 0.171168 0.00553 
FC1242 Q60864 Stress-induced-
phosphoprotein 1 
Stip1 0.162863 0.009476 
FC1242 P50580;D3Y
VH7 
Proliferation-
associated protein 2G4 
Pa2g4 0.314549 0.011916 
FC1242 E9PX72;E9P
X42;P16858;
E9PZH9;E9
QAC7;E9Q9
E5 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
Gapdh 0.233837 0.016735 
FC1242 G5E839;P80
315 
T-complex protein 1 
subunit delta 
Cct4 0.146096 0.036359 
FC1242 Q01853 Transitional 
endoplasmic reticulum 
ATPase 
Vcp 0.177819 0.038687 
FC1242 Q99MN1;Q8
R2P8 
Lysine--tRNA ligase Kars 0.109758 0.0487 
FC1242 O88342 WD repeat-containing 
protein 1 
Wdr1 0.191226 0.064594 
FC1242 Q3U111;P26
043;Q7TSG6 
Radixin Rdx 0.27526 0.082635 
FC1242 Q61468 Mesothelin;Megakaryo
cyte-potentiating 
factor;Mesothelin, 
cleaved form 
Msln 0.220696 0.083461 
FC1242 E9Q2Q0;P97
821 
Dipeptidyl peptidase 1 Ctsc 0.144256 0.144139 
FC1242 P21107-
2;D3Z2H9;Q
8K0Z5;E9Q5
J9 
Tropomyosin alpha-3 
chain 
Tpm3;Tpm
3-rs7 
0.101366 0.15294 
FC1242 Q9D0R2 Threonine--tRNA 
ligase, cytoplasmic 
Tars 0.15914 0.159084 
FC1242 Q8C483;P26
638;A2AFS0 
Serine--tRNA ligase, 
cytoplasmic 
Sars 0.078665 0.201804 
FC1242 Q3TGL4;G5
E8B3;P3788
9-2;P37889 
Fibulin-2 Fbln2 0.114903 0.232764 
FC1242 Q61081 Hsp90 co-chaperone 
Cdc37 
Cdc37 0.056799 0.383233 
FC1242 Q9R0P5 Destrin Dstn 0.086924 0.387918 
FC1242 A2AGN7;B7
ZCF1;O8868
5;F6Q2E3 
26S protease 
regulatory subunit 6A 
Psmc3 0.078311 0.417186 
FC1242 Q8C243;P18
242;F6Y6L6 
Cathepsin D Ctsd 0.123372 0.437337 
FC1242 P62908;D3Y
V43 
40S ribosomal protein 
S3 
Rps3 0.043111 0.459701 
FC1242 P10126;D3Y
Z68;D3Z3I8;
B7ZBW3;P6
2631 
Elongation factor 1-
alpha 1;Elongation 
factor 1-alpha 2 
Eef1a1;Eef
1a2 
0.197636 0.500115 
FC1242 Q3TJ52;P54
728 
UV excision repair 
protein RAD23 
homolog B 
Rad23b 0.036676 0.531032 
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FC1242 P07356;B0V
2N7;B0V2N8 
Annexin A2;Annexin Anxa2 0.021647 0.71453 
FC1242 Q61753 D-3-phosphoglycerate 
dehydrogenase 
Phgdh 0.010067 0.885344 
FC1242 Q91UZ6 DNA segment, Chr 17, 
human D6S56E 5 
D17H6S56
E-5 
0.058041 0.885344 
FC1242 P08249 Malate 
dehydrogenase, 
mitochondrial 
Mdh2 0.003222 0.957459 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
207 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
208 
 
i) Antibodies used for immunoblotting  
Antibody Company Catalogue 
no. 
Dilution Blocking 
agent 
IGF-1 Abcam ab9572 1:500 2.5 % BSA 
IGF-2 Abcam ab9574 1:1000 5 % NFDM 
Phospho-Insulin R 
(Y1162/Y1163)/ 
IGF-I R (Y1135/Y1136) 
Antibody 
R&D AF2507 1:400 5 % NFDM 
Insulin Abcam ab137747 1:1000 2.5 % BSA 
IGF-1R R&D AF305-NA 1:1000 5 % NFDM 
cleaved caspase 3 
Cell 
signalling 
9661 1:1000 5 % NFDM 
Alpha smooth muscle 
actin (αSMA) 
Abcam ab7817 1:1000 2.5 % BSA 
Mesothelin Biorbyt Orb14370 1:500 5 % BSA 
pIRS1 Millipore 09-432 1:1000 5 % BSA 
IRS1 
Cell 
Signalling 
CST23825 1:1000 5% BSA 
pIRS2 Biorbyt Orb34833 1:500 5 % BSA 
IRS2 
Cell 
Signalling 
CST4502s 1:1000 5 % BSA 
pAKT 
Cell 
signalling 
CST4060 1:1000 5% BSA 
AKT 
Cell 
signalling 
CST9272 1:1000 5% BSA 
pMEK 
Cell 
signalling 
CST2338 1:1000 5% BSA 
MEK 
Cell 
signalling 
CST9126s 1:1000 5% BSA 
Tubulin 
Sigma 
Aldrich 
T6199 1:5000 2.5 % BSA 
GAPDH 
Sigma 
Aldrich 
G9545 1:10,000 2.5 % BSA 
Secondary antibodies Company Catalogue 
no. 
Dilution Blocking 
agent 
Rabbit-IgG-HRP linked Cell 
Signalling 
Technology 
7074S 
1:5000  
Mouse-IgG-HRP linked Cell 
Signalling 
Technology 
7076S 
1:5000  
Donkey anti Goat HRP 
linked 
Abcam 
ab97120 
1:10,000  
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ii) Antibodies used for immunohistochemistry: 
Antibody Company Catalogue 
no. 
Dilution Antigen 
retrieval 
pH 
CD206 Abcam ab8919 1:50 low 
Phospho-Insulin R 
(Y1162/Y1163)/ 
IGF-I R 
(Y1135/Y1136)  
R&D AF2507 1:50 high 
CD68 DAKO M081401-2 1:2000 high 
αSMA Abcam ab5694 1:100 low 
Cleaved caspase 3 Cell Signalling 
Technology 
9661 1:300 high 
Phospho-insulinR LS Biosciences LS-C177981 1:100 low 
Phospho-IGF-1R Biorbyt orb97626 1:100 high 
CD31 Cell Signalling 
Technology 
77699 1:100 low 
CD3 Abcam Ab5690 1:100 high 
Mesothelin Biorbyt Orb14370 1:500 high 
 
 
iii) Antibodies for immunofluorescence  
Antibody Company Catalogue no. Dilution 
EpCAM BD pharmingen 552370 1:100 
αSMA Abcam Ab7817 1:100 
F4/80 Biolegend 123102 1:200 
Ki67 Abcam Ab15580 1:1000 
anti mouse 488 Abcam Ab150105 1:500 
anti rat 488 Abcam Ab96887 1:500 
anti rabbit 594 Abcam Ab150080 1:500 
anti mouse 594 Abcam Ab98639 1:500 
DAPI Gibco D21490 1:600 
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iv) Antibodies for flow cytometry  
Antibody Company Cat no. Clone Fluorochrome Dilution 
Sytox viability 
marker 
Life 
Technologies 
S34857  Pacific blue 1:500 
CD45 Biolegend 103113 30-F11 PE-Cy7 1:100 
F4/80 Biolegend 123115 BM8 APC 1:100 
CD206 Biolegend  141715 C068C2 PerCP-Cy5.5 1:100 
 
 
v) Primers for qPCR  
Protein 
Name 
Gene 
Name 
Primer description Reference 
Insulin-like 
growth factor 
1 
Igf-1 Mm_ IGF1_1_SG QuantiTect 
Primer Assay 
QT00154469 
Insulin-like 
growth factor 
2 
Igf-2 Mm_IGF2 _1_SG QuantiTect 
Primer Assay 
QT00109879 
Insulin Insulin Mm_INS _1_SG QuantiTect Primer 
Assay 
QT01660855 
Alpha 
smooth 
muscle actin 
αSMA Mm_Acta2_1_SG QuantiTect 
Primer Assay 
QT00140119   
Mesothelin Msln Mm_Msln_1_SG QuantiTect 
Primer Assay 
QT00104573   
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